

# GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES

England & Wales · Charity number 1115606

## Details

---

**Other names** GLOBAL ALLIANCE FOR LIVESTOCK VACCINES, GALV

**Status** Registered

**Legal form** Charitable company

**Company number** [05393391](#)

**Registered** 2006-07-28

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** Galvmed  
Doherty Building  
Pentlands Science Park  
Bush Loan  
Edinburgh  
SCOTLAND

**Phone** 01314456264

**Email** [info@galvmed.org](mailto:info@galvmed.org)

**Website** [www.galvmed.org](http://www.galvmed.org)

## Activities

---

**Objects:** 1 TO RELIEVE FINANCIAL HARDSHIP AND PROMOTE GOOD HEALTH (INCLUDING IMPROVING FOOD SECURITY) AMONGST LIVESTOCK KEEPERS IN DEVELOPING COUNTRIES THROUGH THE PROMOTION OF AFFORDABLE VACCINES, PHARMACEUTICALS AND DIAGNOSTIC PRODUCTS AND SERVICES AIMED AT IMPROVING THE HEALTH OF THEIR LIVESTOCK; AND2 TO PROMOTE THE EFFECTIVE USE OF RESOURCES TO ACHIEVE THE ABOVE CHARITABLE PURPOSES THROUGH THE IDENTIFICATION, MANAGEMENT, FUNDING AND CO-ORDINATION OF:A) RESEARCH INTO LIVESTOCK VACCINES, PHARMACEUTICALS AND DIAGNOSTIC PRODUCTS AND SERVICES; ANDB) THE DEVELOPMENT AND DELIVERY OF THOSE PRODUCTS AND SERVICES AT AFFORDABLE PRICES,BY WORKING IN PARTNERSHIP WITH OTHERS (WHETHER CHARITIES, GOVERNMENT OR PRIVATE BODIES OR INSTITUTIONS).FOOD SECURITY IS DEFINED BY THE UNITED NATIONS' FOOD AND AGRICULTURE ORGANISATION AS EXISTING WHEN ALL PEOPLE AT ALL TIMES, HAVE PHYSICAL AND ECONOMIC ACCESS TO SUFFICIENT, SAFE AND NUTRITIOUS FOOD TO MEET THEIR DIETARY NEEDS AND FOOD PREFERENCES FOR AN ACTIVE AND HEALTHY LIFE.

**Activities:** GALVmed fosters ground breaking partnerships on a global scale between animal health industry and other organisations. Our aim is to promote the development of accessible and affordable animal vaccines and other animal health products for the poorest farmers in developing countries.

## Classification

---

- **How:** Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research, Acts As An Umbrella Or Resource Body, Other Charitable Activities
- **What:** General Charitable Purposes, The Prevention Or Relief Of Poverty, Animals, Economic/community Development/employment, Other Charitable Purposes
- **Who:** Children/young People, Elderly/old People, Other Defined Groups, The General Public/mankind

## Geography

---

- **Area of benefit:** UNDEFINED. IN PRACTICE, OVERSEAS.
- Bangladesh
- Benin
- Botswana
- Burkina Faso
- Cameroon
- Chad
- Congo (Democratic Republic)
- Ethiopia
- Ghana
- India
- Ivory Coast
- Kenya
- Malawi
- Mali
- Mozambique
- Nepal
- Nigeria
- Rwanda
- Senegal
- South Africa
- South Sudan
- Tanzania
- The Gambia
- Togo
- Uganda
- Zambia
- Zimbabwe

## Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£17,665,060	£12,678,525	£22,852,577	28
2024-03-31	£9,620,053	£10,278,111	£17,866,042	27
2023-03-31	£13,088,352	£11,095,477	£18,524,100	27
2022-03-31	£13,362,922	£11,551,355	£16,531,225	29
2021-03-31	£16,927,327	£11,191,562	£14,001,649	29

## Trustees

Name	Role	Appointed
Dr Alice Hope Banga		2020-09-15
Dr Barbara Wieland		2024-09-16
Dr Fabian Martin Kausche		2020-09-15
Dr Henry Matukho Wamwayi		2021-09-14
Dr Isabelle Dieuzy-Labaye		2018-09-20
Dr Johan Dreesen		2023-03-01
Dr Thomas Mitchell		2024-09-16
Priya Nair		2024-09-16
Professor Cheikh Ly		2023-09-12
Professor Philip Thornton		2023-09-12
Unesu Ushewokunze-Obatolu		2025-09-16

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**

England & Wales - Charity number 1115606

---

# Accounts

---

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

Registered in England No. 05393391  
England and Wales Charity No. 1115606  
Scottish Charity No. SC039197

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2025**



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
For the year ended 31 March 2025

**CONTENTS**

	<b><u>Page</u></b>
<b><u>REFERENCE AND ADMINISTRATIVE DETAILS</u></b>	<b>2</b>
<b><u>REPORT OF THE TRUSTEES</u></b>	
<b>INTRODUCTION</b>	<b>3</b>
<b>OBJECTS, OBJECTIVES AND ACTIVITIES</b>	<b>3</b>
Objects	3
Objectives & Activities	3
<b>STRUCTURE, GOVERNANCE AND MANAGEMENT</b>	<b>3</b>
Trustee Recruitment, Induction, Training and Evaluation	4
Trustees' and Members' Meetings and Business	4
Strategy and Decision Making	4
Key Management Remuneration	4
Diversity	5
Safeguarding	5
Partnerships and Related Parties	5
<b>STRATEGIC REPORT</b>	<b>5</b>
Performance and Achievements	5
- Key Performance Indicators	5
- Key Achievements	6
- Impact of Our Work	7
Financial Review	8
- Income	8
- Expenditure	8
- Balance Sheet	9
- Liquidity Management Policy	9
- Climate Change	9
- Reserves	9
- Unrestricted Reserves Policy	9
Future Plans	9
- Objectives	9
- Financial	10
Principal Risks and Uncertainties	10
- Risk Management	10
<b>GOING CONCERN</b>	<b>11</b>
<b>STATEMENT OF DISCLOSURE OF INFORMATION TO AUDITORS</b>	<b>11</b>
<b>AUDITORS</b>	<b>11</b>
<b><u>RESPONSIBILITIES OF THE TRUSTEES</u></b>	<b>12</b>
<b><u>INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES</u></b>	<b>13</b>
<b><u>INCOME AND EXPENDITURE ACCOUNT AND STATEMENT OF FINANCIAL ACTIVITIES</u></b>	<b>16</b>
<b><u>BALANCE SHEET</u></b>	<b>17</b>
<b><u>STATEMENT OF CASH FLOWS</u></b>	<b>18</b>
<b><u>NOTES TO THE FINANCIAL STATEMENTS</u></b>	<b>19-30</b>



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Trustees**

Dr I Dieuzy-Labayé	Chair
Dr J Maina	Vice-Chair
	Chair of HR Committee and Nominations Committee
Mr S Jha	Chair of Commercial Development Advisory Committee
Dr T Mitchell	Appointed 16 September 2024
	Chair of Finance and Risk Committee (from 16 September 2024)
Dr H Wamwayi	Chair of Technical Scientific Committee
Dr P Thornton	Chair of Impact, Monitoring & Evaluation Advisory Committee
Dr A Banga	
Dr F Kausche	
Dr J Dreesen	
Prof C Ly	
Ms P Nair	Appointed 16 September 2024
Dr B Wieland	Appointed 16 September 2024
Mrs J Stevenson	Resigned 16 September 2024
	Chair of Finance and Risk Committee (to 16 September 2024)

**Chief Executive Officer** Dr C Schumacher

**Company Secretary** Ms R Stewart CA

**Independent Auditors**

Henderson Loggie LLP  
Chartered Accountants  
The Stamp Office, Level 5  
10-14 Waterloo Place  
Edinburgh, EH1 3EG

**Legal Advisors**

Dentons LLP  
Quartermile One  
15 Lauriston Place  
Edinburgh, EH3 9EP

**Bankers**

Lloyds Bank plc  
City Office, PO Box 72  
Bailey Drive, Gillingham Business Park  
Kent, ME8 0LS

**Registered Office**

One Fleet Place  
London, EC4M 7WS

**Principal Office**

Doherty Building  
Pentlands Science Park  
Bush Loan, Edinburgh, EH26 0PZ

**Company No.** 05393391

**England and Wales Charity No.** 1115606

**Scotland Charity No.** SC039197



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a Company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

**INTRODUCTION**

The Trustees have pleasure in presenting their report for the year ended 31 March 2025. This report is prepared in accordance with the *Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)* and in accordance with applicable law.

Global Alliance for Livestock Veterinary Medicines (the Company) has complied with the duty in Section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

Global Alliance for Livestock Veterinary Medicines (GALVmed) is a Company limited by guarantee and is registered as a charity with the Charity Commission and the Office of the Scottish Charity Regulator (OSCR). It is incorporated in the UK with its principal office in Edinburgh, UK. A further office is maintained in Nairobi, Kenya (Africa office). The office in New Delhi, India (South Asia office) was closed as of the 31<sup>st</sup> of March 2025. Other reference and administrative details are set out in the previous page.

**OBJECTS, OBJECTIVES AND ACTIVITIES**

**Objects**

Around 900 million people rely on livestock for their livelihoods. The Company's objects, as set out in its Memorandum of Association, are for the benefit of the public:

- 1) to relieve financial hardship and promote good health (including improving food security) amongst small-holder livestock keepers (small-scale livestock producers – SSPs) in developing countries through the promotion of affordable vaccines, pharmaceutical and diagnostic products and services aimed at improving the health of their livestock; and
- 2) to promote the effective use of resources to achieve the above charitable purposes through the identification, management, funding, and co-ordination of: a) development of livestock vaccines, pharmaceuticals and diagnostics products and services; and b) delivery of these products and services at affordable prices, by working in partnership with others (whether charities, government; institutions or private bodies).

GALVmed's vision is the transformational improvement in the wellbeing and economic progression of SSPs. GALVmed's mission is to contribute to the transformation of SSPs' lives by:

- understanding the constraints to animal health and how to overcome them;
- engaging the animal health industry; and
- ensuring awareness, availability, and adoption of effective animal health interventions.

**Objectives & Activities**

GALVmed achieves its charitable purpose by operating a series of Research and Development (R&D) and Commercialisation programmes, supported by Enabling Environment and Monitoring and Evaluation (M&E) activities, funded principally by the Gates Foundation (TGF) and the UK Government through its Foreign, Commonwealth and Development Office (FCDO). These programmes are designed to identify products that SSPs can use to improve the health of their animals and to make such products more easily accessible. The three largest of these programmes are Veterinary Innovations Transforming Animal Health and Livelihoods 1 and 2 (VITAL), with a budget of \$50m and \$48.3m respectively, and African Animal Trypanosomiasis 3 (AAT 3), with a budget of \$34.3m. 7 other programmes are also being operated, with values ranging from \$1.9m to \$5.0m. All programmes are supported by the funding of project core costs through the VITAL 2 programme, with a budget of \$15.3m, except for AAT 3, AgResults and EDSAP where project staff are funded directly (see note 12 for further information on all programmes). All future programmes will fund project core costs directly.

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

The governance of the Company is the responsibility of the Trustees, and the Company adopts the appropriate principles and recommended practices of the Charity Governance Code.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

The Members elect the Trustees in accordance with the terms of the Memorandum and Articles of Association.

**Trustee Recruitment, Induction, Training and Evaluation**

The maximum number of Trustees permitted by the Company's Articles is 12. Trustees are recruited for their individual skills and experience to fill current or impending vacancies, guided by a comprehensive skills and diversity matrix. Trustees serve a term of 3 years subject to a maximum of 2 consecutive terms and Board and AGM approval. Recruitment of Trustees is managed by a Nominations Committee, comprising 3 Trustees of which one is the HR Committee Chair. Three new Trustees were approved at the AGM following a recruitment process. A further recruitment process is currently ongoing to identify candidates to replace Trustees due to retire at the 2025 AGM and beyond. In certain circumstances the Chair may stand for re-election after the end of their two three-year terms up to a further three years, where it would be deemed detrimental to the organisation for the Chair to change during that period. Their re-election must be approved by the Members annually.

A formal Trustee induction process is in place to ensure clarity of the role of the Trustee and their responsibilities under Company and charity legislation. Trustees, new and current, also receive training on their legal responsibilities annually prior to the AGM. During the year Trustees received training on communications strategy.

Trustee evaluation takes place annually and is based on self-assessment, peer-assessment and annual performance interviews with the Chair and Vice-Chair; the process includes identifying development requirements.

**Trustees' and Members' Meetings and Business**

Trustees meet formally four times a year, with two virtual and two in-person meetings which are held at the same time as the Members' meetings. The two in-person meetings in 2024-25 were in Edinburgh in September 2024 and Nairobi in March 2025. The business of all meetings is minuted.

On 31 March 2025 there were 15 Members and 12 Trustees. Members are subscribers to GALVmed's Memorandum of Association. The organisation appoints a representative to attend all meetings and to undertake their responsibilities as dictated by the Articles of Association. Members have rights and obligations in accordance with the Articles. In addition, observers from 5 organisations, including TGF and FCDO, the Company's major funders, are invited to attend the Members' meetings, with the funders also invited to meet separately with the Board.

The Board is supported by the Finance & Risk and HR committees, to whom aspects of day-to-day accountability and governance are delegated. The HR Committee is also responsible for safeguarding. There are also three advisory committees - the Technical Scientific, Commercial Development (CD) and Impact, Monitoring and Evaluation committees. These committees provide guidance to the Board through the involvement of external experts.

**Strategy and Decision Making**

Development of the Company's strategy for the achievement of its charitable objectives is overseen by the Board of Trustees and delivered by the Executive Directors. The related corporate objectives and budget are set out in the Annual Plan. Progress in achieving these objectives is assessed by the Board through reports by the Chief Executive and the Executive Directors at Board meetings and drawn from monthly and quarterly internal performance monitoring tools. Strategic and operational issues are brought to the Board for assessment and direction as required. GALVmed are currently working towards the achievement of the 2030 Strategy, which was approved by the Board in March 2021, utilising the Strategy Implementation Plan and the Strategy Execution Framework.

**Key Management Remuneration**

Key management includes the Chief Executive (CEO) and Executive/Senior Directors of the Company who operate as the GALVmed Leadership Team (GLT).

The HR Committee has responsibility delegated to it for setting the framework for key management remuneration. The main responsibilities of the Committee in relation to key management remuneration are:

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

- to determine and agree with the Board the broad policy for key management remuneration;
- to approve the design, determine targets and approve payments of any performance related schemes; and
- to determine the total remuneration package of each member of the GLT.

The performance related pay scheme, which is based on departmental and individual objectives developed from the corporate objectives, is applicable to all employees. An organisational review was carried out in November 2024. Several new positions were created which will be recruited in 2025-26. Following this, GALVmed will have sufficient qualified and experienced staff to deliver programmes for the duration of VITAL 2 to 31 December 2029.

**Diversity**

The diversity of the Trustees, GLT and staff at 31 March 2025 is:

	Gender		Ethnicity		
	Male	Female	African	Asian	Caucasian
Trustees	8	4	4	2	6
GLT	2	4	1	-	5
Staff	8	21	15	2	12

**Safeguarding**

GALVmed is committed to addressing safeguarding throughout its work. It does so through a specific set of policies and procedures that include: Safeguarding Policy (which explicitly addresses prevention, reporting and response); Trustee and GLT training (on commencement and biennial thereafter); all-staff awareness; safeguarding risk assessments and contractual commitments to safeguarding by its partners and consultants. No safeguarding issues were reported in the year.

**Partnerships and Related Parties**

Partnerships with entities to whom research and development, commercialisation and other work can be subcontracted is a key part of the way the Company operates and is instrumental in allowing it to pursue its charitable objectives. The Company initiates, facilitates, brokers, and contributes to such partnerships from two perspectives: 1) partnerships to deliver and support programme achievement and impact; and 2) strategic partnerships to initiate and advance the livestock agenda. All such relationships are formalised through Memoranda of Understanding, Confidentiality Agreements or Contractual Agreements. All contractual arrangements and related party transactions (detailed in Note 17 to the Financial Statements) are conducted at arm's length.

**STRATEGIC REPORT**

**Performance and Achievements**

*Key Performance Indicators*

The Trustees and GLT assess the financial and operational performance of each programme using the following key performance indicators (KPI):

- detailed milestones within specific activities as defined in the funder agreement for each programme;
- quarterly KPI dashboards, providing quantitative and qualitative measure of delivery across all functions;
- monthly and quarterly actual expenditure against Board approved budget and forecasts; and
- achievement of the annual corporate objectives.

The Advisory and Board Committees oversee the financial and operational performance of organisational and programme activities quarterly.

In addition, service level agreements have been established for all service-related support functions, performance of which is assessed quarterly.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

*Key Achievements*

The Company made good progress during the year in achieving its charitable purpose. Its corporate objectives for the year to 31 March 2025 together with key achievements are:

<b>Objective</b>	<b>Achievements</b>
<b>Tactical</b>	
Support programme functions and project managers with required financial, human, operational and project management resources to deliver 2024-25 project targets.	<ul style="list-style-type: none"> <li>➤ Resource current projects appropriately and deliver to plan, deliverables, and financials.</li> <li>➤ Ensure GALVmed facilitated vaccines currently in development are licensed or nearing licensed in all key countries, supported by comprehensive and well-coordinated launch and commercialisation plans.</li> </ul>
<b>Rating of Progress:</b>  <i>Achieved</i>	<p>There has been progress on R&amp;D &amp; Commercial Development delivery with most projects being on target and in line with budget. Specific achievements include:</p> <ul style="list-style-type: none"> <li>• Two quadrivalent Foot &amp; Mouth Disease vaccines specifically tailored to East Africa were registered, the first of their kind.</li> <li>• Market authorisation has been received for all combination vaccines developed during VITAL 1 in their country of origin and one combination vaccine registered in one country of use. The combo launch has been part of an integrated portfolio registration strategy with 190 vaccines expected to be registered in three countries.</li> <li>• Several major deliveries were achieved in Enabling Environment including the completion and validation of the Veterinary Ectoparasiticide Guidelines which will now be rolled out across 8 countries in Eastern Africa.</li> <li>• VITAL 1 Hester India &amp; Nepal and Laprovect distribution projects are complete with strong business performance demonstrated. The PREVENT project is progressing towards completion with targets exceeded (128m day-old-chicks vaccinated against 52m planned), and with exceptionally good net economic benefit (\$581 per customer per annum) generated for the SSP customers.</li> <li>• Digital market intelligence &amp; telehealth platform (SEAMLiSS) phase 1 is complete, with MVP (minimum viable product) delivered.</li> </ul> <p>We also continue to have strong engagement with key stakeholders across the animal health industry, NGOs and academia.</p>
<b>Strategic</b>	
Secure new funds to deliver GALVmed's mission of improving availability, access & adoption of quality animal health products for VITAL 2, R&D, digital transformation, and vaccination scale-up in sub-Saharan Africa and South Asia.	<ul style="list-style-type: none"> <li>➤ Secure VITAL 2 programme funding and prepare for implementation kick-off, ensuring organisational sustainability through sufficient direct and indirect core contributions.</li> <li>➤ Ensure "improved regulation" grant signed and prepared for implementation kick off.</li> <li>➤ Review R&amp;D strategy and define new project portfolio and partnership models, with funding proposal advanced to the stage of negotiation with current or new funders.</li> <li>➤ Funder Diversification: Profile new funders and evaluate new funding mechanisms for their potential to diversify GALVmed's funder base.</li> </ul>
<b>Rating of Progress:</b>  <i>Partially Achieved</i>	<p>Funding of \$48.3m was secured from TGF and FCDO in the year for VITAL 2, an ambitious programme which aims to increase ruminant vaccination rates in Sub-Saharan Africa by establishing a sustainable private sector market in the region. Through VITAL 2, organisational sustainability is secured until December 2029 through sufficient direct and indirect core cost contributions. A comprehensive implementation planning exercise was also completed for VITAL 2, with the programme expected to be launched from April 2025. Funding of \$5m for the Better Regulation programme was secured from TGF, as was \$3.3m for a poultry diagnostics project, jointly funded by TGF and FCDO. Although some work has taken place to diversify our funder base, including the submission of a \$20m proposal to the Qatar Fund for Development, this will be a key area of focus in 2025-26 to leverage VITAL</p>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

<p>2 activities now that implementation has commenced. The R&amp;D Strategy was also reviewed, with funding under discussion with existing funders for several priority areas and landscaping ongoing to develop a broader funding strategy for R&amp;D work.</p>	
<p><b>Impact Evaluation</b></p>	
<p>Strengthen focus on measuring impact to deliver transformational results through GALVmed's current and future projects, and effectively communicate GALVmed's impact, achievements and learnings.</p> <ul style="list-style-type: none"> <li>➤ Improve GALVmed transformational market change (TMC) and impact by achieving greater levels of vaccination and adoption of innovation at SSP level in accordance with the VITAL 2 goals.</li> <li>➤ Continue development of Monitoring &amp; Evaluation (M&amp;E) modelling methodology to ensure that GALVmed's project outputs, outcomes and impact are comprehensively captured, communicated, translated into learnings, and used to strengthen project design &amp; institutional knowledge.</li> <li>➤ Continue to translate GALVmed outputs and outcomes into impactful communication materials to increase the organisation's visibility, reputation and recognition as a competent livestock development partner and honest broker among stakeholders in the global south.</li> </ul>	
<p><b>Rating of Progress:</b></p> <p><i>Achieved</i></p>	<p>Throughout the year, all GALVmed functions, staff and projects have worked closely and collaboratively towards improving GALVmed's TMC and impact as witnessed by achieving greater levels of vaccination and adoption of innovation at SSP-level in accordance with the VITAL 2 goals. We have developed an innovative TMC framework and a TMC Measurement Matrix, and further tools to broaden our ability to measure the changes induced by GALVmed's work. We have also improved our M&amp;E methodology with a much strengthened framework now available and implemented for project evaluation. This has allowed GALVmed to identify learnings from prior projects which have been used extensively in VITAL 2 programme design to ensure future impact amongst our beneficiaries is maximised. We have effectively communicated this M&amp;E modelling and impact measurement work, thus increasing external understanding of our work and success.</p>
<p><b>Process</b></p>	
<p>Efficiently manage GALVmed staff through the VITAL 1/VITAL 2 transition and ensure that GALVmed's future ambitions and needs are supported by an appropriate legal and office structure with a lean and appropriately skilled staff team.</p> <ul style="list-style-type: none"> <li>➤ Maintain proximity to and clear communication with staff through transition to VITAL 2 and apply staff retention mechanisms as appropriate.</li> <li>➤ Review GALVmed's organisational setup and ensure future GALVmed organisational and skill needs are met.</li> <li>➤ Refresh and further develop leadership skills of all GALVmed Senior Leaders and evolve GALVmed's current learning and development programme.</li> </ul>	
<p><b>Rating of Progress:</b></p> <p><i>Partially Achieved</i></p>	<p>The transition to VITAL 2 has been successfully managed, despite the added uncertainty surrounding the impending departure of two senior leaders in 2025-26, with clear communication to staff throughout. Progress with the VITAL 2 funding submission was well communicated to staff, who were regularly updated through virtual town halls and in-person department meetings. A comprehensive organisational review was completed and a structure developed to ensure that GALVmed has sufficient and appropriate skilled staff to deliver on programmes, which was subsequently ratified by the Board and funders. A leadership development programme was completed during the year to strengthen GALVmed's leadership and while the learning and development programme remains outstanding, GALVmed is well positioned to deliver this during 2025-26. Following a review of GALVmed's South Asia operations it was concluded that it was not possible to achieve transformational impact at scale in the region and the decision was made to suspend activities until at least 2026 and close the South Asia office with effect from 31<sup>st</sup> March 2025, resulting in one staff redundancy.</p>

*The Impact of our Work*

GALVmed has delivered significant impact in the livestock sector and for SSPs, driving change through a diverse portfolio of projects. Some achievements are measurable and immediately visible, with certain initiatives generating

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

tangible results within a year. Others, such as AAT 3 (a \$70m investment over 12 years) progress more slowly due to their nature. Some of our most important contributions, such as strengthening market systems and catalysing long-term impact and sustainability, are less visible but no less important.

Measuring our results and achievements is essential to understanding our progress and impact. Over time, our approach to measurement has evolved, ensuring that we capture meaningful results and lessons that inform our strategic direction. With a more structured M&E framework now in place, GALVmed is better equipped to capture and compare achievements and impact across projects. Additionally, we have expanded our metrics with a framework for capturing transformational market systems change, recognising its central role in catalysing impact and its primary focus in GALVmed's future strategy. Our comprehensive M&E framework will track progress across R&D, enabling environment, and commercial development, providing the insights needed to refine strategies, scale impact, and better capture our achievements. Additionally, greater emphasis on creating and capturing legacy impact and market systems change will ensure GALVmed's contribution towards shaping the sector is recognised.

Each year, GALVmed carries out a process for measuring Organisational Performance to understand what has been achieved during GALVmed's lifetime. During this exercise, we documented that:

- GALVmed initiatives over 2014 – 2023 have collectively sold an estimated 3.7 billion doses of vaccines, therapeutics, and other animal health products to SSP customers, via GALVmed's commercial partners, averting approximately 45 million livestock deaths.
- During the period from 2014 – 2023, a cumulative annual estimate of 6.6m SSP customers were reached with GALVmed-supported market development initiatives.
- Based on all products sold, the total estimated Gross Economic Benefit from doses sold of commercial development-enabled products was \$490m (not reflecting present day values).
- The total estimated Net Additional Benefit from doses sold of Commercial Development-enabled products is \$167m.
- Since 2010, six products have been taken to full development.

Data from our 2024 achievements is currently undergoing validation and quality control. The benefit is likely to be much larger over time, as these figures do not consider products which are currently in development and have yet to reach market or legacy impact from products taken to development and then commercialised post-project. Overall, progress in delivering benefit to our beneficiaries is positive. However, not all projects have met expectations where the VITAL 1 programme, in particular, fell short of its projected impact targets in serving SSPs despite a strong business performance. By analysing impact of past projects and applying these lessons, improvements can be identified such that GALVmed is better positioned to achieve greater scale and create lasting impact for SSPs.

**Financial Review**

Income in the year was £17.7m (2024: £9.6m) and total expenditure was £12.7m (2024: £10.3m).

*Income*

Restricted income of £16.3m (2024: £8.6m) includes £6.8m in respect of VITAL 2, £6.5m for AAT 3, £1.0m for VITAL 1, £1.0m for VITAL Bridging and £0.8m for EDSAP; funding for other programmes totalled £0.2m. Unrestricted income of £1.3m was received (2024: £1.0m) from contributions from programmes to overheads, and from interest.

*Expenditure*

Expenditure has increased to £12.3m (2024: £9.9m). AAT 3 costs of £3.4m make up the largest proportion of expenditure, 28% (2024: £2.9m, 29%). Expenditure on VITAL 1 increased to £2.7m, 22% (2024: £1.3m, 13%) and expenditure on VITAL Bridging decreased to £2.1m, 17% (2024: £2.5m, 25%). Unrestricted spend has increased marginally to £1.0m (2024: £0.9m).

An unrealised exchange loss of £0.4m has arisen (2023-24: loss of £0.4m) on the conversion of foreign currency balances at year end exchange rates. The loss is a result of the strengthening of Sterling against the US Dollar (in which most of the Company's funding is received) from 1.26 to 1.29 in the year. The Company minimises the effects of currency fluctuations by taking several steps, including contracting in the funded currency where possible and optimising the timing of foreign currency conversions.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a Company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

*Balance Sheet*

The level of cash held has increased from £16.1m to £20.9m in the year because of advanced VITAL 2, AAT 3 and EDSAP funding.

*Liquidity Management Policy*

The Company's liquidity management and investment objectives, responsibilities, risk, and strategy are clearly set out in a Liquidity Management Policy which is subject to review annually. The related liquidity and investment activity is reviewed quarterly by the Finance & Risk Committee. GALVmed's Liquidity Management Policy is driven by the need to have funds readily available to fund its activities in diverse geographies as well as to maintain the infrastructure of the organisation. As such, longer term investments are not appropriate in maintaining adequate cashflow.

*Climate Change*

The Board is committed to reducing the Company's greenhouse gas emissions, particularly those resulting from air travel. The Company generated and offset 470 tonnes of emissions in the year (2023-24: 332 tonnes). Carbon is offset through like-purposed initiatives. GALVmed has reviewed their approach to reducing their carbon footprint and identified several actions including the need to observe and support livestock-related climate change actors, and to support staff in actively reducing their individual ecological footprints in and outside the office, particularly by only travelling when necessary, with alternatives to air travel now a pre-requisite consideration before travel is undertaken.

*Reserves*

Reserves at 31 March 2025 total £22.9m (2024: £17.9m), of which available funds not tied up in fixed assets amount to £22.9m (2024: £17.9m). Reserves related to restricted funds of £19.3m (2024: £14.6m) mainly relate to advance funding for AAT 3 and VITAL 2.

*Unrestricted Reserves Policy*

Unrestricted reserves at 31 March 2025 amount to £3.5m (2024: £3.3m). From this amount, the Trustees have established a designated fund of £1.9m (2024: £1.6m) which comprises unrestricted reserves that have been set aside for any future shortfall in the recovery of overhead costs from programmes.

The objective of the Company's Unrestricted Reserves Strategy is to build sufficient funds to protect the Company from any adverse changes in its financial circumstances and to pursue operational opportunities that, in the initial phase, are not funded by 3<sup>rd</sup> parties. By considering a variety of risks, the Trustees have concluded that £1.2m of general unrestricted reserves is the minimum that should be held. General unrestricted reserves are currently held in excess of this to allow for the future investment in the 2030 Strategy and to ensure financial sustainability in the event of a reduction in funding during the VITAL 2 programme. The unrestricted reserves policy is reviewed every 6 months to ensure that it reflects current circumstances.

**Future Plans**

*Objectives*

GALVmed is operating in accordance with the vision of the 2030 Strategy. This builds upon the evolution of the Company since inception as a product development partnership working on a strong portfolio of new products, technologies and processes while continuing to facilitate scale-orientated private sector driven commercial development initiatives.

GALVmed has identified the following key strategic corporate objectives for 2025-26:



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

Objective	
1.	Delivery of GALVmed's funded projects in line with GALVmed purpose & project plans.
2.	Launch of VITAL 2 in line with funder approved VITAL 2 Implementation Plan.
3.	Develop new R&D project portfolio and corresponding R&D funding strategy.
4.	Explore options and make progress in delivering funds through funder diversification.
5.	Operate GALVmed transition to a new CEO and new Senior Director of Corporate Services & Finance without negative effects on business continuity and GALVmed sustainability.
6.	Analyse options for GALVmed's future Business Model (GALVmed 2030 & Beyond).

*Financial*

The 2025-26 expenditure budget is £17.4m, a 41% increase on 2024-25 actual expenditure. This increase is mainly because of the increased AAT 3 activity as the programme progresses through the next phase of development and spend in the first year of the VITAL 2 programme.

**Principal Risks and Uncertainties**

*Risk Management*

The Company's governance structure includes risk management. The Risk Management Policy details the Company's risk management objectives, processes, reporting and responsibilities. The Corporate Risk Register highlights the major risks to which the Company is exposed and for each risk the score, lead risk owner, mitigations and actions stated. It is maintained to support strategic, financial, and operational planning and therefore to assist in achieving the Company's objectives and targets. The key risks, that GALVmed faces at the time of this report, and key mitigations, are:

Risk	Key Mitigations
Limitations in design and implementation of project which affects achievement of wellbeing and economic impact for SSPs	Ensure that achieving SSP-impact is considered from conception to delivery of every GALVmed project and periodically evaluated and optimised throughout project implementation; and programme targets based on exemplar regions, initiatives and states, with assumptions confirmed with key stakeholders.
Barriers to product registration and importation reduces product availability	Support harmonisation of product registration in Africa; and engage with regulatory authorities, industry partners and international organisations.
Loss of highly experienced key staff impacts on project delivery, reputation & staff morale	Transition plan to ensure seamless handover and business continuity on recruitment of new CEO and Senior Director of Corporate Services & Finance; succession planning and managing staff expectations on career progression perspective; and development of training & development platform.
Change in government policy impacts on GALVmed's ability to achieve programme objectives or impact for SSPs at scale	Robust governance processes in place to allow effective decision making should a change in government priorities necessitate a change in geographic focus.
Geo-political instability impacts on GALVmed's beneficiaries, operations, and resources	Adopt a prudent approach to selecting countries of operation to safeguard partners and staff and increase level of success.
Working with selective commercial partners results in market distortion or perception of unfair practices	Ongoing implementation of the alliance approach to bring benefit to the wider vaccine market, and communication of this approach to challenge the perception of market distortion.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2025**

As well as the strategic risks noted in the table above, important financial risks are monitored and include the possible loss of bank deposits through fraud or theft, currency risk, liquidity risk and dependency on limited funding sources. The risk of loss of bank deposits is managed through the bank mandates in place and continued vigilance. Currency and liquidity risk are managed by following the Liquidity Management Policy. The 2030 Strategy and Funder Relations Strategy aims to address the limited funding sources issue.

**GOING CONCERN**

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. VITAL 2 commenced in January 2025 and combined with other ongoing programmes, will cover all direct (project support) costs to December 2029. Contributions from VITAL 2 and other current programmes are also forecast to be sufficient to fully cover indirect (organisational) costs during this time. Other programmes are fully funded.

The recent announcement of cuts to the British Government foreign aid budget may impact GALVmed in future years, but funding is assured from FCDO until at least March 2026. Beyond this and in the event of a funding reduction, cuts to project delivery may be required. There are, however, sufficient designated funds to cover any shortfall in direct or indirect costs until at least June 2026.

General unrestricted reserves are also sufficient to maintain the minimum balance of £1.2m required within the reserves policy. There are therefore sufficient funds to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

**STATEMENT OF DISCLOSURE OF INFORMATION TO AUDITORS**

Each of the Trustees who held office at the date of this Trustees Annual Report confirms that (a) so far as the Trustee is aware, there is no relevant information of which the organisation's auditor is unaware; and (b) he/or she has taken all steps that he/she ought to have taken as a Trustee to make himself/herself aware of any relevant audit information and to establish that the auditors are aware of that information.

**AUDITORS**

Henderson Loggie LLP, Chartered Accountants, were reappointed as auditors to the Company at the Annual General Meeting in 2024. Their re-appointment was approved for an initial three-year term from 2022 subject to annual consideration by both parties.

The Directors' Annual Report is signed by the Chair on behalf of the Board of Directors. The Directors also approve the Strategic Report, which is contained within the Annual Report, in their capacity as Company directors.

  
Isabelle Dieuzy-Labaye - 2025-06-26, 15:39:21 UTC

Dr I Dieuzy-Labaye



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a Company limited by guarantee)**

**RESPONSIBILITIES OF THE TRUSTEES**  
**For the year ended 31 March 2025**

The Trustees (who are also the Directors for the purposes of Company law) are responsible for the preparation of the Trustees' Report, including the Strategic Report, and financial statements in accordance with applicable law and regulations.

Law applicable to incorporated charities in Scotland requires the Trustees to prepare an annual report and financial statements for each financial year in accordance with applicable law and regulations. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).

Under Company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity at the end of the year and of its financial activities including its income and expenditure during the year then ended. In preparing those financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper and adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006, with the Charities and Trustee Investment (Scotland) Act 2005, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the maintenance and integrity of the charity.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2025

**Opinion**

We have audited the financial statements of Global Alliance for Livestock Veterinary Medicines (the 'charitable Company') for the year ended 31 March 2025 which comprise the Income and Expenditure Account and Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable Company's affairs as at 31 March 2025, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charitable Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the Trustees' (who are also the directors of the charitable Company for the purpose of Company law) use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2025

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable Company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report, included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement, as set out on page 12, the trustees (who are also the directors of the charitable Company for the purposes of Company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable Company or to cease operations, or have no realistic alternative but to do so.

**Auditor responsibilities for the audit of the financial statements**

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below:

As part of our planning process:

- We enquired of management the systems and controls the charitable Company has in place, the areas of the financial statements that are mostly susceptible to the risk of irregularities and fraud, and whether there was any known, suspected or alleged fraud.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2025

- We obtained an understanding of the legal and regulatory frameworks applicable to the charitable Company. We determined that the following were most relevant: FRS 102; environmental waste; employment law (including the Working Time Directive); and compliance with the UK Companies Act and charity legislation;
- We considered the incentives and opportunities that exist in the charitable Company, including the extent of management bias, which present a potential for irregularities and fraud to be perpetrated, and tailored our risk assessment accordingly; and
- Using our knowledge of the charitable Company, together with the discussions held with management at the planning stage, we formed a conclusion on the risk of misstatement due to irregularities including fraud and tailored our procedures according to this risk assessment.

The key procedures we undertook to detect irregularities including fraud during the course of the audit included:

- Enquiries with management about any known or suspected instances of non-compliance with laws and regulations and fraud;
- Reviewing Board meeting minutes for discussions of irregularities including fraud;
- Reading correspondence with regulators to determine the extent of compliance;
- Challenging assumptions and judgements made by management in their significant accounting estimates, in particular in relation to the carrying value of tangible assets and accruals;
- Auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness;
- Testing key revenue lines, in particular cut-off, for evidence of management bias; and
- Reviewing the financial statement disclosures and determining whether accounting policies have been appropriately applied

Owing to the inherent limitations of an audit, there is unavoidable risk that some material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISAs (UK). For instance, the further removed non-compliance is from the events and transactions reflected in the financial statements, the less likely the auditor is to become aware of it or to recognise the non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. The primary responsibility for the prevention and detection of irregularities and fraud rests with the Trustees.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

### **Use of our report**

This report is made solely to the charitable Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable Company's Trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable Company's members and Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable Company, the charitable Company's members as a body and the charitable Company's Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

  
Keith Macpherson – 2025-06-26, 16:49:15 UTC

### **Keith Macpherson (Senior Statutory Auditor)**

For and on behalf of Henderson Loggie LLP  
Chartered Accountants  
Statutory Auditor

Henderson Loggie LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006.  
The Stamp Office, Level 5  
10-14 Waterloo Place, Edinburgh, EH1 3EG

..... 2025

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**INCOME AND EXPENDITURE ACCOUNT AND  
STATEMENT OF FINANCIAL ACTIVITIES**  
For the year ended 31 March 2025

	Notes	Unrestricted £	Restricted £	Total 2025 £	Total 2024 £
<b>Income from:</b>					
Charitable Activities	<b>2</b>	1,243,361	16,016,594	17,259,955	9,078,485
Investments		92,421	312,684	405,105	541,568
<b>Total Income</b>		<u>1,335,782</u>	<u>16,329,278</u>	<u>17,665,060</u>	<u>9,620,053</u>
<b>Expenditure on:</b>					
Charitable Activities	<b>3</b>	1,018,643	11,284,882	12,303,525	9,922,453
Other: Loss on Foreign Exchange	<b>6</b>	81,138	293,862	375,000	355,658
<b>Total Expenditure</b>		<u>1,099,781</u>	<u>11,578,744</u>	<u>12,678,525</u>	<u>10,278,111</u>
<b>Net Income/(Expenditure)</b>	<b>5</b>	<u>236,001</u>	<u>4,750,534</u>	<u>4,986,535</u>	<u>(658,058)</u>
Net Movement in Funds		236,001	4,750,534	4,986,535	(658,058)
<b>Reconciliation of Funds</b>					
Total Funds Brought Forward at 1 April 2024	<b>12</b>	<u>3,307,302</u>	<u>14,558,740</u>	<u>17,866,042</u>	<u>18,524,100</u>
Total Funds Carried Forward at 31 March 2025	<b>12</b>	<u>3,543,303</u>	<u>19,309,274</u>	<u>22,852,577</u>	<u>17,866,042</u>

All the results of the Company relate to continuing activities.

The Company has no recognised gains or losses other than those set out above.


The notes on pages 19 to 30 form part of these financial statements

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**BALANCE SHEET**  
As at 31 March 2025

	Notes	2025		2024	
		£	£	£	£
<b>Fixed Assets</b>					
Tangible Assets	8		38,574		38,763
<b>Current Assets</b>					
Debtors	9	2,429,265		2,246,514	
Bank and Cash Balances	10	20,854,917		16,061,958	
		<u>23,284,182</u>		<u>18,308,472</u>	
<b>Liabilities</b>					
Creditors: Amounts Falling Due Within One Year	11	(470,179)		(481,193)	
<b>Net Current Assets</b>			22,814,003		17,827,279
<b>Total Net Assets</b>			<u>22,852,577</u>		<u>17,866,042</u>
<b>Unrestricted Funds</b>					
General Reserve	12		1,679,031		1,735,025
Designated Funds	12		1,864,272		1,572,277
Total Unrestricted Funds			<u>3,543,303</u>		<u>3,307,302</u>
<b>Restricted Income Funds</b>	12		19,309,274		14,558,740
<b>Total Funds</b>			<u>22,852,577</u>		<u>17,866,042</u>

The financial statements were considered and approved by the Trustees on the 11 June 2025 and signed on their behalf by:

  
 Tom Mitchell - 2025-06-25, 10:57:22 UTC

Dr. T Mitchell  
**Company No: 05393391**

The notes on pages 19 to 30 form part of these financial statements

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**STATEMENT OF CASH FLOWS**  
For the year ended 31 March 2025

	Notes	2025 £	2024 £
<b>Cash Flows from Operating Activities:</b>			
<b>Net Cash Provided/(Used) by Operating Activities</b>	<b>16</b>	4,568,925	(3,424,589)
<i>Cash Flows from Investing Activities:</i>			
Interest from Investments		617,977	516,110
Purchase of Property, Plant and Equipment		(18,943)	(41,138)
Net Cash Used in Investing Activities		<u>599,034</u>	<u>474,972</u>
<b>Change in Cash and Cash Equivalents in the Reporting Period</b>		5,167,959	(2,949,617)
Cash and Cash Equivalents at the Beginning of the Reporting Period		16,061,958	19,367,233
Change in Cash and Cash Equivalents due to Exchange Rate Movements		(375,000)	(355,658)
<b>Cash and Cash Equivalents at the End of the Reporting Period</b>		<u><u>20,854,917</u></u>	<u><u>16,061,958</u></u>
 <b>Analysis of Cash and Cash Equivalents</b>			
Bank and Cash Balances		<u><u>20,854,917</u></u>	<u><u>16,061,958</u></u>

The notes on pages 19 to 30 form part of these financial statements



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a Company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2025**

**1. Accounting Policies**

*Basis of accounting*

GALVmed is a public benefit entity. It is a Company limited by guarantee and is registered as a charity with the Charity Commission and the Office of the Scottish Charity Regulator (OSCR). It is incorporated in the UK with its registered office in London, UK and its principal office in Edinburgh, UK (see Reference & Administrative Details on page 2). The financial statements have therefore been prepared in accordance with the Companies Act 2006, applicable accounting standards, Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 as amended in 2010, and the Charities Act 2011. They have also been prepared under historical cost accounting rules. The financial statements are prepared in Sterling, which is the functional currency of the Company. Monetary amounts in these financial statements are rounded to the nearest pound.

*Going concern*

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. VITAL 2 commenced in January 2025 and combined with other ongoing programmes, will cover all direct (project support) costs to December 2029. Contributions from VITAL 2 and other current programmes are also forecast to be sufficient to fully cover indirect (organisational) costs during this time. Other programmes are fully funded.

The recent announcement of cuts to the British Government foreign aid budget may impact GALVmed in future years, but fundings is assured from FCDO until at least March 2026. Beyond this and in the event of a funding reduction, cuts to project delivery may be required. There is, however, sufficient designated funds to cover any shortfall in direct or indirect costs until at least June 2026.

General unrestricted reserves are also sufficient to maintain the minimum balance of £1.2m required within the reserves policy. There are therefore sufficient funds to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

*Fund accounting*

Funds received on which no restrictions are placed as to their use are accounted for as unrestricted funds. Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in note 12.

Funds received for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose, are accounted for as restricted funds.

*Income*

Funds received are recognised as income from charitable activities once there is entitlement, reasonable probability of receipt and the amount can be measured with sufficient reliability. Income is deferred where funder-imposed conditions that specify the performance conditions or time period in which the funds can be spent have not yet been met.

Investment income is recognised as earned.

*Value Added Tax (VAT)*

Expenditure is accounted for inclusive of VAT where appropriate as the Company is not registered for VAT.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**1. Accounting Policies (continued)**

*Pension scheme*

The Company provides a defined contribution pension scheme for its staff and the pension charge in the Statement of Financial Activities (SOFA) represents the amounts payable by the Company to the Company Personal Pension Scheme in respect of the year.

*Operating leases*

Rentals payable under operating leases are charged to the SOFA on the straight-line basis over the lease term.

*Expenditure*

Expenditure is recognised on the accruals basis when a legal and/or constructive obligation exists. Expenditure through contractual agreements is recognised as goods and services are supplied. Grant payments are recognised as expenditure when payments are due in accordance with the terms of the contract.

Costs incurred by the Company in the delivery of its activities and services are accounted for as charitable expenditure and categorised in the SOFA by the main activities of the Company. Each category includes direct costs and support costs and, where support costs cannot be directly attributed to a category, they are apportioned on the basis of headcount.

Costs that, whilst necessary to deliver an activity do not themselves contribute directly to GALVmed's activity, are accounted for as support costs. Support costs include central office functions such as management, finance, information systems and administration activities.

*Foreign currency*

Foreign currency transactions are recorded in Sterling at the previous month's month-end rate of exchange. Monetary assets and liabilities denominated in foreign currencies are translated into Sterling at the exchange rate at the balance sheet date.

All exchange differences are recognised through the SOFA.

*Tangible fixed assets*

Tangible fixed assets costing more than £1,000 are capitalised and stated at cost and depreciated over their useful economic lives as follows:

Office equipment	4 years
Computer equipment & software	3 years
Leasehold improvements	over the life of the lease

Assets are only depreciated when they are brought into use and depreciated up to, but not including the month of disposal.

*Financial instruments*

The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

*Debtors and prepayments*

Debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**1. Accounting Policies (continued)**

*Cash at bank and in hand*

Cash at bank and in hand includes cash and short term highly liquid investments with a maturity of six months or less from the date of acquisition or opening of the deposit or similar account.

*Creditors*

Creditors are recognised where the Company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party in the future and the amount due to settle obligations can be measured or estimated reliably. Creditors are recognised at their settlement amount.

*Critical accounting judgements and estimation uncertainty*

In preparing the financial statements, the Trustees are required to make judgements, estimates and assumptions, which may affect reported income, expenditure, assets and liabilities. The estimates and associated assumptions are based on historical experience and other factors considered relevant. Actual results may differ from such estimates. Judgements made in preparing these financial statements comprise:

- The applicability of the estimated useful lives of fixed assets used to calculate the period over which depreciation is applied.
- The review of fixed assets for impairment or obsolescence.
- The assessment of leases to determine whether the risks and rewards of ownership remain with the lessor or are transferred to GALVmed.

**2. Income from Charitable Activities**

	UK Grant Funding - FCDO £	UK Grant - Other £	Overseas Grant Funding £	2025 £	2024 £
<b>Restricted income</b>					
AAT 3	1,377,157	(11,548)	5,041,275	6,406,884	2,113,151
VITAL 2	137,225	(17,948)	6,677,385	6,796,662	-
VITAL 1	1,354,156	(59,297)	(315,736)	979,123	1,912,019
AgResults Brucellosis	-	-	(13,005)	(13,005)	(16,011)
Regulatory Harmonisation	-	-	(77,549)	(77,549)	1,749,081
AgResults FMD	-	-	346,942	346,942	446,133
EDSAP	164,132	(21,407)	624,755	767,480	-
MoTAR	-	-	(115,232)	(115,232)	1,275,931
MAHABA	-	-	(1,683)	(1,683)	745,053
Bovine TB	-	-	(17,630)	(17,630)	(48,842)
PREVENT	-	-	(42,132)	(42,132)	405,533
VITAL Bridging	-	-	986,734	986,734	(375,774)
Boehringer Ingelheim	-	-	-	-	(5,830)
<b>Total restricted income</b>	<b>3,032,670</b>	<b>(110,200)</b>	<b>13,094,124</b>	<b>16,016,594</b>	<b>8,200,444</b>
<b>Unrestricted income</b>	<b>-</b>	<b>110,200</b>	<b>1,133,161</b>	<b>1,243,361</b>	<b>878,041</b>
<b>Total income</b>	<b>3,032,670</b>	<b>-</b>	<b>14,227,285</b>	<b>17,259,955</b>	<b>9,078,485</b>

The negative income noted for each programme above is because of indirect core contributions towards unrestricted funds, with the exception of PREVENT, which also includes a historic income adjustment.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**3. Analysis of Expenditure**

	<b>Support</b>	<b>Governance</b>	<b>Staff</b>	<b>Direct Cost</b>	<b>Total 2025</b>	<b>Total 2024</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
AAT 3	1,202	-	29,447	3,402,106	3,432,755	2,861,357
VITAL 2	57,406	-	285,836	119,077	462,319	-
VITAL 1	197,724	-	384,248	2,096,470	2,678,442	1,290,529
AgResults Brucellosis	1,372	-	-	85,330	86,702	106,737
Regulatory Harmonisation	379	-	22,484	969,360	992,223	-
AgResults FMD	4,139	-	98,082	239,699	341,920	287,488
EDSAP	-	-	7,612	251,333	258,945	-
MoTAR	-	-	-	768,214	768,214	974
MAHABA	-	-	-	33,654	33,654	744,703
Bovine TB	-	-	-	117,531	117,531	325,615
PREVENT	-	-	-	47,128	47,128	787,133
VITAL Bridging	158,989	-	520,486	1,385,574	2,065,049	2,505,161
Boehringer Ingelheim	-	-	-	-	-	109,297
Unrestricted	119,318	155,022	502,001	242,302	1,018,643	903,459
<b>Total 2025</b>	<b>540,529</b>	<b>155,022</b>	<b>1,850,196</b>	<b>9,757,778</b>	<b>12,303,525</b>	<b>9,922,453</b>
<b>Total 2024</b>	<b>461,970</b>	<b>129,336</b>	<b>1,738,585</b>	<b>7,592,562</b>		<b>9,922,453</b>

**Analysis of Support Costs**

	<b>Professional Fees</b>	<b>Office Costs</b>	<b>Information Technology</b>	<b>Audit Fees</b>	<b>Total 2025</b>	<b>Total 2024</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
AAT 3	-	-	1,202	-	1,202	1,474
VITAL 2	5,295	29,997	22,114	-	57,406	-
VITAL 1	124,055	38,115	35,554	-	197,724	2,254
AgResults Brucellosis	-	264	1,108	-	1,372	1,246
Regulatory Harmonisation	-	-	379	-	379	-
AgResults FMD	-	-	4,139	-	4,139	3,828
VITAL Bridging	32,372	84,366	42,368	(117)	158,989	388,858
Unrestricted	53,596	31,458	16,909	17,355	119,318	64,310
<b>Total 2025</b>	<b>215,318</b>	<b>184,200</b>	<b>123,773</b>	<b>17,238</b>	<b>540,529</b>	<b>461,970</b>
<b>Total 2024</b>	<b>134,097</b>	<b>190,717</b>	<b>121,400</b>	<b>15,756</b>		<b>461,970</b>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**4. Staff Costs**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Total staff costs were as follows:		
Salaries	1,574,451	1,479,848
Social security costs	127,857	123,734
Pension contributions	105,138	95,504
Other employee benefits	42,750	39,499
	<u>1,850,196</u>	<u>1,738,585</u>

The average number of employees during the year was:

	<b>Number</b>	<b>Number</b>
Management	3	5
Project staff	11	10
Support staff	14	12
	<u>28</u>	<u>27</u>

During the year, the Company incurred expenses of £3,449 on behalf of, or reimbursed expenses to, 9 Trustees in connection with their governance responsibilities (2024: £6,761, 7 Trustees). Two face-to-face meetings took place in 2024-25. No expenses were incurred for persons or entities connected with the Trustees (2024: £nil). No Trustees received remuneration in relation to consultancy services provided (2024: £nil).

GALVmed provides to its UK-based staff a defined contribution pension scheme, the GALVmed Personal Pension Scheme, which is operated by Aviva. Total employer contributions in the year were £65,850 (2024: £62,255). The total number of members in the scheme at 31 March 2025 was 17 (2024: 17).

To compensate for the fact that there is currently no pension scheme for international staff, an employer contribution of 6% of salary is paid to such staff on the understanding that this contribution should be paid into a pension scheme of their choice. The total of such contributions in respect of the year were £39,288 (2024: £33,249).

The following number of employees received total employee salary and benefits (excluding employer pension) in excess of £60,000 in the period:

	<b>2025</b>	<b>2024</b>
£60,000 - £69,999	4	3
£70,000 - £79,999	2	2
£80,000 - £89,999	2	2
£90,000 - £99,999	1	-
£160,000 - £169,999	-	1
£170,000 - £179,999	1	-

GALVmed considers the key management of the Company to be the GALVmed Leadership Team (GLT), comprising the Chief Executive Officer, Executive Directors, and Senior Directors. The total cost of the employment of key management in the year was £478,963 (2024: £537,988), with a further £253,927 paid to two consultants (2024: £192,578, paid to two consultants). Employer pension contributions for key management totalled £25,751 (2024: £28,887).

One position was made redundant during 2024-25. Redundancy costs of £26,066 (2024: £7,392) were incurred in the year. There are no redundancy payments outstanding at the year end.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**5. Net Income**

	<b>2025</b>	<b>2024</b>
	£	£
This is stated after charging:		
- Auditor's remuneration – audit fees	17,238	15,756
- Depreciation	19,132	17,618
- Operating leases		
Land and buildings	120,100	122,240
Equipment	1,000	1,162

Auditors' remuneration includes £1,698 (2024: £1,416) for audit fees payable in India and £15,540 (2024: £14,340) for audit fees in the UK.

**6. Exchange Gains and Losses**

Unrealised gains and losses on foreign exchange relate to the revaluation of GALVmed's net current assets at 31 March 2025 and are included in other expenditure (see note 12 for breakdown by programme). The loss of £375,000 (2024: £355,658 loss) relates to advance funding in US Dollars and a strengthening of Sterling against the US Dollar.

In addition, a realised loss of £452 (2024: £25,194 loss) is included in expenditure on charitable activities, which is a result of the difference between the currency rate invoiced and the currency rate paid to suppliers. GALVmed undertakes a variety of exchange mechanisms throughout the year to minimise realised exchange differences and help ensure there are adequate resources to deliver the programme outputs.

**7. Taxation**

The Company has charitable status and is not liable for Corporation or Capital Gains tax on income and gains which is applied to its charitable purposes.

**8. Tangible Assets**

	<b>Leasehold improvements</b>	<b>Office equipment</b>	<b>Computer equipment</b>	<b>Total</b>
	£	£	£	£
<b>Cost</b>				
At 1 April 2024	12,430	7,267	249,564	269,261
Additions	-	-	18,943	18,943
Disposals	-	-	(3,375)	(3,375)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2025	12,430	7,267	265,132	284,829
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
<b>Depreciation</b>				
At 1 April 2024	12,343	7,267	210,888	230,498
Charge for year	87	-	19,045	19,132
Eliminated on disposal	-	-	(3,375)	(3,375)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2025	12,430	7,267	226,558	246,255
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
<b>Net book value</b>				
At 31 March 2025	-	-	38,574	38,574
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
At 31 March 2024	87	-	38,676	38,763
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**9. Debtors**

	<b>2025</b>	<b>2024</b>
	£	£
Prepayments and accrued income	2,388,232	1,993,151
Other debtors	41,033	253,363
	2,429,265	2,246,514
	2,429,265	2,246,514

Prepayments and accrued income include £86,458 (2024: £131,400) of accrued income in relation to the AgResults Foot and Mouth Disease (FMD) programme, £1,170,825 (2024: £nil) of accrued income for the AAT 3 programme, £571,319 (2024: £nil) of accrued income for the VITAL 1 programme, £137,224 (2024: £nil) of accrued income for the VITAL 2 programme, £164,132 (2024: £nil) of accrued income for the EDSAP programme and £nil (2024: £1,749,081) of accrued income for the Regulatory Harmonisation programme. Other debtors include accrued investment income of £2,824 (2024: £215,696).

**10. Bank and Cash Balances**

	<b>2025</b>	<b>GBP</b>	<b>USD</b>	<b>Other currencies</b>	<b>Total</b>
		£	£	£	£
Lloyds Bank		1,385,399	7,800,417	468,213	9,654,029
Bank of Scotland		-	6,825,789	-	6,825,789
NatWest		-	4,366,788	-	4,366,788
Standard Chartered		-	5,011	-	5,011
Cash		328	1,661	1,311	3,300
		1,385,727	18,999,666	469,524	20,854,917
		1,385,727	18,999,666	469,524	20,854,917
				<b>Other currencies</b>	<b>Total</b>
				£	£
Lloyds Bank		1,041,725	5,225,579	57,373	6,324,677
Bank of Scotland		516,699	2,928,465	941,899	4,387,063
NatWest		-	5,326,686	-	5,326,686
Standard Chartered		-	-	19,589	19,589
Cash		392	2,743	808	3,943
		1,558,816	13,483,473	1,019,669	16,061,958
		1,558,816	13,483,473	1,019,669	16,061,958

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**11. Creditors: Amounts Falling Due Within One Year**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Trade creditors	244,536	261,472
Accruals	217,166	199,535
Deferred income	-	-
Other creditors	8,477	20,186
	<b>470,179</b>	<b>481,193</b>
	<b>470,179</b>	<b>481,193</b>
Deferred income reconciliation:	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Balance brought forward	-	210,076
Amount released to the Statement of Financial Activities	-	(210,076)
Amount deferred in the year	-	-
	-	-
Balance carried forward	-	-

**12. Funds Movement**

	31 March 2024	Income	Expenditure	Exchange (loss)/gain	Transfers	31 March 2025
<b>2025</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
<b>Restricted funds:</b>						
AAT 3	3,483,597	6,537,779	(3,432,755)	(113,191)	-	6,475,430
VITAL 2	-	6,801,371	(462,319)	18,306	-	6,357,358
VITAL 1	4,590,094	1,040,341	(2,678,442)	(39,692)	-	2,912,301
AgResults Brucellosis	1,068,004	21,350	(86,702)	(22,279)	-	980,373
Regulatory Harmonisation	1,749,081	(49,036)	(992,223)	(52,726)	-	655,096
AgResults FMD	580,077	357,715	(341,920)	(14,984)	-	580,888
EDSAP	-	771,451	(258,945)	31,227	-	543,733
MoTAR	1,291,164	(90,168)	(768,214)	(54,962)	-	377,820
MAHABA	394,550	1,584	(33,654)	(19,716)	-	342,764
Bovine TB	129,218	(15,615)	(117,531)	47,399	-	43,471
PREVENT	139,372	(42,132)	(47,128)	(10,072)	-	40,040
VITAL Bridging	1,133,583	994,638	(2,065,049)	(63,172)	-	-
Total restricted funds	<b>14,558,740</b>	<b>16,329,278</b>	<b>(11,284,882)</b>	<b>(293,862)</b>	<b>-</b>	<b>19,309,274</b>
	<b>14,558,740</b>	<b>16,329,278</b>	<b>(11,284,882)</b>	<b>(293,862)</b>	<b>-</b>	<b>19,309,274</b>
<b>Unrestricted funds:</b>						
General reserve	1,735,025	1,335,782	(1,018,643)	(81,138)	(291,995)	1,679,031
Designated funds:						
Indirect future costs	1,572,277	-	-	-	291,995	1,864,272
Total unrestricted funds	<b>3,307,302</b>	<b>1,335,782</b>	<b>(1,018,643)</b>	<b>(81,138)</b>	<b>-</b>	<b>3,543,303</b>
	<b>3,307,302</b>	<b>1,335,782</b>	<b>(1,018,643)</b>	<b>(81,138)</b>	<b>-</b>	<b>3,543,303</b>
<b>Total funds</b>	<b>17,866,042</b>	<b>17,665,060</b>	<b>(12,303,525)</b>	<b>(375,000)</b>	<b>-</b>	<b>22,852,577</b>
	<b>17,866,042</b>	<b>17,665,060</b>	<b>(12,303,525)</b>	<b>(375,000)</b>	<b>-</b>	<b>22,852,577</b>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**12. Funds Movement (continued)**

2024	31 March 2023	Income	Expenditure	Exchange (loss)/gain	Transfers	31 March 2024
	£	£	£	£	£	£
<b>Restricted funds:</b>						
AAT 3	4,196,382	2,219,596	(2,861,357)	(71,024)	-	3,483,597
VITAL 1	3,872,664	2,076,521	(1,290,529)	(68,562)	-	4,590,094
AgResults Brucellosis	1,172,091	26,349	(106,737)	(23,699)	-	1,068,004
Regulatory Harmonisation	-	1,749,081	-	-	-	1,749,081
AgResults FMD	415,468	452,272	(287,488)	(175)	-	580,077
MoTAR	-	1,283,595	(974)	8,543	-	1,291,164
MAHABA	398,248	748,919	(744,703)	(7,914)	-	394,550
Bovine TB	501,982	(34,597)	(325,615)	(12,552)	-	129,218
PREVENT	529,183	409,951	(787,133)	(12,629)	-	139,372
VITAL Bridging	4,025,404	(295,954)	(2,505,161)	(90,706)	-	1,133,583
Boehringer Ingelheim	113,759	(5,830)	(109,297)	1,368	-	-
Total restricted funds	<u>15,225,181</u>	<u>8,629,903</u>	<u>(9,018,994)</u>	<u>(277,350)</u>	<u>-</u>	<u>14,558,740</u>
<b>Unrestricted funds:</b>						
General reserve	1,753,614	990,150	(903,459)	(78,308)	(26,972)	1,735,025
Designated funds:						
Indirect future costs	1,545,305	-	-	-	26,972	1,572,277
Total unrestricted funds	<u>3,298,919</u>	<u>990,150</u>	<u>(903,459)</u>	<u>(78,308)</u>	<u>-</u>	<u>3,307,302</u>
<b>Total funds</b>	<u><u>18,524,100</u></u>	<u><u>9,620,053</u></u>	<u><u>(9,922,453)</u></u>	<u><u>(355,658)</u></u>	<u><u>-</u></u>	<u><u>17,866,042</u></u>

*Programme Objectives and Funding*

The purpose of the AAT 3 programme is to build upon the success of the work carried out under previous AAT programmes resulting in the improved tools for the control of Animal African Trypanosomiasis. The specific objective of AAT 3 is the commercial development of a registered therapeutic trypanocidal product, ready for sale through GALVmed's commercial partner in the AAT 3 programme, Boehringer Ingelheim. This programme is funded by both TGF (\$28.9m) and FCDO (\$5.4m).

The VITAL 2 programme aims to support commercial vaccine manufacturers in their development of the African vaccine ruminant market and in doing so, deliver the nucleus of a private vaccine market capable of stimulating further investments to increase vaccination coverage rates. It also aims to further expand the portfolio of ruminant vaccines available to the private sector through R&D product development work. This programme is jointly funded by TGF (\$35.8m) and FCDO (\$12.5m).

The VITAL 1 programme has two strands: product development and commercial development. The broad objectives are: 1) to develop six new high impact livestock vaccines ready for commercial production and suitable for widespread use by smallholders in Africa and South Asia; and 2) to partner the animal health industry to establish five large scale portfolio distribution networks in Africa and South Asia with each initiative being capable of generating positive cash flows by year 4 and achieving subsequent growth and expansion through these cash flows. The programme is jointly funded by TGF (80%) and FCDO (20%). This programme was contracted to end on 30 September 2022 but was then awarded a no-cost extension to December 2025 for TGF and March 2025 for FCDO because of delays associated with COVID-19. This will allow the programme objectives to be fully achieved beyond the initial contractual end date.

The AgResults Brucellosis programme is a competition, managed by GALVmed, to develop and register a safe and efficacious vaccine against *Brucella melitensis*, the main cause of human infections with Brucella and a significant economic burden in developing countries. It is fully funded by the AgResults consortium.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a Company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2025**

**12. Funds Movement (continued)**

Regulatory Harmonisation programme is fully funded by TGF and is carried out in partnership with Veterinary Medicines Directorate, World Organisation for Animal Health and East African Community. Its objective is to improve the registration system for veterinary medicines across Sub-Saharan Africa countries and harmonise the requirements to simplify the process, improve affordability, save time, and resources and to help ensure quality, safety, and efficacy of products.

The AgResults Foot and Mouth programme is a competition, managed by GALVmed, to encourage the development and uptake of an improved FMD vaccine tailored for the needs and requirements of East Africa. It is fully funded by the AgResults Consortium.

The EDSAP programme seeks to contribute to improved disease surveillance in Africa through improved laboratory diagnostic capacities and improved capabilities of three private sector poultry companies in Ethiopia, Tanzania and Nigeria. The programme is jointly funded by TGF (\$1.5m) and FCDO (\$1.8m).

The MoTAR programme is fully funded by TGF and is carried out in partnership with Makerere University. It aims to provide Uganda with an effective means of controlling tick acaricide resistance (TAR) and tick-borne diseases (TBD), key constraints in sustainable livestock production. This will be achieved through the development of an online mapping tool showing relevant distribution patterns and through the establishment of a network of laboratories capable of delivering the necessary diagnostic and testing services for TAR/TBD on an ongoing, sustainable basis.

The MAHABA (Managing Animal Health and Acaricides for a Better Africa) programme is fully funded by TGF and is carried out in partnership with Elanco Animal Health. The aim of the programme is to create effective tick control for SSPs, by building a clear understanding of acaricide usage, developing innovative methods to help educate on the effective use and by providing practical methods to counter resistance, avoid failures and allow sustainable tick control.

The Bovine TB programme aims to enable and accelerate the development and implementation of rational evidence-based approaches to control TB, with a focus on India, and to provide a strong foundation for the development of control programmes in other developing countries. This project will establish and publish Target Product Profiles for novel tools to control TB and develop a roadmap for product development and commercialisation of novel diagnostic tests in India.

The PREVENT (Promoting and Enabling Vaccination Efficiently, Now and Tomorrow) programme is fully funded by TGF and is carried out in partnership with Ceva Santé Animale. The aim of this programme is to create an efficient sector of medium-sized African hatcheries applying hatchery vaccination and proactive marketing methods to initiate and increase vaccinated chick sales to poultry small scale producers.

The VITAL Bridging programme aims to support the development and initiation of new programmes of work which will progress the next phase of work beyond VITAL 1 and reflect the essence of the GALVmed 2030 strategy. This programme is funded by TGF (\$7.7m).

The Boehringer Ingelheim (BI) programme is fully funded by TGF and is carried out in partnership with BI. Its objective is to deliver a viable business model for providing quality veterinary healthcare to smallholder farmers in Africa. The key activities for this programme are 1) a registration initiative of BI products in three key markets; and 2) a distribution and awareness initiative which accelerates the accessibility of a portfolio of products to areas which are normally very difficult to access through usual distribution networks.

The general reserve represents the free funds of the charity. Designated funds comprise unrestricted funds that have been set aside by the Trustees for a particular purpose. Organisational (indirect) costs need to be covered by contributions from all programmes. Cumulative net indirect core cost contributions have been designated by the Board at 31 March 2025 to fund future indirect costs.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**13. Total Assets – Analysed Between Funds**

<b>2025</b>	<b>Fixed assets £</b>	<b>Net current assets £</b>	<b>Total £</b>
<b>Restricted funds</b>			
AAT 3	2,127	6,473,303	6,475,430
VITAL 2	-	6,357,358	6,357,358
VITAL 1	-	2,912,301	2,912,301
AgResults Brucellosis	992	979,381	980,373
Regulatory Harmonisation	1,511	653,585	655,096
AgResults FMD	986	579,902	580,888
EDSAP	-	543,733	543,733
MoTAR	-	377,820	377,820
MAHABA	-	342,764	342,764
Bovine TB	-	43,471	43,471
PREVENT	-	40,040	40,040
	5,616	19,303,658	19,309,274
<b>Unrestricted funds</b>			
General reserve	32,958	1,646,073	1,679,031
Designated funds	-	1,864,272	1,864,272
<b>Total</b>	38,574	22,814,003	22,852,577

<b>2024</b>	<b>Fixed assets £</b>	<b>Net current assets £</b>	<b>Total £</b>
<b>Restricted funds</b>			
AAT 3	1,081	3,482,516	3,483,597
VITAL 1	-	4,590,094	4,590,094
AgResults Brucellosis	1,586	1,066,418	1,068,004
Regulatory Harmonisation	-	1,749,081	1,749,081
AgResults FMD	2,301	577,776	580,077
MoTAR	-	1,291,164	1,291,164
MAHABA	-	394,550	394,550
Bovine TB	-	129,218	129,218
PREVENT	-	139,372	139,372
VITAL Bridging	-	1,133,583	1,133,583
	4,968	14,553,772	14,558,740
<b>Unrestricted funds</b>			
General reserve	33,795	1,701,230	1,735,025
Designated funds	-	1,572,277	1,572,277
<b>Total</b>	38,763	17,827,279	17,866,042

**14. Operating Lease Commitments**

At 31 March 2025 GALVmed was committed to a total of future minimum lease payments under non-cancellable operating leases for land, buildings, and equipment for each of the following periods:

	<b>2025 £</b>	<b>2024 £</b>
Not later than one year	57,301	80,019
Later than one year and not later than five years	88,969	18,198
<b>Total</b>	146,270	98,217

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a Company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2025

**15. Share Capital**

The Company is limited by guarantee and does not have share capital.

**16. Reconciliation of Net Income to Net Cash Flow from Operating Activities**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
<b>Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)</b>	4,986,535	(658,058)
<b>Adjustments for:</b>		
Loss on foreign exchange transactions	375,000	355,658
Depreciation charges	19,132	17,618
Interest from investments	(405,105)	(541,568)
(Increase) in debtors	(395,623)	(1,802,404)
(Decrease) in creditors	(11,014)	(795,835)
<b>Net cash provided/(used) by operating activities</b>	<b>4,568,925</b>	<b>(3,424,589)</b>

Debtors contains accrued investment income of £2,824 (2024: £215,696). The movement on accrued investment income is included in investments within the cash flow statement.

**17. Related Parties**

During the year £182,417 (2024: £160,895) was paid to International Livestock Research Institute (ILRI), a Company in which Fabian Kausche, Trustee, is the Deputy Director of Research and Innovation. The amount paid included £53,400 (2024: £54,308) relating to rental charges for the Nairobi office and £129,017 (2024: £106,587) relating to contracted work for livestock disease surveyance in Kenya as part of the VITAL 1 programme and quantitative gender analysis as part of the PREVENT programme. At the year end, a balance of £691 (2024: £627) was owing.

The Trustees consider all the transactions during the year to have been undertaken on an arm's length basis.

**18. Ultimate Controlling Party**

GALVmed is constituted under its Memorandum and Articles of Association and is managed by its appointed Board of Trustees.



## Certificate Summary

ENVELOPE SUBJECT: Approval required  
DOCUMENT: 2024-25 Trustees' Report Financial Statements.pdf  
DOCUMENT ORIGINATOR: Louise Gillies (louise.gillies@hlca.co.uk)

CERTIFICATE STATUS: Completed  
DELIVERED: Jun 25, 2025 10:48 AM UTC  
DOCUMENT PAGES: 31 CERTIFICATE PAGES: 1 TOTAL ENVELOPE PAGES: 32

ENVELOPE ID: 4b86f217-41ea-4535-bb44-95f13ac2bea2  
DOCUMENT ID: 276f67fd-8b0b-4391-b6a5-64c39b9b4184  
ORIGINATOR IP ADDRESS: 87.246.91.14

COMPLETED SIGNATORIES: 3 / 3  
COMPLETED IN PLACE SIGNATURES: 3 / 3  
COMPLETED IN PLACE INITIALS: 0 / 0  
CARBON COPY RECIPIENTS: 0

## Signatures

## Timeline

E-SIGNED BY: Isabelle Dieuzy-Labaye (isabelle.dieuzy.labaye@gmail.com)  
SECURITY LEVEL: Secure Email (Authenticated)  
E-SIGNATURE ID: e0651d2b-ebb1-4a6e-803b-31343fbeat32

SENT: Jun 25, 2025 10:48 AM UTC  
VIEWED: Jun 26, 2025 3:38 PM UTC  
SIGNED: Jun 26, 2025 3:39 PM UTC  
USING IP ADDRESS: 90.7.220.49

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: Isabelle Dieuzy-Labaye EMAIL: isabelle.dieuzy.labaye@gmail.com

E-SIGNED BY: Tom Mitchell (tom@cgpm-consulting.co.uk)  
SECURITY LEVEL: Secure Email (Authenticated)  
E-SIGNATURE ID: 9295eaf0-6581-4011-9530-48fe0b38e4e5

SENT: Jun 25, 2025 10:48 AM UTC  
VIEWED: Jun 25, 2025 10:54 AM UTC  
SIGNED: Jun 25, 2025 10:57 AM UTC  
USING IP ADDRESS: 94.174.56.21

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: Tom Mitchell EMAIL: tom@cgpm-consulting.co.uk

E-SIGNED BY: Keith Macpherson (keith.macpherson@hlca.co.uk)  
SECURITY LEVEL: Secure Email (Authenticated)  
E-SIGNATURE ID: e2f09691-bac3-4a38-af3a-7a14dde315d1

SENT: Jun 25, 2025 10:48 AM UTC  
VIEWED: Jun 26, 2025 4:47 PM UTC  
SIGNED: Jun 26, 2025 4:49 PM UTC  
USING IP ADDRESS: 87.246.91.14

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: Keith Macpherson EMAIL: keith.macpherson@hlca.co.uk

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**

England & Wales - Charity number 1115606

---

# Accounts

---

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

Registered in England No. 05393391  
England and Wales Charity No. 1115606  
Scottish Charity No. SC039197

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2024**



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**For the year ended 31 March 2024**

**CONTENTS**

	<b><u>Page</u></b>
<b><u>REFERENCE AND ADMINISTRATIVE DETAILS</u></b>	<b>2</b>
<b><u>REPORT OF THE TRUSTEES</u></b>	
<b>INTRODUCTION</b>	<b>3</b>
<b>OBJECTS, OBJECTIVES AND ACTIVITIES</b>	<b>3</b>
Objects	3
Objectives & Activities	3
<b>STRUCTURE, GOVERNANCE AND MANAGEMENT</b>	<b>3</b>
Trustee Recruitment, Induction, Training and Evaluation	4
Trustees' and Members' Meetings and Business	4
Strategy and Decision Making	4
Key Management Remuneration	4
Diversity	5
Safeguarding	5
Partnerships and Related Parties	5
<b>STRATEGIC REPORT</b>	<b>5</b>
Performance and Achievements	5
- Key Performance Indicators	5
- Key Achievements	6
- Impact of Our Work	7
Financial Review	7
- Income	7
- Expenditure	8
- Balance Sheet	8
- Liquidity Management Policy	8
- Climate Change	8
- Reserves	8
- Unrestricted Reserves Policy	8
Future Plans	9
- Objectives	9
- Financial	9
Principal Risks and Uncertainties	9
- Risk Management	9
<b>GOING CONCERN</b>	<b>10</b>
<b>STATEMENT OF DISCLOSURE OF INFORMATION TO AUDITORS</b>	<b>10</b>
<b>AUDITORS</b>	<b>10</b>
<b><u>RESPONSIBILITIES OF THE TRUSTEES</u></b>	<b>11</b>
<b><u>INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES</u></b>	<b>12</b>
<b><u>INCOME AND EXPENDITURE ACCOUNT AND STATEMENT OF FINANCIAL ACTIVITIES</u></b>	<b>15</b>
<b><u>BALANCE SHEET</u></b>	<b>16</b>
<b><u>STATEMENT OF CASH FLOWS</u></b>	<b>17</b>
<b><u>NOTES TO THE FINANCIAL STATEMENTS</u></b>	<b>18-30</b>



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Trustees**

Dr I Dieuzy-Labayé	Chair
Dr J Maina	Vice-Chair
	Chair of HR Committee
Mr S Jha	Chair of Commercial Development Advisory Committee
Mrs. J Stevenson FCA	Chair of Finance & Risk Committee
Dr A Banga	
Dr F Kausche	
Dr H Wamwayi	Chair of Technical Scientific Committee
Dr J Dreesen	
Dr P Thornton	Appointed 12 September 2023
	Chair of Impact, Monitoring & Evaluation Advisory Committee (from 12 September 2023)
Prof C Ly	Appointed 12 September 2023
Prof M Gill	Resigned 12 September 2023
	Chair of Impact, Monitoring & Evaluation Advisory Committee (to 12 September 2023)

**Chief Executive Officer**

Dr C Schumacher

**Company Secretary**

Ms R Stewart CA – Appointed 8th December 2023  
Ms H Stevenson CA – Resigned 8<sup>th</sup> December 2023

**Independent Auditors**

Henderson Loggie LLP  
Chartered Accountants  
Ground Floor, 11-15 Thistle Street  
Edinburgh, EH2 1DF

**Legal Advisors**

Dentons LLP  
Quartermile One  
15 Lauriston Place  
Edinburgh, EH3 9EP

**Bankers**

Lloyds Bank plc  
City Office, PO Box 72  
Bailey Drive, Gillingham Business Park  
Kent, ME8 0LS

**Registered Office**

One Fleet Place  
London, EC4M 7WS

**Principal Office**

Doherty Building  
Pentlands Science Park  
Bush Loan, Edinburgh, EH26 0PZ

**Company No.** 05393391

**England and Wales Charity No.** 1115606

**Scotland Charity No.** SC039197



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2024**

**INTRODUCTION**

The Trustees have pleasure in presenting their report for the year ended 31 March 2024. This report is prepared in accordance with the *Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)* and in accordance with applicable law.

Global Alliance for Livestock Veterinary Medicines (the company) has complied with the duty in Section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

Global Alliance for Livestock Veterinary Medicines (GALVmed) is a company limited by guarantee and is registered as a charity with the Charity Commission and the Office of the Scottish Charity Regulator (OSCR). It is incorporated in the UK with its principal office in Edinburgh, UK. Other offices are maintained in New Delhi, India (South Asia office); and Nairobi, Kenya (Africa office). Other reference and administrative details are set out in the previous page.

**OBJECTS, OBJECTIVES AND ACTIVITIES**

**Objects**

Around 900 million people rely on livestock for their livelihoods. The company's objects, as set out in its Memorandum of Association, are for the benefit of the public:

- 1) to relieve financial hardship and promote good health (including improving food security) amongst small-holder livestock keepers (small-scale livestock producers – SSPs) in developing countries through the promotion of affordable vaccines, pharmaceutical and diagnostic products and services aimed at improving the health of their livestock; and
- 2) to promote the effective use of resources to achieve the above charitable purposes through the identification, management, funding, and co-ordination of: a) development of livestock vaccines, pharmaceuticals and diagnostics products and services; and b) delivery of these products and services at affordable prices, by working in partnership with others (whether charities, government; private bodies or institutions).

GALVmed's vision is the transformational improvement in the wellbeing and economic progression of SSPs. GALVmed's mission is to contribute to the transformation of SSPs' lives by:

- understanding the constraints to animal health and how to overcome them;
- engaging the animal health industry; and
- ensuring awareness, availability, and adoption of effective animal health interventions.

**Objectives & Activities**

GALVmed achieves its charitable purpose by operating a series of Research and Development (R&D) and Commercialisation programmes, supported by Enabling Environment and Monitoring and Evaluation (M&E) activities, funded principally by the Bill and Melinda Gates Foundation (BMGF) and the UK Government through its Foreign, Commonwealth and Development Office (FCDO). These programmes are designed to identify products that SSPs can use to improve the health of their animals and to make such products more easily accessible. The two largest of these programmes are Veterinary Innovations Transforming Animal Health and Livelihoods (VITAL), with a budget of \$50m, and African Animal Trypanosomiasis 3 (AAT), with a budget of \$22.5m. 7 other programmes are also being operated, with values ranging from \$1.2m to \$5.0m. All programmes are supported by the funding of project core costs through the VITAL Bridging programme, with a budget of \$7.7m, except for AAT 3 and Agresults where project staff are funded directly (see note 12 for further information on all programmes).

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

The governance of the company is the responsibility of the Trustees, and the company adopts the appropriate principles and recommended practices of the Charity Governance Code.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**TRUSTEES' REPORT  
For the year ended 31 March 2024**

The Members elect the Trustees in accordance with the terms of the Memorandum and Articles of Association.

**Trustee Recruitment, Induction, Training and Evaluation**

The maximum number of Trustees permitted by the company's Articles is 12 (increased from 10 at the AGM in September 2023). Trustees are recruited for their individual skills and experience to fill current or impending vacancies, guided by a comprehensive skills and diversity matrix. Trustees serve a term of 3 years subject to a maximum of 2 consecutive terms and Board and AGM approval. Recruitment of Trustees is managed by a Nominations Committee, comprising 3 Trustees of which one is the HR Committee Chair. Two replacement Trustees were approved at the AGM following a recruitment process. A further recruitment process is currently ongoing to identify candidates to replace Trustees due to retire at the 2024 AGM and beyond. In certain circumstances the Chair may stand for re-election after the end of their two three-year terms up to a further three years, where it would be deemed detrimental to the organization for the Chair to change during that period. Their re-election must be approved by the Members annually.

A formal Trustee induction process is in place to ensure clarity of the role of the Trustee and their responsibilities under company and charity legislation. Trustees, new and current, also receive training on their legal responsibilities annually prior to the AGM. During the year trustees received training on trustees' governance responsibilities.

Trustee evaluation takes place annually and is based on self-assessment, peer-assessment and annual performance interviews with the Chair and Vice-Chair; the process includes identifying development requirements.

**Trustees' and Members' Meetings and Business**

Trustees meet formally four times a year, with two virtual and two in-person meetings which are held at the same time as the Members' meetings. The two in-person meetings in 2023-24 were in Edinburgh in September 2023 and Arusha (Tanzania) in March 2024. The business of all meetings is minuted.

On 31 March 2024 there were 15 Members and 10 Trustees. Members are subscribers to GALVmed's Memorandum of Association. The organisation appoints a representative to attend all meetings and to undertake their responsibilities as dictated by the Articles of Association. Members have rights and obligations in accordance with the Articles. In addition, observers from 5 organisations, including BMGF and FCDO, the company's major funders, are invited to attend the Members' meetings, with the funders also invited to meet separately with the Board.

The Board is supported by the Finance & Risk and HR committees, to whom aspects of day-to-day accountability and governance are delegated. The HR Committee is also responsible for safeguarding. There are also three advisory committees - the Technical Scientific, Commercial Development (CD) and Impact, Monitoring and Evaluation committees. These committees provide guidance to the Board through the involvement of external experts.

**Strategy and Decision Making**

Development of the company's strategy for the achievement of its charitable objectives is overseen by the Board of Trustees and evolved by the Executive Directors. The related corporate objectives and budget are set out in the Annual Plan. Progress in achieving these objectives is assessed by the Board through reports by the Chief Executive and the Executive Directors at Board meetings, drawn from monthly and quarterly internal performance monitoring tools. Strategic and operational issues are brought to the Board for assessment and direction as required. GALVmed are currently working towards the achievement of the 2030 Strategy, which was approved by the Board in March 2021, utilising the Strategy Implementation Plan and the Strategy Execution Framework.

**Key Management Remuneration**

Key management includes the Chief Executive (CEO) and Executive/Senior Directors of the company who operate as the GALVmed Leadership Team (GLT).

The HR Committee has responsibility delegated to it for setting the framework for key management remuneration. The main responsibilities of the Committee in relation to key management remuneration are:

- to determine and agree with the Board the broad policy for key management remuneration;



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2024

- to approve the design, determine targets and approve payments of any performance related schemes; and
- to determine the total remuneration package of each member of the GLT.

The performance related pay scheme, which is based on departmental, and individual objectives developed from the corporate objectives, is applicable to all employees. A benchmarking exercise was carried out in March 2024 where it was concluded that GALVmed's salaries are sufficiently competitive to attract high quality, qualified and experienced staff.

**Diversity**

The diversity of the Trustees, GLT and staff at 31 March 2024 is:

	Gender		Ethnicity		
	Male	Female	African	Asian	Caucasian
Trustees	7	3	4	1	5
GLT	2	4	1	-	5
Staff	6	17	8	3	12

**Safeguarding**

GALVmed is committed to addressing safeguarding throughout its work. It does so through a specific set of policies and procedures that include: Safeguarding Policy (which explicitly addresses prevention, reporting and response); Trustee and GLT training (on commencement and biennial thereafter); all-staff awareness; and contractual commitment to safeguarding by its partners and consultants. No safeguarding issues were reported in the year.

**Partnerships and Related Parties**

Partnerships with entities to whom research and development, commercialisation and other work can be subcontracted is a key part of the way the company operates and is instrumental in allowing it to pursue its charitable objectives. The company initiates, facilitates, brokers, and contributes to such partnerships from two perspectives: 1) specific partnerships to deliver and support programme achievement and impact; and 2) higher level strategic partnerships to initiate and advance the livestock agenda. All such relationships are formalised through Memoranda of Understanding, Confidentiality Agreements and Contractual Agreements. All contractual arrangements and related party transactions (detailed in Note 17 to the Financial Statements) are conducted at arm's length.

**STRATEGIC REPORT**

**Performance and Achievements**

*Key Performance Indicators*

The Trustees and GLT assess the financial and operational performance of each programme using the following key performance indicators (KPI):

- detailed milestones within specific activities as defined in the funder agreement for each programme;
- quarterly KPI dashboards, providing quantitative and qualitative measure of delivery across all functions;
- monthly and quarterly actual expenditure against Board approved budget and forecasts; and
- achievement of the annual corporate objectives.

The Advisory and Board Committees oversee the financial and operational performance of organisational and programme activities quarterly.

In addition, service level agreements have been established for all service-related support functions, performance of which is assessed quarterly.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2024

*Key Achievements*

The company made good progress during the year in achieving its charitable purpose. Its corporate objectives for the year to 31 March 2024 together with key achievements are:

Objective	Achievements
<b>Strategic</b>	
	<p>Develop proposals for achieving new funding to deliver GALVmed’s mission of improving availability and SSP access to quality animal health products in sub-Saharan Africa and South Asia, with proposals expected to be in an advanced stage of negotiation with funders. Specifically:</p> <ul style="list-style-type: none"> <li>➢ New comprehensive project portfolio designed, and funding proposal developed.</li> <li>➢ Multiple smaller and three large new funders evaluated and approached regarding co-funding of future GALVmed work.</li> </ul>
<p><b>Rating of Progress:</b></p> <p><i>Achieved</i></p>	<p>In 2023-2024 combined fundraising efforts have achieved \$7m of new project funding. There has been significant progress during the year towards further funding with efforts to be finalised in 2024-25. Two new programmes were approved in 2023-24:</p> <ul style="list-style-type: none"> <li>• the MoTAR programme - a two-year, \$2m BMGF funded programme to provide Uganda with an effective means of managing the twin, key constraint in sustainable livestock production: tick acaricide resistance and the associated burden of tick-borne diseases.</li> <li>• Improving Veterinary Regulation in Africa – a three-year, \$5m BMGF funded programme to improve access to quality veterinary products through improvements to regulation.</li> </ul> <p>Considerable progress has been made to achieve long term funding for GALVmed to achieve its aims. An extension of \$11.2m to the AAT 3 grant to August 2028 was submitted and is progressing well. The VITAL2 concept note was submitted in January 2024 and following positive feedback from the funders, will now move towards final funding proposal submission by June 2024. Should these two further initiatives be approved, GALVmed sustainability will be secured to 2030. Multiple smaller funders have been evaluated and approached regarding co-funding of future GALVmed work. Efforts in 2024-25 will continue to identify additional funding to support South Asia, SEAMLiSS and the R&amp;D portfolio, including through funder diversification.</p>
<b>Tactical</b>	
	<p>Programme functions and project managers enabled to deliver 2023-24 project targets supported by required financial, human resource, operational and project management support. Specifically:</p> <ul style="list-style-type: none"> <li>➢ Current projects delivered as close as possible to plan, deliverables, and financials.</li> <li>➢ Project to launch combination vaccines developed during VITAL (combo launch) and VITAL2 funding proposal development activity planned &amp; executed with excellence and supported by project management and advocacy support.</li> </ul>
<p><b>Rating of Progress:</b></p> <p><i>Achieved</i></p>	<p>There has been progress on R&amp;D &amp; Commercial Development delivery with most projects on target and in line with budget. Specific achievements include:</p> <ul style="list-style-type: none"> <li>• Regulatory submissions achieved for three combo vaccines in country of origin and two quadrivalent Foot &amp; Mouth Disease vaccines tailored to East Africa, with two others expected in late 2024 or early 2025.</li> <li>• Several major deliveries were achieved in Enabling Environment including the completion of the Veterinary Parasiticide Draft Legislative Proposal which will now undergo EAC validation, and the AU-IBAR/PANVAC agreement to roll out EAC-MRP guidelines for PPR-vaccine registration across Africa in support of global PPR eradication campaign.</li> <li>• VITAL1 Hester India &amp; Nepal distribution projects are complete. CEVA projects LAPROVET distribution and PREVENT are ahead of sales plan.</li> <li>• Digital market intelligence &amp; telehealth platform (SEAMLiSS) design is progressing towards MVP (minimum viable product).</li> </ul> <p>We also continue to have strong engagement with key stakeholders across the animal health industry, NGOs and academia. The combo launch plans are progressing, supported by well-defined and executed project management and advocacy support.</p>



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2024

<b>Process</b>	
<p>Ensure GALVmed have a strong focus on delivering impact and transformational results through current and future projects and GALVmed's impact, achievements and learnings are communicated. Specifically:</p> <ul style="list-style-type: none"> <li>➤ Review the M&amp;E modelling methodology and framework to document organizational (transformational) achievements and develop GALVmed's impact and other project outcomes to comprehensively capture and communicate learnings and utilize these to optimize GALVmed's future programme design.</li> <li>➤ Identify and build partnerships that drive uptake of quality livestock vaccines by SSPs, in preparation for the VITAL Combo-launch.</li> <li>➤ Develop and disseminate a strong impact, learnings and achievements communication plan with success stories disseminated.</li> </ul>	
<b>Rating of Progress:</b>	Excellent progress in Monitoring & Evaluation, with the development of multiple expanded and new models allowing the measurement of GALVmed impact and ability to drive systems change. Throughout the year, GALVmed have placed strong focus on building evidence of and communicating GALVmed achievements. In preparation for combo launches and VITAL2, major ecosystem studies were conducted to further strengthen understanding of the livestock ecosystem and policy environment. Impact achieved at SSP levels continue to fall short of expectations. Lessons learnt have been absorbed and are systematically used in the design and development of new projects to increase impact and SSP benefits of GALVmed facilitated work.
<i>Achieved</i>	

*The Impact of our Work*

During the year, GALVmed has created a framework and process for measuring Organisational Performance. The aim of the exercise was to understand what has been achieved during GALVmed's lifetime. A broad portfolio of animal health products has been sold through multiple initiatives across various geographies through GALVmed's work. This exercise assessed the impact brought about through the use of GALVmed-supported animal health products. A further aim was to consider, along with past performance, improvements to GALVmed's future performance to increase the impact in transforming the lives of SSPs.

During this exercise, we discovered that:

- GALVmed initiatives over 2014 – 2022 have collectively sold an estimated 1.2 billion doses of vaccines, therapeutics, and other animal health products to SSP customers, via GALVmed's commercial partners, averting approximately 23.7 million livestock deaths.
- During the period from 2014 – 2022, a cumulative annual estimate of 5.7m SSP customers were reached with GALVmed-supported market development initiatives.
- Based on all products sold, the total estimated Gross Economic Benefit from doses sold of commercial development-enabled products was \$319m (not reflecting present day values).
- The total estimated Net Additional Benefit from doses sold of Commercial Development-enabled products is \$110m, driven primarily by the Protecting Livestock, Saving Human Life (PLSH) 2 programme (not reflecting present day values).

The benefit is likely to be much larger over time, as these figures do not consider products which are currently in development and have yet to reach market.

**Financial Review**

Income in the year was £9.6m (2023: £13.1m) and total expenditure was £10.3m (2023: £11.1m).

*Income*

Restricted income of £8.6m (2023: £11.1m) includes £2.2m in respect of AAT 3, £2.1m in respect of VITAL and £1.7m in respect of Regulatory Harmonisation; funding for other programmes totalled £2.6m. Unrestricted income of £1.0m was received (2023: £1.0m) from contributions from programmes to overheads, and from interest.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2024**

*Expenditure*

Expenditure has reduced to £9.9m (2023: £11.1m). AAT 3 costs of £2.9m make up the largest proportion of expenditure, 29% (2023: £3.4m, 30%). Expenditure on VITAL has decreased to £1.3m, 13% (2023: £3.5m, 32%). Unrestricted spend has remained consistent at £0.9m (2023: £0.8m).

An unrealised exchange loss of £0.4m has arisen (2022-23: gain of £1.0m) on the conversion of foreign currency balances at year end exchange rates. The loss is a result of the strengthening of Sterling against the US Dollar (in which most of the company's funding is received) from 1.24 to 1.26 in the year. The company minimises the effects of currency fluctuations by taking several steps, including contracting in the funded currency where possible and optimising the timing of foreign currency conversions.

*Balance Sheet*

The level of cash held has decreased from £19.4m to £16.1m in the year, but remains high because of advanced AAT 3, VITAL and VITAL Bridging funding provided in previous years.

*Liquidity Management Policy*

The company's liquidity management and investment objectives, responsibilities, risk, and strategy are clearly set out in a Liquidity Management Policy which is subject to review annually. The related liquidity and investment activity is reviewed quarterly by the Finance & Risk Committee. GALVmed's Liquidity Management Policy is driven by the need to have funds readily available to fund its activities in diverse geographies as well as to maintain the infrastructure of the organisation. As such, longer term investments are not appropriate in maintaining adequate cashflow.

*Climate Change*

The Board is committed to reducing the company's greenhouse gas emissions, particularly those resulting from air travel. The Company generated and offset 332 tonnes of emissions in the year (2022-23: 122 tonnes). Carbon offset is through investment in like-purposed initiatives. GALVmed reviewed their approach to reducing their carbon footprint in 2022 and identified several actions including the need to observe and support livestock-related climate change actors, and to support staff in actively reducing their individual ecological footprints in and outside the office. As part of this, while higher this year, travel has still reduced substantially since pre-pandemic levels, where alternatives to air travel are now a pre-requisite consideration before travel is undertaken.

*Reserves*

Reserves at 31 March 2024 total £17.9m (2023: £18.5m), of which available funds not tied up in fixed assets amount to £17.9m (2023: £18.5m). Reserves related to restricted funds of £14.6m (2023: £15.2m) mainly relate to advance funding for AAT 3, VITAL, MoTAR and Regulatory Harmonisation.

*Unrestricted Reserves Policy*

Unrestricted reserves at 31 March 2024 amount to £3.3m (2023: £3.3m). From this amount, the Trustees have established a designated fund of £1.6m (2023: £1.5m) which comprises unrestricted reserves that have been set aside for any future shortfall in the recovery of overhead costs from programmes.

The objective of the company's Unrestricted Reserves Strategy is to build sufficient funds to protect the company from any adverse changes in its financial circumstances and to pursue operational opportunities that, in the initial phase, are not funded by 3<sup>rd</sup> parties. By considering a variety of risks, the Trustees have concluded that £1.2m of general unrestricted reserves is the minimum that should be held. General unrestricted reserves are currently held in excess of this to allow for the future investment in the 2030 Strategy and to ensure financial sustainability beyond the end of VITAL (December 2024 for BMGF and March 2025 for FCDO) should additional funding not be awarded. The unrestricted reserves policy is reviewed every 6 months to ensure that it reflects current circumstances.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**TRUSTEES' REPORT  
For the year ended 31 March 2024**

**Future Plans**

*Objectives*

GALVmed is operating in accordance with the vision of the 2030 Strategy. This builds upon the evolution of the company since inception as a product development partnership working on a strong portfolio of new products, technologies and processes while continuing to facilitate scale-orientated commercial development initiatives.

GALVmed has identified the following key strategic corporate objectives for 2023-24:

<b>Objective</b>	
1.	New funds to deliver GALVmed's mission, of improving availability, access and adoption of quality animal health products, secured for VITAL2, R&D, digital transformation, and vaccination scale-up in sub-Saharan Africa and South Asia.
2.	Programme functions and project managers supported by required financial, human, operational and project management resources to deliver on 2024-25 project targets.
3.	Strengthened focus on delivering impact and transformational results through GALVmed's current and future projects, and with GALVmed impact, achievements and learnings efficiently communicated.
4.	Efficiently manage GALVmed staff through the VITAL1-VITAL2 transition and ensure that GALVmed's future ambitions and needs are supported by an appropriate legal and office structure with a lean and appropriately skilled human resources population.

*Financial*

The 2024-25 expenditure budget is £14.6m, a 47% increase on 2023-24 actual expenditure. This increase is mainly because of the increased AAT 3 activity as the programme progresses through the next phase of development.

**Principal Risks and Uncertainties**

*Risk Management*

The company's governance structure includes risk management. The Risk Management Policy details the company's risk management objectives, processes, reporting and responsibilities. The Corporate Risk Register highlights the major risks to which the company is exposed and for each risk the score, lead risk owner, mitigations and actions stated. It is maintained to support strategic, financial, and operational planning and therefore to assist in achieving the company's objectives and targets. The key risks, that GALVmed faces at the time of this report, and key mitigations, are:

<b>Risk</b>	<b>Key Mitigations</b>
Failure to deliver and/or to align strategic proposals, impacts on future funding	Multi-pronged interaction with funders to ensure our strategy continues to align with funders evolving strategies and to identify how GALVmed fits into the animal health landscape
Failure to design and implement projects which achieve economic impact for SSPs	Ensure that achieving SSP-impact is considered from conception to delivery of every GALVmed project and periodically evaluated and optimized throughout project implementation
Loss of highly experienced key staff impacts on project delivery, reputation & staff morale	Succession planning and managing staff expectations on career progression perspective; development of retention strategy for key talent, and leadership development programme for key staff
Geo-political instability impacts on GALVmed's beneficiaries, operations, and resources	Adopt a prudent approach to selecting countries of operation to safeguard partners and staff and increase level of success



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2024

<b>Risk</b>	<b>Key Mitigations</b>
Data security breach results in loss of, or corrupted, data	Multiple systems, software, support, and user awareness approaches to ensure robust mechanisms and being ever vigilant
Barriers to product registration reduces product availability	Support harmonisation of product registration in Africa and engage with international organisations
Dependency on limited funding sources impacts on delivery of the 2030 Strategy	Funder relations department resource increased to allow consideration of best approach to convert project ideas to funding proposals and increase opportunity for funder diversification

As well as the strategic risks noted in the table above, important financial risks are monitored and include the possible loss of bank deposits through fraud or theft, currency risk, liquidity risk and dependency on limited funding sources. The risk of loss of bank deposits is managed through the bank mandates in place and continued vigilance. Currency and liquidity risk are managed by following the Liquidity Management Policy. The 2030 Strategy and Funder Relations Strategy aims to address the limited funding sources issue.

**GOING CONCERN**

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding of the VITAL Bridging programme ends in September 2024. Prior to this, all direct (project support) costs are funded under VITAL Bridging (to September 2024) or under VITAL (October – December 2024) with sufficient contribution from this, and all other current programmes to fully cover indirect (organisational) costs. Other programmes are fully funded.

GALVmed is in the process of applying for funding for VITAL2 from the Bill & Melinda Gates Foundation and FCDO for a five-year programme. This programme would see a continuation of work following on from the success of the VITAL programme and would also fully cover direct costs. While formal confirmation of funding is not expected until later in 2024, based on discussions with our funders there is confidence that funding will be approved.

In the event that VITAL2 funding is not received, or confirmation is delayed, there are sufficient designated reserves to cover direct costs and the shortfall in indirect costs to June 2025. General unrestricted reserves will still be maintained at the minimum balance as required within the reserves policy. There are therefore sufficient reserves to maintain GALVmed as a going concern for at least 12 months from the date of signing the financial statements.

**STATEMENT OF DISCLOSURE OF INFORMATION TO AUDITORS**

Each of the Trustees who held office at the date of this Trustees Annual Report confirms that (a) so far as the Trustee is aware, there is no relevant information of which the organisation’s auditors are unaware; and (b) he/or she has taken all steps that he/she ought to have taken as a Trustee to make himself/herself aware of any relevant audit information and to establish that the auditors are aware of that information.

**AUDITORS**

Henderson Loggie LLP, Chartered Accountants, were reappointed as auditors to the company at the Annual General Meeting in 2023. Their re-appointment was approved for an initial three-year term from 2022 subject to annual consideration by both parties.

The Directors’ Annual Report is signed by the Chair on behalf of the Board of Directors. The Directors also approve the Strategic Report, which is contained within the Annual Report, in their capacity as company directors.

*Isabelle Dieuzy-Labaye*  
Isabelle Dieuzy-Labaye – 2024-06-27, 07:53:36 UTC

Dr I Dieuzy-Labaye



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**RESPONSIBILITIES OF THE TRUSTEES**  
**For the year ended 31 March 2024**

The Trustees (who are also the Directors for the purposes of company law) are responsible for the preparation of the Trustees' Report, including the Strategic Report, and financial statements in accordance with applicable law and regulations.

Law applicable to incorporated charities in Scotland requires the Trustees to prepare an annual report and financial statements for each financial year in accordance with applicable law and regulations. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).

Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity at the end of the year and of its financial activities including its income and expenditure during the year then ended. In preparing those financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper and adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006, with the Charities and Trustee Investment (Scotland) Act 2005, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the maintenance and integrity of the charity.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2024

**Opinion**

We have audited the financial statements of Global Alliance for Livestock Veterinary Medicines (the 'charitable company') for the year ended 31 March 2024 which comprise the Income and Expenditure Account and Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2024, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' (who are also the directors of the charitable company for the purpose of company law) use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
**For the year ended 31 March 2024**

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report, included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement, as set out on page 11, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor responsibilities for the audit of the financial statements**

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below:

As part of our planning process:

- We enquired of management the systems and controls the charitable company has in place, the areas of the financial statements that are mostly susceptible to the risk of irregularities and fraud, and whether there was any known, suspected or alleged fraud. Management informed us that there were no instances of known, suspected or alleged fraud;



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
**For the year ended 31 March 2024**

- We obtained an understanding of the legal and regulatory frameworks applicable to the charitable company. We determined that the following were most relevant: employment law in all relevant jurisdictions, GDPR, Health and Safety, and compliance with the UK Companies Act and charity legislation.
- We considered the incentives and opportunities that exist in the charitable company, including the extent of management bias, which present a potential for irregularities and fraud to be perpetrated, and tailored our risk assessment accordingly; and
- Using our knowledge of the charitable company, together with the discussions held with management at the planning stage, we formed a conclusion on the risk of misstatement due to irregularities including fraud and tailored our procedures according to this risk assessment.

The key procedures we undertook to detect irregularities including fraud during the course of the audit included:

- Enquiries with management about any known or suspected instances of non-compliance with laws and regulations and fraud;
- Reviewing Board meeting minutes for discussions of irregularities including fraud;
- Reading correspondence with regulators to determine the extent of compliance;
- Challenging assumptions and judgements made by management in their significant accounting estimates, in particular in relation to the carrying value of tangible assets and accruals;
- Auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness;
- Testing key revenue lines, in particular cut-off, for evidence of management bias; and
- Reviewing the financial statement disclosures and determining whether accounting policies have been appropriately applied

Owing to the inherent limitations of an audit, there is unavoidable risk that some material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISAs (UK). For instance, the further removed non-compliance is from the events and transactions reflected in the financial statements, the less likely the auditor is to become aware of it or to recognise the non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation. The primary responsibility for the prevention and detection of irregularities and fraud rests with the trustees.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

*Keith Macpherson*  
Keith Macpherson - 2024-06-27, 12:33:58 UTC

**Keith Macpherson (Senior Statutory Auditor)**

For and on behalf of Henderson Loggie LLP  
Chartered Accountants  
Statutory Auditor

Henderson Loggie LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006.  
Ground Floor  
11-15 Thistle Street  
Edinburgh  
EH2 1DF

..... 2024

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INCOME AND EXPENDITURE ACCOUNT AND  
STATEMENT OF FINANCIAL ACTIVITIES**  
For the year ended 31 March 2024

	Notes	Unrestricted £	Restricted £	Total 2024 £	Total 2023 £
<b>Income from:</b>					
Charitable Activities	2	878,041	8,200,444	9,078,485	11,767,683
Investments		112,109	429,459	541,568	362,592
Other: Gain on Foreign Exchange	6	-	-	-	958,077
<b>Total Income</b>		990,150	8,629,903	9,620,053	13,088,352
<b>Expenditure on:</b>					
Charitable Activities	3	903,459	9,018,994	9,922,453	11,095,477
Other: Loss on Foreign Exchange	6	78,308	277,350	355,658	-
<b>Total Expenditure</b>		981,767	9,296,344	10,278,111	11,095,477
<b>Net Income/(Expenditure)</b>	5	8,383	(666,441)	(658,058)	1,992,875
Net Movement in Funds		8,383	(666,441)	(658,058)	1,992,875
<b>Reconciliation of Funds</b>					
Total Funds Brought Forward at 1 April 2023	12	3,298,919	15,225,181	18,524,100	16,531,225
Total Funds Carried Forward at 31 March 2024	12	3,307,302	14,558,740	17,866,042	18,524,100

All the results of the company relate to continuing activities.

The company has no recognised gains or losses other than those set out above.


The notes on pages 18 to 30 form part of these financial statements

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**BALANCE SHEET**  
As at 31 March 2024

	Notes	2024		2023	
		£	£	£	£
<b>Fixed Assets</b>					
Tangible Assets	8		38,763		15,243
<b>Current Assets</b>					
Debtors	9	2,246,514		418,652	
Bank and Cash Balances	10	16,061,958		19,367,233	
		<u>18,308,472</u>		<u>19,785,885</u>	
<b>Liabilities</b>					
Creditors: Amounts Falling Due Within One Year	11	(481,193)		(1,277,028)	
<b>Net Current Assets</b>			<u>17,827,279</u>		<u>18,508,857</u>
<b>Total Net Assets</b>			<u><u>17,866,042</u></u>		<u><u>18,524,100</u></u>
<b>Unrestricted Funds</b>					
General Reserve	12		1,735,025		1,753,614
Designated Funds	12		1,572,277		1,545,305
			<u>3,307,302</u>		<u>3,298,919</u>
Total Unrestricted Funds			3,307,302		3,298,919
<b>Restricted Income Funds</b>	12		14,558,740		15,225,181
			<u>17,866,042</u>		<u>18,524,100</u>
<b>Total Funds</b>			<u><u>17,866,042</u></u>		<u><u>18,524,100</u></u>

The financial statements were authorised for issue and approved by the Trustees on 12th June 2024.

  
 Jandy Stevenson – 2024-06-19, 14:49:18 UTC

Mrs. J Stevenson  
**Company No: 05393391**

The notes on pages 18 to 30 form part of these financial statements

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**STATEMENT OF CASH FLOWS**  
For the year ended 31 March 2024

	Notes	2024 £	2023 £
<b>Cash Flows from Operating Activities:</b>			
<b>Net Cash Provided by Operating Activities</b>	<b>16</b>	(3,424,589)	1,000,506
<i>Cash Flows from Investing Activities:</i>			
Interest from Investments		516,110	175,506
Purchase of Property, Plant and Equipment		(41,138)	(10,151)
Proceeds on disposal of fixed assets		-	1,068
Net Cash Used in Investing Activities		<u>474,972</u>	<u>166,423</u>
<b>Change in Cash and Cash Equivalents in the Reporting Period</b>		<b>(2,949,617)</b>	<b>1,166,929</b>
Cash and Cash Equivalents at the Beginning of the Reporting Period		19,367,233	17,242,227
Change in Cash and Cash Equivalents due to Exchange Rate Movements		(355,658)	958,077
<b>Cash and Cash Equivalents at the End of the Reporting Period</b>		<b><u>16,061,958</u></b>	<b><u>19,367,233</u></b>
 <b>Analysis of Cash and Cash Equivalents</b>			
Bank and Cash Balances		<u>16,061,958</u>	<u>19,367,233</u>

The notes on pages 18 to 30 form part of these financial statements



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2024**

**1. Accounting Policies**

*Basis of accounting*

GALVmed is a public benefit entity. The financial statements have therefore been prepared in accordance with the Companies Act 2006, applicable accounting standards, Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 as amended in 2010, and the Charities Act 2011. They have also been prepared under historical cost accounting rules. The financial statements are prepared in Sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

*Going concern*

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding of the VITAL Bridging programme ends in September 2024. Prior to this, all direct (project support) costs are funded under VITAL Bridging (to September 2024) or under VITAL (October – December 2024) with sufficient contribution from this, and all other current programmes to fully cover indirect (organisational) costs. Other programmes are fully funded.

GALVmed is in the process of applying for funding for VITAL2 from the Bill & Melinda Gates Foundation and FCDO for a five-year programme. This programme would see a continuation of work following on from the success of the VITAL programme and would also fully cover direct costs. While formal confirmation of funding is not expected until later in 2024, based on discussions with our funders there is confidence that funding will be approved.

In the event that VITAL2 funding is not received, or confirmation is delayed, there are sufficient designated reserves to cover direct costs and the shortfall in indirect costs to June 2025. General unrestricted reserves will still be maintained at the minimum balance as required within the reserves policy. There are therefore sufficient reserves to maintain GALVmed as a going concern for at least 12 months from the date of signing the financial statements.

*Fund accounting*

Funds received on which no restrictions are placed as to their use are accounted for as unrestricted funds. Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in note 12.

Funds received for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose, are accounted for as restricted funds.

*Income*

Funds received are recognised as income from charitable activities once there is entitlement, reasonable probability of receipt and the amount can be measured with sufficient reliability. Income is deferred where funder-imposed conditions that specify the performance conditions or time period in which the funds can be spent have not yet been met.

Investment income is recognised as earned.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2024**

**1. Accounting Policies (continued)**

*Value Added Tax (VAT)*

Expenditure is accounted for inclusive of VAT where appropriate as the company is not registered for VAT.

*Pension scheme*

The company provides a defined contribution pension scheme for its staff and the pension charge in the Statement of Financial Activities (SOFA) represents the amounts payable by the company to the Company Personal Pension Scheme in respect of the year.

*Operating leases*

Rentals payable under operating leases are charged to the SOFA on the straight-line basis over the lease term.

*Expenditure*

Expenditure is recognised on the accruals basis when a legal and/or constructive obligation exists. Expenditure through contractual agreements is recognised as goods and services are supplied. Grant payments are recognised as expenditure when payments are due in accordance with the terms of the contract.

Costs incurred by the company in the delivery of its activities and services are accounted for as charitable expenditure and categorised in the SOFA by the main activities of the company. Each category includes direct costs and support costs and, where support costs cannot be directly attributed to a category, they are apportioned on the basis of headcount.

Costs that, whilst necessary to deliver an activity do not themselves contribute directly to GALVmed's activity, are accounted for as support costs. Support costs include central office functions such as management, finance, information systems and administration activities.

*Foreign currency*

Foreign currency transactions are recorded in Sterling at the previous month's month-end rate of exchange. Monetary assets and liabilities denominated in foreign currencies are translated into Sterling at the exchange rate at the balance sheet date.

All exchange differences are recognised through the SOFA.

*Tangible fixed assets*

Tangible fixed assets costing more than £1,000 are capitalised and stated at cost and depreciated over their useful economic lives as follows:

Office equipment	4 years
Computer equipment & software	3 years
Leasehold improvements	over the life of the lease

Assets are only depreciated when they are brought into use and depreciated up to, but not including the month of disposal.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2024**

**1. Accounting Policies (continued)**

*Debtors and prepayments*

Debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

*Cash at bank and in hand*

Cash at bank and in hand includes cash and short term highly liquid investments with a maturity of six months or less from the date of acquisition or opening of the deposit or similar account.

*Creditors*

Creditors are recognised where the company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party in the future and the amount due to settle obligations can be measured or estimated reliably. Creditors are recognised at their settlement amount.

*Critical accounting judgements and estimation uncertainty*

In preparing the financial statements, the Trustees are required to make judgements, estimates and assumptions, which may affect reported income, expenditure, assets and liabilities. The estimates and associated assumptions are based on historical experience and other factors considered relevant. Actual results may differ from such estimates. Judgements made in preparing these financial statements comprise:

- The applicability of the estimated useful lives of fixed assets used to calculate the period over which depreciation is applied.
- The review of fixed assets for impairment or obsolescence.
- The assessment of leases to determine whether the risks and rewards of ownership remain with the lessor or are transferred to GALVmed.

*Financial instruments*

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**2. Income from Charitable Activities**

	UK Grant Funding £	Overseas Grant Funding £	2024 £	2023 £
<b>Restricted income</b>				
VITAL	329,699	1,582,320	1,912,019	3,322,648
AAT 3	1,513,266	599,885	2,113,151	730,330
Regulatory Harmonisation	-	1,749,081	1,749,081	-
MoTAR	-	1,275,931	1,275,931	-
VITAL Bridging	-	(375,774)	(375,774)	4,852,379
AgResults Brucellosis	-	(16,011)	(16,011)	(18,356)
AgResults FMD	-	446,133	446,133	346,470
MAHABA	-	745,053	745,053	736,041
PREVENT	-	405,533	405,533	927,066
Bovine TB	-	(48,842)	(48,842)	(18,688)
Boehringer Ingelheim	-	(5,830)	(5,830)	-
TAHSSL	-	-	-	(66,290)
<b>Total restricted income</b>	<b>1,842,965</b>	<b>6,357,479</b>	<b>8,200,444</b>	<b>10,811,600</b>
<b>Unrestricted income</b>	<b>44,995</b>	<b>833,046</b>	<b>878,041</b>	<b>956,083</b>
<b>Total income</b>	<b>1,887,960</b>	<b>7,190,525</b>	<b>9,078,485</b>	<b>11,767,683</b>

There is negative income in the VITAL Bridging, AgResults Brucellosis, Bovine TB and Boehringer Ingelheim programmes because of indirect core contributions towards unrestricted funds.

**3. Analysis of Expenditure**

	Support £	Governance £	Staff £	Direct Cost £	Total 2024 £	Total 2023 £
VITAL	2,254	-	51,319	1,236,956	1,290,529	3,528,632
AAT 3	1,474	-	-	2,859,883	2,861,357	3,362,366
MoTAR	-	-	-	974	974	-
VITAL Bridging	388,858	-	1,074,658	1,041,645	2,505,161	913,396
AgResults Brucellosis	1,246	-	-	105,491	106,737	122,422
AgResults FMD	3,828	-	89,587	194,073	287,488	298,845
MAHABA	-	-	-	744,703	744,703	695,676
PREVENT	-	-	-	787,133	787,133	928,342
Bovine TB	-	-	-	325,615	325,615	408,660
Boehringer Ingelheim	-	-	-	109,297	109,297	-
TAHSSL	-	-	-	-	-	16,710
Health for Animals	-	-	-	-	-	2,275
Unrestricted	64,310	129,336	523,021	186,792	903,459	818,153
<b>Total 2024</b>	<b>461,970</b>	<b>129,336</b>	<b>1,738,585</b>	<b>7,592,562</b>	<b>9,922,453</b>	<b>11,095,477</b>
<b>Total 2023</b>	<b>341,758</b>	<b>130,536</b>	<b>1,696,338</b>	<b>8,926,845</b>	<b>11,095,477</b>	<b>11,095,477</b>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**3. Analysis of Expenditure (continued)**

**Analysis of Support Costs**

	Professional Fees £	Office Costs £	Information Technology £	Audit Fees £	Total 2024 £	Total 2023 £
VITAL	522	86	1,646	-	2,254	125,925
AAT 3	-	424	1,050	-	1,474	1,412
VITAL Bridging	114,252	171,378	101,812	1,416	388,858	140,380
AgResults Brucellosis	-	196	1,050	-	1,246	1,385
AgResults FMD	-	8	3,820	-	3,828	6,731
TAHSSL	-	-	-	-	-	192
Unrestricted	19,323	18,625	12,022	14,340	64,310	65,733
<b>Total 2024</b>	<u>134,097</u>	<u>190,717</u>	<u>121,400</u>	<u>15,756</u>	<u>461,970</u>	<u>341,758</u>
<b>Total 2023</b>	<u>48,676</u>	<u>184,446</u>	<u>93,529</u>	<u>15,107</u>		<u>341,758</u>

**4. Staff Costs**

	2024 £	2023 £
Total staff costs were as follows:		
Salaries	1,479,848	1,440,791
Social security costs	123,734	113,603
Pension contributions	95,504	98,452
Other employee benefits	39,499	43,492
	<u>1,738,585</u>	<u>1,696,338</u>

The average number of employees during the year was:

	Number	Number
Management	5	5
Project staff	10	11
Support staff	12	11
	<u>27</u>	<u>27</u>

During the year, the company incurred expenses of £6,761 on behalf of, or reimbursed expenses to, 7 Trustees in connection with their governance responsibilities (2023: £3,446, 7 Trustees). 2 face-to-face meetings took place in 2023-24. No expenses were incurred for persons or entities connected with the Trustees (2023: £nil). No Trustees received remuneration in relation to consultancy services provided (2023: £nil).

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**4. Staff Costs (continued)**

GALVmed provides to its UK-based staff a defined contribution pension scheme, the GALVmed Personal Pension Scheme, which is operated by Aviva, a life assurance company. Total employer contributions in the year were £62,255 (2023: £58,189). The total number of members in the scheme at 31 March 2024 was 17 (2023: 15).

To compensate for the fact that there is currently no pension scheme for international staff, an employer contribution of 6% of salary is paid to such staff on the understanding that this contribution should be paid into a pension scheme of their choice. Total such contributions in respect of the year were £33,249 (2023: £40,263).

The following number of employees received total employee salary and benefits (excluding employer pension) in excess of £60,000 in the period:

	<b>2024</b>	<b>2023</b>
£60,000 - £69,999	3	-
£70,000 - £79,999	2	1
£80,000 - £89,999	2	1
£90,000 - £99,999	-	1
£100,000 - £109,999	-	1
£160,000 - £169,999	1	1

GALVmed considers the key management of the company to be the GALVmed Leadership Team (GLT), comprising the Chief Executive Officer, Executive Directors, and Senior Directors. The total cost of the employment of key management in the year was £537,988 (2023: £537,515), with a further £192,578 paid to two consultants (2023: £99,218, paid to one consultant). Employer pension contributions for key management totalled £28,887 (2023: £28,492).

One position was made redundant during 2023-24. Redundancy costs of £7,392 (2023: £nil) were incurred in the year. There are no redundancy payments outstanding at the year end.

**5. Net Income**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
This is stated after charging:		
- Auditor's remuneration – audit fees	15,756	15,107
- Depreciation	17,618	25,398
- Loss on disposal of fixed assets	-	99
- Operating leases		
Land and buildings	122,240	123,688
Equipment	1,162	943

Auditors' remuneration includes £1,416 (2023: £1,760) for audit fees payable in India and £14,340 (2023: £13,347) for audit fees in the UK.

**6. Exchange Gains and Losses**

Unrealised gains and losses on foreign exchange relate to the revaluation of GALVmed's net current assets at 31 March 2024 and are included in other expenditure (see note 12 for breakdown by programme). The loss of £355,658 (2023: £958,077 gain) relates to advance funding in US Dollars and a strengthening of Sterling against the US Dollar.

In addition, a realised loss of £25,194 (2023: £13,005 loss) is included in expenditure on charitable activities, which is a result of the difference between the currency rate invoiced and the currency rate paid to suppliers. GALVmed undertakes a variety of exchange mechanisms throughout the year to minimise realised exchange differences and help ensure there are adequate resources to deliver the programme outputs.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**7. Taxation**

The company has charitable status and is not liable for tax.

**8. Tangible Assets**

	Leasehold improvements £	Office equipment £	Computer equipment £	Total £
<b>Cost</b>				
At 1 April 2023	12,430	7,267	224,536	244,233
Additions	-	-	41,138	41,138
Disposals	-	-	(16,110)	(16,110)
	<u>12,430</u>	<u>7,267</u>	<u>249,564</u>	<u>269,261</u>
At 31 March 2024	<u>12,430</u>	<u>7,267</u>	<u>249,564</u>	<u>269,261</u>
<b>Depreciation</b>				
At 1 April 2023	11,378	7,267	210,345	228,990
Charge for year	965	-	16,653	17,618
Eliminated on disposal	-	-	(16,110)	(16,110)
	<u>12,343</u>	<u>7,267</u>	<u>210,888</u>	<u>230,498</u>
At 31 March 2024	<u>12,343</u>	<u>7,267</u>	<u>210,888</u>	<u>230,498</u>
<b>Net book value</b>				
At 31 March 2024	<u>87</u>	<u>-</u>	<u>38,676</u>	<u>38,763</u>
At 31 March 2023	<u>1,052</u>	<u>-</u>	<u>14,191</u>	<u>15,243</u>

**9. Debtors**

	2024 £	2023 £
Prepayments and accrued income	1,993,151	201,912
Other debtors	253,363	216,740
	<u>2,246,514</u>	<u>418,652</u>

Prepayments and accrued income include £131,400 (2023: £94,841) of accrued income in relation to the AgResults Foot and Mouth Disease (FMD) programme and £1,749,081 (2023: nil) of accrued income in relation to Regulatory Harmonisation programme. Other debtors include accrued investment income of £215,696 (2023: £190,238).

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**10. Bank and Cash Balances**

<b>2024</b>	<b>GBP</b> £	<b>USD</b> £	<b>Other</b> currencies £	<b>Total</b> £
Lloyds Bank	1,041,725	5,225,579	57,373	6,324,677
Bank of Scotland	516,699	2,928,465	941,899	4,387,063
NatWest	-	5,326,686	-	5,326,686
Standard Chartered	-	-	19,589	19,589
Cash	392	2,743	808	3,943
	<u>1,558,816</u>	<u>13,483,473</u>	<u>1,019,669</u>	<u>16,061,958</u>
	<u>1,558,816</u>	<u>13,483,473</u>	<u>1,019,669</u>	<u>16,061,958</u>
<b>2023</b>	<b>GBP</b> £	<b>USD</b> £	<b>Other</b> currencies £	<b>Total</b> £
Lloyds Bank	765,980	5,144,606	6,138	5,916,724
Bank of Scotland	503,696	6,498,255	-	7,001,951
NatWest	-	6,437,321	-	6,437,321
Standard Chartered	-	-	8,118	8,118
Cash	231	1,039	1,849	3,119
	<u>1,269,907</u>	<u>18,081,221</u>	<u>16,105</u>	<u>19,367,233</u>
	<u>1,269,907</u>	<u>18,081,221</u>	<u>16,105</u>	<u>19,367,233</u>

**11. Creditors: Amounts Falling Due Within One Year**

	<b>2024</b> £	<b>2023</b> £
Trade creditors	261,472	310,533
Accruals	199,535	741,962
Deferred income	-	210,076
Other creditors	20,186	14,457
	<u>481,193</u>	<u>1,277,028</u>
	<u>481,193</u>	<u>1,277,028</u>
<b>Deferred income reconciliation:</b>	<b>2024</b>	<b>2023</b>
	£	£
Balance brought forward	210,076	247,594
Amount released to the Statement of Financial Activities	(210,076)	(247,594)
Amount deferred in the year	-	210,076
	<u>-</u>	<u>210,076</u>
Balance carried forward	-	210,076
	<u>-</u>	<u>210,076</u>

The movement in accruals is because of a large, contracted payment due to the partner for the MAHABA programme which was accrued in 2022-23. The comparative charge for 2023-24 was invoiced and paid by 31<sup>st</sup> March 2024.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**12. Funds Movement**

<b>2024</b>	<b>31 March 2023</b>	<b>Income</b>	<b>Expenditure</b>	<b>Exchange gain/(loss)</b>	<b>Transfers</b>	<b>31 March 2024</b>
	£	£	£	£	£	£
<b>Restricted funds:</b>						
VITAL	3,872,664	2,076,521	(1,290,529)	(68,562)	-	4,590,094
AAT 3	4,196,382	2,219,596	(2,861,357)	(71,024)	-	3,483,597
Regulatory Harmonisation	-	1,749,081	-	-	-	1,749,081
MoTAR	-	1,283,595	(974)	8,543	-	1,291,164
VITAL Bridging	4,025,404	(295,954)	(2,505,161)	(90,706)	-	1,133,583
AgResults Brucellosis	1,172,091	26,349	(106,737)	(23,699)	-	1,068,004
AgResults FMD	415,468	452,272	(287,488)	(175)	-	580,077
MAHABA	398,248	748,919	(744,703)	(7,914)	-	394,550
PREVENT	529,183	409,951	(787,133)	(12,629)	-	139,372
Bovine TB	501,982	(34,597)	(325,615)	(12,552)	-	129,218
Boehringer Ingelheim	113,759	(5,830)	(109,297)	1,368	-	-
<b>Total restricted funds</b>	<b>15,225,181</b>	<b>8,629,903</b>	<b>(9,018,994)</b>	<b>(277,350)</b>	<b>-</b>	<b>14,558,740</b>
<b>Unrestricted funds:</b>						
General reserve	1,753,614	990,150	(903,459)	(78,308)	(26,972)	1,735,025
Designated funds:						
Indirect future costs	1,545,305	-	-	-	26,972	1,572,277
<b>Total unrestricted funds</b>	<b>3,298,919</b>	<b>990,150</b>	<b>(903,459)</b>	<b>(78,308)</b>	<b>-</b>	<b>3,307,302</b>
<b>Total funds</b>	<b>18,524,100</b>	<b>9,620,053</b>	<b>(9,922,453)</b>	<b>(355,658)</b>	<b>-</b>	<b>17,866,042</b>
<b>2023</b>	<b>31 March 2022</b>	<b>Income</b>	<b>Expenditure</b>	<b>Exchange gain/(loss)</b>	<b>Transfers</b>	<b>31 March 2023</b>
	£	£	£	£	£	£
<b>Restricted funds:</b>						
VITAL	3,826,130	3,405,174	(3,528,632)	169,992	-	3,872,664
AAT 3	6,319,826	824,660	(3,362,366)	414,262	-	4,196,382
VITAL Bridging	-	4,939,553	(913,396)	(753)	-	4,025,404
AgResults Brucellosis	1,208,562	5,257	(122,422)	80,694	-	1,172,091
AgResults FMD	347,707	346,486	(298,845)	20,120	-	415,468
MAHABA	339,336	737,453	(695,676)	17,135	-	398,248
PREVENT	493,349	932,046	(928,342)	32,130	-	529,183
Bovine TB	863,071	(12,686)	(408,660)	60,257	-	501,982
Boehringer Ingelheim	111,614	-	-	2,145	-	113,759
TAHSSL	80,362	(66,290)	(16,710)	2,638	-	-
Health for Animals	2,264	-	(2,275)	11	-	-
<b>Total restricted funds</b>	<b>13,592,221</b>	<b>11,111,653</b>	<b>(10,277,324)</b>	<b>798,631</b>	<b>-</b>	<b>15,225,181</b>
<b>Unrestricted funds:</b>						
General reserve	1,617,810	1,018,622	(818,153)	159,446	(224,111)	1,753,614
Designated funds:						
Indirect future costs	1,321,194	-	-	-	224,111	1,545,305
<b>Total unrestricted funds</b>	<b>2,939,004</b>	<b>1,018,622</b>	<b>(818,153)</b>	<b>159,446</b>	<b>-</b>	<b>3,298,919</b>
<b>Total funds</b>	<b>16,531,225</b>	<b>12,130,275</b>	<b>(11,095,477)</b>	<b>958,077</b>	<b>-</b>	<b>18,524,100</b>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2024**

**12. Funds Movement (continued)**

*Programme Objectives and Funding*

The VITAL programme has two strands: product development and commercial development. The broad objectives are: 1) to develop six new high impact livestock vaccines ready for commercial production and suitable for widespread use by smallholders in Africa and South Asia; and 2) to partner the animal health industry to establish five large scale portfolio distribution networks in Africa and South Asia with each initiative being capable of generating positive cash flows by year 4 and achieving subsequent growth and expansion through these cash flows. The programme is jointly funded by BMGF (80%) and FCDO (20%). This programme was contracted to end on 30 September 2022 but has since been awarded a no-cost extension to December 2024 for BMGF and March 2025 for FCDO because of delays associated with COVID-19. This will allow the programme objectives to be fully achieved beyond the initial contractual end date.

The purpose of the AAT 3 programme is to build upon the success of the work carried out under previous AAT programmes resulting in the improved tools for the control of Animal African Trypanosomiasis. The specific objective of AAT 3 is the commercial development of a registered therapeutic trypanocidal product, ready for sale through GALVmed's commercial partner in the AAT 3 programme, Boehringer Ingelheim. This programme is funded by both BMGF (\$19m) and FCDO (\$3.5m).

Regulatory Harmonisation programme is fully funded by BMGF and is carried out in partnership with Veterinary Medicines Directorate, World Organisation for Animal Health and East African Community. Its objective is to improve the registration system for veterinary medicines across Sub-Saharan Africa countries and harmonize the requirements to simplify the process, improve affordability, save time, and resources and to help ensure quality, safety, and efficacy of products.

The MoTAR programme is fully funded by BMGF and is carried out in partnership with Makerere University. It aims to provide Uganda with an effective means of controlling tick acaricide resistance (TAR) and tick-borne diseases (TBD), key constraints in sustainable livestock production. This will be achieved through the development of an online mapping tool showing relevant distribution patterns and through the establishment of a network of laboratories capable of delivering the necessary diagnostic and testing services for TAR/TBD on an ongoing, sustainable basis.

The VITAL Bridging programme aims to support the development and initiation of new programmes of work which will progress the next phase of work beyond VITAL and reflect the essence of the GALVmed 2030 strategy. This programme is funded by BMGF (\$7.7m).

The AgResults Brucellosis programme is a competition, managed by GALVmed, to develop and register a safe and efficacious vaccine against *Brucella melitensis*, the main cause of human infections with Brucella and a significant economic burden in developing countries. It is fully funded by the AgResults consortium.

The AgResults Foot and Mouth programme is a competition, managed by GALVmed, to encourage the development and uptake of an improved FMD vaccine tailored for the needs and requirements of East Africa. It is fully funded by the AgResults Consortium.

The MAHABA (Managing Animal Health and Acaricides for a Better Africa) programme is fully funded by BMGF and is carried out in partnership with Elanco Animal Health. The aim of the programme is to create effective tick control for SSPs, by building a clear understanding of acaricide usage, developing innovative methods to help educate on the effective use and by providing practical methods to counter resistance, avoid failures and allow sustainable tick control.

The PREVENT (Promoting and Enabling Vaccination Efficiently, Now and Tomorrow) programme is fully funded by BMGF and is carried out in partnership with Ceva Santé Animale. The aim of this programme is to create an efficient sector of medium-sized African hatcheries applying hatchery vaccination and proactive marketing methods to initiate and increase vaccinated chick sales to poultry small scale producers.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**12. Funds Movement (continued)**

The Bovine TB programme aims to enable and accelerate the development and implementation of rational evidence-based approaches to control TB, with a focus on India, and to provide a strong foundation for the development of control programmes in other developing countries. This project will establish and publish Target Product Profiles for novel tools to control TB and develop a roadmap for product development and commercialisation of novel diagnostic tests in India.

The Boehringer Ingelheim (BI) programme is fully funded by BMGF and is carried out in partnership with BI. Its objective is to deliver a viable business model for providing quality veterinary healthcare to smallholder farmers in Africa. The key activities for this programme are 1) a registration initiative of BI products in three key markets; and 2) a distribution and awareness initiative which accelerates the accessibility of a portfolio of products to areas which are normally very difficult to access through usual distribution networks.

The general reserve represents the free funds of the charity. Designated funds comprise unrestricted funds that have been set aside by the Trustees for a particular purpose. Organisational (indirect) costs need to be covered by contributions from all programmes. Cumulative net indirect core cost contributions have been designated by the Board at 31 March 2024 to fund future indirect costs.

**13. Total Assets – Analysed Between Funds**

2024	Fixed assets £	Net current assets £	Total £
<b>Restricted funds</b>			
VITAL	-	4,590,094	4,590,094
AAT 3	1,081	3,482,516	3,483,597
Regulatory Harmonisation	-	1,749,081	1,749,081
MoTAR	-	1,291,164	1,291,164
VITAL Bridging	-	1,133,583	1,133,583
AgResults Brucellosis	1,586	1,066,418	1,068,004
AgResults FMD	2,301	577,776	580,077
MAHABA	-	394,550	394,550
PREVENT	-	139,372	139,372
Bovine TB	-	129,218	129,218
	4,968	14,553,772	14,558,740
<b>Unrestricted funds</b>			
General reserve	33,795	1,701,230	1,735,025
Designated funds	-	1,572,277	1,572,277
	38,763	17,827,279	17,866,042
<b>Total</b>	38,763	17,827,279	17,866,042

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**13. Total Assets – Analysed Between Funds (continued)**

2023	Fixed assets £	Net current assets £	Total £
<b>Restricted funds</b>			
VITAL	-	3,872,664	3,872,664
AAT 3	-	4,196,382	4,196,382
VITAL Bridging	624	4,024,780	4,025,404
AgResults Brucellosis	-	1,172,091	1,172,091
AgResults FMD	3,725	411,743	415,468
MAHABA	-	398,248	398,248
PREVENT	-	529,183	529,183
Bovine TB	-	501,982	501,982
Boehringer Ingelheim	-	113,759	113,759
TAHSSL	-	-	-
Health for Animals	-	-	-
	4,349	15,220,832	15,225,181
<b>Unrestricted funds</b>			
General reserve	10,894	1,742,720	1,753,614
Designated funds	-	1,545,305	1,545,305
	15,243	18,508,857	18,524,100
<b>Total</b>	15,243	18,508,857	18,524,100

**14. Operating Lease Commitments**

At 31 March 2024 GALVmed was committed to a total of future minimum lease payments under non-cancellable operating leases for land, buildings, and equipment for each of the following periods:

	2024 £	2023 £
Not later than one year	80,019	86,188
Later than one year and not later than five years	18,198	30,166
<b>Total</b>	98,217	116,354

**15. Share Capital**

The company is limited by guarantee and does not have share capital.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2024

**16. Reconciliation of Net Income to Net Cash Flow from Operating Activities**

	<b>2024</b>	<b>2023</b>
	£	£
<b>Net (expenditure)/income for the reporting period (as per the Statement of Financial Activities)</b>	(658,058)	1,992,875
<b>Adjustments for:</b>		
Loss/(Gain) on foreign exchange transactions	355,658	(958,077)
Depreciation charges	17,618	25,398
Loss on sale of assets	-	99
Interest from investments	(541,568)	(362,592)
(Increase)/Decrease in debtors	(1,802,404)	36,424
(Decrease)/Increase in creditors	(795,835)	266,379
<b>Net cash (used)/provided by operating activities</b>	<u>(3,424,589)</u>	<u>1,000,506</u>

Debtors contains accrued investment income of £215,696 (2023: £190,238). The movement on accrued investment income is included in investments within the cash flow statement.

**17. Related Parties**

There were no related party transactions in this or the prior year, other than the expenses as disclosed in note 4 of these accounts. The Trustees consider all the transactions during the year to have been undertaken on an arm's length basis.

**18. Ultimate Controlling Party**

GALVmed is constituted under its Memorandum and Articles of Association and is managed by its appointed Board of Trustees.



## Certificate Summary

ENVELOPE SUBJECT: **Approval required**  
DOCUMENT: **2023-24 Trustees' Report Financial Statements.pdf**  
DOCUMENT ORIGINATOR: **Louise Gillies (louise.gillies@hlca.co.uk)**

CERTIFICATE STATUS: **Completed**  
DELIVERED: **Jun 18, 2024 11:04 AM UTC**  
DOCUMENT PAGES: **31** CERTIFICATE PAGES: **1** TOTAL ENVELOPE PAGES: **32**

ENVELOPE ID: **ca20e7cc-d753-43c3-821f-6680279399b0**  
DOCUMENT ID: **a03c8ad3-1bbf-4bd2-a1a1-a6ce9e36bf2c**  
ORIGINATOR IP ADDRESS: **87.246.91.14**

COMPLETED SIGNATORIES: **3 / 3**  
COMPLETED IN PLACE SIGNATURES: **3 / 3**  
COMPLETED IN PLACE INITIALS: **0 / 0**  
CARBON COPY RECIPIENTS: **0**

## Signatures

## Timeline

E-SIGNED BY: **Isabelle Dieuzy-Labaye (isabelle.dieuzy.labaye@gmail.com)**  
SECURITY LEVEL: **Secure Email (Authenticated)**  
E-SIGNATURE ID: **4762e092-5dab-4343-b904-a30f5038f64a**

SENT: **Jun 18, 2024 11:04 AM UTC**  
VIEWED: **Jun 27, 2024 7:47 AM UTC**  
SIGNED: **Jun 27, 2024 7:53 AM UTC**  
USING IP ADDRESS: **90.79.181.175**

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: **Isabelle Dieuzy-Labaye** EMAIL: **isabelle.dieuzy.labaye@gmail.com**

E-SIGNED BY: **Jandy Stevenson (jandystevenson@yahoo.co.uk)**  
SECURITY LEVEL: **Secure Email (Authenticated)**  
E-SIGNATURE ID: **2067b46f-ecf6-421d-b4b8-a3687608cde1**

SENT: **Jun 18, 2024 11:04 AM UTC**  
VIEWED: **Jun 19, 2024 2:24 PM UTC**  
SIGNED: **Jun 19, 2024 2:49 PM UTC**  
USING IP ADDRESS: **86.172.242.68**

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: **Jandy Stevenson** EMAIL: **jandystevenson@yahoo.co.uk**

E-SIGNED BY: **Keith Macpherson (keith.macpherson@hlca.co.uk)**  
SECURITY LEVEL: **Secure Email (Authenticated)**  
E-SIGNATURE ID: **8ef4fc03-f8c2-4ac2-ae7e-6eb6b593690a**

SENT: **Jun 18, 2024 11:04 AM UTC**  
VIEWED: **Jun 27, 2024 12:23 PM UTC**  
SIGNED: **Jun 27, 2024 12:33 PM UTC**  
USING IP ADDRESS: **87.246.91.14**

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: **Keith Macpherson** EMAIL: **keith.macpherson@hlca.co.uk**

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**

England & Wales - Charity number 1115606

---

# Accounts

---

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

Registered in England No. 05393391  
England and Wales Charity No. 1115606  
Scottish Charity No. SC039197

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2023**



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**For the year ended 31 March 2023**

**CONTENTS**

	<u>Page</u>
<b><u>REFERENCE AND ADMINISTRATIVE DETAILS</u></b>	2
<b><u>REPORT OF THE TRUSTEES</u></b>	
<b>INTRODUCTION</b>	<b>3</b>
<b>OBJECTS, OBJECTIVES AND ACTIVITIES</b>	<b>3</b>
Objects	3
Objectives & Activities	3
<b>STRUCTURE, GOVERNANCE AND MANAGEMENT</b>	<b>3</b>
Trustee Recruitment, Induction, Training and Evaluation	4
Trustees' and Members' Meetings and Business	4
Strategy and Decision Making	4
Key Management Remuneration	4
Diversity	5
Safeguarding	5
Partnerships and Related Parties	5
<b>STRATEGIC REPORT</b>	<b>5</b>
Performance and Achievements	5
- Key Performance Indicators	5
- Key Achievements	6
- Impact of Our Work	7
Financial Review	7
- Income	7
- Expenditure	8
- Balance Sheet	8
- Liquidity Management Policy	8
- Climate Change	8
- Reserves	8
- Unrestricted Reserves Policy	8
Future Plans	9
- Objectives	9
- Financial	9
Principal Risks and Uncertainties	9
- Risk Management	9
<b>GOING CONCERN</b>	<b>10</b>
<b>AUDITORS</b>	<b>11</b>
<b>STATEMENT OF DISCLOSURE OF INFORMATION TO AUDITORS</b>	<b>11</b>
<b><u>RESPONSIBILITIES OF THE TRUSTEES</u></b>	<b>12</b>
<b><u>INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES</u></b>	<b>13</b>
<b><u>INCOME AND EXPENDITURE ACCOUNT AND STATEMENT OF FINANCIAL ACTIVITIES</u></b>	<b>16</b>
<b><u>BALANCE SHEET</u></b>	<b>17</b>
<b><u>STATEMENT OF CASH FLOWS</u></b>	<b>18</b>
<b><u>NOTES TO THE FINANCIAL STATEMENTS</u></b>	<b>19-31</b>



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Trustees**

Dr I Dieuzy-Labayé	Chair (from 13 <sup>th</sup> September 2022) Chair of Commercial Development Advisory Committee (to 15 June 2022)
Dr J Maina	Vice-Chair Chair of HR Committee
Prof M Gill	Chair of Impact, Monitoring & Evaluation Advisory Committee
Mr S Jha	Chair of Commercial Development Advisory Committee (from 15 June 2022)
Mrs. J Stevenson FCA	Chair of Finance & Risk Committee
Dr A Banga	
Dr F Kausche	
Dr H Wamwayi	Chair of Technical Scientific Committee (from 13 <sup>th</sup> September 2022)
Dr J Dreesen	Appointed 1 <sup>st</sup> March 2023
Prof P Wood	Resigned 13 <sup>th</sup> September 2022 Chair (to 13 <sup>th</sup> September 2022) Chair of Technical Scientific Committee (to 13 <sup>th</sup> September 2022)

**Chief Executive Officer** Dr C Schumacher

**Company Secretary** Ms H Stevenson CA

**Independent Auditors**

Henderson Loggie LLP  
Chartered Accountants  
Ground Floor, 11-15 Thistle Street  
Edinburgh, EH2 1DF

**Legal Advisors**

Dentons LLP  
Quartermile One  
15 Lauriston Place  
Edinburgh, EH3 9EP

**Bankers**

Lloyds Bank plc  
City Office, PO Box 72  
Bailey Drive, Gillingham Business Park  
Kent, ME8 0LS

**Registered Office**

One Fleet Place  
London, EC4M 7WS

**Principal Office**

Doherty Building  
Pentlands Science Park  
Bush Loan, Edinburgh, EH26 0PZ

**Company No.** 05393391

**England and Wales Charity No.** 1115606

**Scotland Charity No.** SC039197



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2023**

## **INTRODUCTION**

The Trustees have pleasure in presenting their report for the year ended 31 March 2023. This report is prepared in accordance with the *Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)* and in accordance with applicable law.

Global Alliance for Livestock Veterinary Medicines (the company) has complied with the duty in Section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

Global Alliance for Livestock Veterinary Medicines (GALVmed) is a company limited by guarantee and is registered as a charity with the Charity Commission and the Office of the Scottish Charity Regulator (OSCR). It is incorporated in the UK with its principal office in Edinburgh, UK. Other offices are maintained in New Delhi, India (South Asia office); and Nairobi, Kenya (Africa office). Other reference and administrative details are set out in the previous section.

## **OBJECTS, OBJECTIVES AND ACTIVITIES**

### **Objects**

Around 900 million poor people rely on livestock for their livelihoods. The company's objects, as set out in its Memorandum of Association, are for the benefit of the public:

- 1) to relieve financial hardship and promote good health (including improving food security) amongst small-holder livestock keepers (small-scale livestock producers – SSPs) in developing countries through the promotion of affordable vaccines, pharmaceutical and diagnostic products and services aimed at improving the health of their livestock; and
- 2) to promote the effective use of resources to achieve the above charitable purposes through the identification, management, funding, and co-ordination of: a) development of livestock vaccines, pharmaceuticals and diagnostics products and services; and b) delivery of these products and services at affordable prices, by working in partnership with others (whether charities, government; private bodies or institutions).

GALVmed's vision is the transformational improvement in the wellbeing and economic progression of SSPs. GALVmed's mission is to contribute to the transformation of SSPs' lives by:

- understanding the constraints to animal health and how to overcome them;
- engaging the animal health industry; and
- ensuring awareness, availability, and adoption of effective animal health interventions.

### **Objectives & Activities**

GALVmed achieves its charitable purpose by operating a series of Research and Development (R&D) and Commercialisation programmes, supported by Enabling Environment and Monitoring and Evaluation (M&E) activities, funded principally by the Bill and Melinda Gates Foundation (BMGF) and the UK Government through its Foreign, Commonwealth and Development Office (FCDO). These programmes are designed to identify products that SSPs can use to improve the health of their animals and to make such products more easily accessible. The two largest of these programmes are Veterinary Innovations Transforming Animal Health and Livelihoods (VITAL), with a budget of \$50m, and African Animal Trypanosomiasis 3 (AAT), with a budget of \$22.5m. 6 other programmes are also being operated, with values ranging from \$1.2m to \$5.0m. All programmes are supported by the funding of project core costs through the VITAL Bridging programme, with a budget of \$7.7m, except for AAT 3 and Agresults where project staff are funded directly (see note 12 for further information on all programmes).

## **STRUCTURE, GOVERNANCE AND MANAGEMENT**

The governance of the company is the responsibility of the Trustees, and the company adopts the appropriate principles and recommended practices of the Charity Governance Code.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2023**

The Members elect the Trustees in accordance with the terms of the Memorandum and Articles of Association.

**Trustee Recruitment, Induction, Training and Evaluation**

The maximum number of Trustees permitted by the company's Articles is 10. Trustees are recruited for their individual skills and experience to fill current or impending vacancies, guided by a comprehensive skills and diversity matrix. Trustees serve a term of 3 years subject to a maximum of 2 consecutive terms and Board and AGM approval. Recruitment of Trustees is managed by a Trustee Selection Panel comprising 3 Trustees of which one is the HR Committee Chair. The Chair of the Board retired and a replacement Chair was appointed at the 2022 AGM. A replacement Trustee was also approved at the AGM and appointed in March 2023 following an extensive recruitment process. A further recruitment process is currently ongoing to identify candidates to replace Trustees due to retire at the 2023 AGM.

A formal Trustee induction process is in place to ensure clarity of the role of the Trustee and their responsibilities under company and charity legislation. Trustees, new and current, also receive training on their legal responsibilities annually prior to the AGM. During the year trustees received training on risk management.

Trustee evaluation takes place annually and is based on self-assessment, peer-assessment and annual performance interviews with the Chair and Vice-Chair; the process includes identifying development requirements.

**Trustees' and Members' Meetings and Business**

Trustees meet formally four times a year, normally with two virtual and two physical meetings which are held at the same time as the Members' meetings. Following the relaxation of COVID-19 rules in early 2022, both physical meetings took place as expected in the year (Edinburgh in September 2022 and Nairobi in March 2023). The business of all meetings is minuted.

On 31 March 2023 there were 15 Members and 9 Trustees. Members are subscribers to GALVmed's Memorandum of Association. The organisation appoints a representative to attend all meetings and to undertake their responsibilities as dictated by the Articles of Association. Members have rights and obligations in accordance with the Articles. In addition, observers from 5 organisations, including BMGF and FCDO, the company's major funders, are invited to attend the Members' meetings, with the funders also invited to meet separately with the Board.

The Board is supported by the Finance & Risk and HR committees, to whom aspects of day-to-day accountability and governance are delegated. The HR Committee is also responsible for safeguarding. There are also three advisory committees - the Technical Scientific, Commercial Development (CD) and Impact, Monitoring and Evaluation committees. These committees provide guidance to the Board through the involvement of external experts.

**Strategy and Decision Making**

Development of the company's strategy for the achievement of its charitable objectives is overseen by the Board of Trustees and evolved by the Executive Directors. The related corporate objectives and budget are set out in the Annual Plan. Progress in achieving these objectives is assessed by the Board through reports by the Chief Executive and the Executive Directors at Board meetings, drawn from monthly and quarterly internal performance monitoring tools. Strategic and operational issues are brought to the Board for assessment and direction as required. GALVmed are currently working towards the achievement of the 2030 Strategy, which was approved by the Board in March 2021, utilising the Strategy Implementation Plan and the Strategy Execution Framework. During the year, a series of Industry Engagement Deep Dives were held with 8 commercial partners to direct the project portfolio for future programmes.

**Key Management Remuneration**

Key management includes the Chief Executive (CEO) and Executive Directors of the company who operate as the GALVmed Leadership Team (GLT).

The HR Committee has responsibility delegated to it for setting the framework for key management remuneration. The main responsibilities of the Committee in relation to key management remuneration are:

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2023**

- to determine and agree with the Board the broad policy for key management remuneration;
- to approve the design, determine targets and approve payments of any performance related schemes; and
- to determine the total remuneration package of each member of the GLT.

The performance related pay scheme, which is based on departmental, and individual objectives developed from the corporate objectives, is applicable to all employees.

**Diversity**

The diversity of the Trustees, GLT and staff at 31 March 2023 is:

	Gender		Ethnicity		
	Male	Female	African	Asian	Caucasian
Trustees	5	4	3	1	5
GLT	2	3	1	-	4
Staff	6	16	9	3	10

**Safeguarding**

GALVmed is committed to addressing safeguarding throughout its work. It does so through a specific set of policies and procedures that include: Safeguarding Policy (which explicitly addresses prevention, reporting and response); Trustee and GLT training (on commencement and biennial thereafter); all-staff awareness; and contractual commitment to safeguarding by its partners and consultants. No safeguarding issues were reported in the year.

**Partnerships and Related Parties**

Partnerships with entities to whom research and development, commercialisation and other work can be subcontracted is a key part of the way the company operates and is instrumental in allowing it to pursue its charitable objectives. The company initiates, facilitates, brokers, and contributes to such partnerships from two perspectives: 1) specific partnerships to deliver and support programme achievement and impact; and 2) higher level strategic partnerships to initiate and advance the livestock agenda. All such relationships are formalised through Memoranda of Understanding, Confidentiality Agreements and Contractual Agreements. All contractual arrangements and related party transactions (detailed in Note 17 to the Financial Statements) are conducted at arm's length.

**STRATEGIC REPORT**

**Performance and Achievements**

*Key Performance Indicators*

The Trustees and GLT assess the financial and operational performance of each programme using the following key performance indicators (KPI):

- detailed milestones within specific activities as defined in the funder agreement for each programme;
- quarterly KPI dashboards, providing quantitative and qualitative measure of delivery across all functions;
- monthly and quarterly actual expenditure against Board approved budget and forecasts; and
- achievement of the annual corporate objectives.

The Advisory and Board Committees oversee the financial and operational performance of organisational and programme activities quarterly.

In addition, service level agreements have been established for all service-related functions, performance of which is assessed quarterly.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2023**

*Key Achievements*

The company made good progress during the year in achieving its charitable purpose. Its corporate objectives for the year to 31 March 2023 together with key achievements are:

<b>Objective</b>	<b>Achievements</b>
<b>Strategic</b>	
Execute GALVmed 2030 Strategy including: developing R&D project pipelines and analysing the strategic themes; evolving the Commercial Development (CD) SEAMLiSS (Systematically Enhancing African Health Markets for Livestock Producers in Small-Scale Settings) platform and business case; developing downstream last-mile bridging strategies; and developing the proposal for R&D and CD project portfolios in South Asia.	
<i>Rating of progress:</i> Partially Achieved	Execution of the 2030 Strategy continued including the ongoing development of the R&D and CD portfolio proposals for the next round of major programme funding, expected to be submitted in Q2 2023. This included 1) the development of R&D project pipelines following the industry engagement deep dive exercise with several commercial partners – 30 ideas were generated and assessed resulting in 8 to 10 proposals for further expansion. The other R&D strategic aims of New Technology Platforms and Manufacturing Capacity platforms remain under development; 2) a SEAMLiSS CD platform concept note was submitted in August, following an expansion of the business case and an evolution of the proposal in both Africa and South Asia. 3) A marketing manager was recruited to drive the development of formal marketing/launch plans for all VITAL R&D combination products (combos) ensuring an ongoing focus on SSPs.
<b>Tactical</b>	
Deliver VITAL R&D, AgResults Brucella & FMD, Tryps, ASF, Bovine TB, TAHSSL, VITAL CD, PREVENT, MAHABA on plan and on budget.	
<i>Rating of progress:</i> Achieved	All programmes are progressing well and are on target, despite some delays, to the satisfaction of partners and funders. The VITAL programme is progressing well for most projects with a no-cost extension (NCE) approved to March 2024 for FCDO and December 2024 for BMGF to accommodate delays. A costed extension was also successfully negotiated for the Brucella programme for a further 6 years to 2028. Impact achieved is noted on page 7.
<b>Process</b>	
Ensure strategy and project delivery is underpinned by appropriate human resourcing and efficient processes through: implementing a new staff learning & development programme; evolving the M&E methodology to evaluate & reflect GALVmed's output, outcomes and impact generation; identifying key principles of knowledge management processes; rolling out and embedding the Strategy Execution Handbook; embedding 6-4 Project Management principles into all new projects; assessing key systems including project risk management; and ensuring that GALVmed is staffed appropriately with succession plans in place.	
<i>Rating of progress:</i> Achieved	Substantial improvement in processes in the year including: leadership development learning programme undertaken by all senior managers; new theory of change and framework to monitor organisational performance developed and being tested by M&E as well as revisiting the 2030 Goals framework; SharePoint now embedded across the organisation to ensure core knowledge is accessible with further work on knowledge management to be completed in the future; Strategy Execution Handbook rolled out; project management principles embedded; excellent progress on project risk management with project risk registers now in place for all programmes; and succession plans now in place for all key positions.
<b>Outreach</b>	
Expand GALVmed's engagement with external stakeholders by: finalising and launching the GALVmed 2030 Strategy communication plan and tools; updating the corporate communication deck; cultivating active partner engagement; and supporting new Members and Trustees identification and induction.	
<i>Rating of progress:</i> Achieved	The 2030 Strategy communication plan was finalised and launched, with good external visibility. This was further enhanced through the industry engagement exercise, where deep dives were completed with 8 commercial partners. There has also been fundamental work delivered by M&E in 2022 which is now embedded in CD to drive SSP-centricity and impact, and to ensure greater communication of GALVmed's achievements, and greater interaction with stakeholders. One new trustee was recruited to the Board, and their induction supported.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2023

<b>Development</b>	
Broaden GALVmed's funding base and secure fresh funding in line with GALVmed 2030 Strategy, including: securing funding for TAHSSL and VITAL bridging; ensuring future sustainability of core costs; engaging with new funders including the exploration of the African funding environment; and consideration of the long-term sustainability of GALVmed.	
<i>Rating of progress:</i> Partially Achieved	The funding for VITAL Bridging (to support the VITAL NCE to December 2024) was secured, ensuring the future sustainability of GALVmed until December 2024. As part of VITAL Bridging, R&D and CD strategic project proposals will be developed and evolved into the next major programme funding proposal which will be required to fund future core costs and therefore ensure long term organisational sustainability. GALVmed chose to leave the TAHSSL programme for legal and budgetary reasons. A Board working group has been set up to explore the African funding environment, and this along with further funder diversification will be considered once future funding is secured.

*The Impact of our Work*

Monitoring and Evaluating (M&E) activities have developed an impact model to quantify the increase in livestock productivity (expressed in dollar terms) that is brought about through the use of GALVmed-supported animal health products. A broad portfolio of animal health products has been sold through multiple initiatives across various geographies. Initiatives including VITAL, BI Last Mile and PREVENT have collectively sold an estimated 1 billion doses of vaccines, therapeutics, and other animal health products to SSP customers, via GALVmed's commercial partners, across 15 countries since inception of each of the respective projects (VITAL, October 2017; BI Last Mile, January 2018; PREVENT, November 2020) (India, Nepal, Kenya, Tanzania, Senegal, Ghana, Cameroon, Mali, Nigeria, Burkina Faso, Ethiopia, Chad, Rwanda, Zimbabwe, and Ivory Coast). This includes an estimated 0.5 billion doses sold over the past year, reaching over 200,000 SSPs.

The generation of impact through these initiatives is key and, at the same time, a primary objective of the CD initiatives is financial viability. Therefore, both components are actively monitored and reported on.

The objectives, achievements and impact of two active programmes, for example, are:

- BI Last Mile: The initiative aims to bridge the gap ("last mile") in access, availability, and awareness of animal healthcare solutions in hard-to-reach areas. This initiative has reached more than 40,000 farmers in 6 countries. This equates to 2,820 farmer meetings, 23,242 farm visits, 20,453 retailer visits and 10,686 vet visits. This improves productivity and income generation, ensuring food security and livelihood for the local communities.
- PREVENT: This programme works with medium-sized hatcheries spread across 8 African countries to provide high-quality, vaccinated day-old chicks to SSPs together with practical advice and guidance from a team of field technicians. To date, 24 hatcheries have been equipped and trained. This equates to the vaccination of 37m day-old chicks, to the benefit of 6,000 farmers. There have also been 1,800 farm visits undertaken and over 100 farmer meetings held by PREVENT Field Technicians, which have been attended by 1,500 farmers. This project builds a uniquely comprehensive picture of poultry disease in Sub-Saharan Africa.

All GALVmed programmes have different objectives and timelines and are therefore at different stages in their execution. As programmes progress, we will continue to quantify the impact that all GALVmed's work has on SSPs.

**Financial Review**

Income in the year was £13.1m (2022: £14.1m) and total expenditure was £11.1m (2022: £11.6m).

*Income*

Restricted income (excluding exchange gains) of £11.1m (2022: £12.2m) includes £4.9m in respect of VITAL Bridging and £3.4m in respect of VITAL; funding for other programmes totalled £2.8m. Unrestricted income of £1.0m was received (2022: £1.1m) from contributions from programmes to overheads, and from interest.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2023**

An unrealised exchange gain of £1.0m has arisen (2021-22: gain of £0.7m) on the conversion of foreign currency balances at year end exchange rates. The gain is a result of the weakening of Sterling against the US Dollar (in which most of the company's funding is received) from 1.32 to 1.24 in the year. The company minimises the effects of currency fluctuations by taking several steps, including contracting in the funded currency where possible and optimising the timing of foreign currency conversions.

*Expenditure*

Expenditure remained broadly consistent at £11.1m (2022: £11.6m). VITAL costs of £3.5m continue to make up the largest proportion of expenditure, 32% (2022: £5.6m, 48%). Expenditure on AAT 3 has increased to £3.4m, 30% (2022: £2.5m, 22%). Unrestricted spend has remained consistent at £0.8m (2022: £0.8m).

*Balance Sheet*

The level of cash held has increased from £17.2m to £19.4m in the year because of advanced AAT 3, VITAL and VITAL Bridging funding.

*Liquidity Management Policy*

The company's liquidity management and investment objectives, responsibilities, risk, and strategy are clearly set out in a Liquidity Management Policy which is subject to review annually. The related liquidity and investment activity is reviewed quarterly by the Finance & Risk Committee. GALVmed's Liquidity Management Policy is driven by the need to have funds readily available to fund its activities in diverse geographies as well as to maintain the infrastructure of the organisation. As such, longer term investments are not appropriate in maintaining adequate cashflow.

*Climate Change*

The Board is committed to reducing the company's greenhouse gas emissions, particularly those resulting from air travel. The Company generated and offset 122 tonnes of emissions in the year (2021-22: 68 tonnes). Carbon offset is through investment in like-purposed initiatives. A Board/Staff joint meeting was held in September 2022 to discuss how GALVmed could decrease its carbon footprint, with several actions identified including the need to observe and support livestock-related climate change actors, and to support staff in actively reducing their individual ecological footprints in and outside the office. As part of this, travel has reduced substantially since pre-pandemic levels, where alternatives to air travel are now a pre-requisite consideration before travel is undertaken.

*Reserves*

Reserves at 31 March 2023 total £18.5m (2022: £16.5m), of which available funds not tied up in fixed assets amount to £18.5m (2022: £16.5m). Reserves related to restricted funds of £15.2m (2022: £13.6m) mainly relate to advance funding for AAT 3, VITAL and VITAL Bridging.

*Unrestricted Reserves Policy*

Unrestricted reserves at 31 March 2023 amount to £3.3m (2022: £2.9m). From this amount, the Trustees have established a designated fund of £1.5m (2022: £1.3m) which comprises unrestricted reserves that have been set aside for any future shortfall in the recovery of overhead costs from programmes.

The objective of the company's Unrestricted Reserves Strategy is to build sufficient funds to protect the company from any adverse changes in its financial circumstances and to pursue operational opportunities that, in the initial phase, are not funded by 3<sup>rd</sup> parties. By considering a variety of risks, the Trustees have concluded that £1.2m of general unrestricted reserves is the minimum that should be held. General unrestricted reserves are currently held in excess of this to allow for the future investment in the 2030 Strategy and to ensure financial sustainability beyond the end of VITAL Bridging in September 2024 (especially continuity of delivery of the VITAL programme to December 2024) should additional funding not be awarded. The unrestricted reserves policy is reviewed every 6 months to ensure that it reflects current circumstances.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2023

**Future Plans**

*Objectives*

GALVmed is operating in accordance with the vision of the 2030 Strategy. This builds upon the evolution of the company since inception as a product development partnership working on a strong portfolio of new products, technologies and processes while continuing to facilitate scale-orientated commercial development initiatives.

GALVmed has identified the following key strategic corporate objectives for 2023-24:

<b>Objective</b>	
<b>1.</b>	New funds to deliver GALVmed's mission of improving availability and SSP access to quality animal health products in sub-Saharan Africa and South Asia in advanced stage of negotiation with funders (target of ~\$50M)
<b>a.</b>	- New comprehensive project portfolio designed (concept note outlined 2Q23, full concept noted 3Q23) and VITAL2 program funding proposal submitted to current funders (1Q24).
<b>b.</b>	- Multiple smaller and three large new funders evaluated and approached regarding co-funding of future GALVmed work (1Q24).
<b>2.</b>	Program functions and project managers enabled to deliver 2023/24 project targets with required financial, human resource, operational and project management support
<b>a.</b>	- Current projects delivered as close as possible to plan, deliverables, and financials (1Q24).
<b>b.</b>	- Combo launch project and VITAL2 funding proposal development activity planned & executed with excellence and supported by project management and advocacy support (throughout the year up to end of 1Q24).
<b>3.</b>	Strong focus on delivering impact and transformational results through GALVmed's current and future projects and GALVmed's impact, achievements and learnings communicated
<b>a.</b>	- M&E modelling methodology reviewed and framework to document organizational (transformational) achievements developed to ensure that GALVmed's impact and other project outcomes are comprehensively captured, and learnings communicated and used to optimize GALVmed's future program design (1Q24).
<b>b.</b>	- In preparation of the VITAL Combo-launch, identify and build partnerships that drive uptake of quality livestock vaccines by SSPs (by 1Q24).
<b>c.</b>	- Strong impact, learnings and achievements communication plan developed (2Q23) and success stories disseminated (ongoing to 1Q24).

*Financial*

The 2023-24 expenditure budget is £10.6m, a 5% decrease on 2022-23 actual expenditure. This decrease is mainly because of the reduced VITAL sub-award activity as the programme progresses through to the final stages of delivery.

**Principal Risks and Uncertainties**

*Risk Management*

The company's governance structure includes risk management. During the year significant work was undertaken to strengthen risk management where project risk management was overhauled, with project risk registers now in place for all ongoing projects and a tool developed to analyse, aggregate, and escalate project risks. The Risk Management Policy details the company's risk management objectives, processes, reporting and responsibilities. This was updated to incorporate the concept of project risk management, highlighting synergies with corporate risk management, and ultimately ensuring greater visibility, aggregation, and escalation of project risks.

The Corporate Risk Register highlights the major risks to which the company is exposed and for each risk the score, lead risk owner, mitigations and actions stated. It is maintained to support strategic, financial, and operational planning and therefore to assist in achieving the company's objectives and targets. The key risks, that GALVmed faces at the time of this report, and key mitigations, are:

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2023

<b>Risk</b>	<b>Key Mitigations</b>
Failure to deliver and/or to align strategic proposals, impacts on future funding	Multi-pronged interaction with funders to ensure our strategy continues to align with funders evolving strategies and to identify how GALVmed fits into animal health landscape
Failure to design and implement projects which achieve economic impact for SSPs	Pursue the routes to SSP markets before product development is completed
Geo-political instability impacts on GALVmed's beneficiaries, operations, and resources	Adopt a prudent approach to selecting countries of operation to safeguard partners and staff and increase level of success
Loss of highly experienced key staff impacts on project delivery, reputation & staff morale	Succession planning and managing staff expectations on career progression perspective; development of retention strategy for key talent
Data security breach results in loss of, or corrupted, data	Multiple systems, software, support and user awareness approaches to ensure robust mechanisms and being ever vigilant
Barriers to product registration reduces product availability	Support harmonisation of product registration in Africa and engage with international organisations
Inability to secure future funding impacts on sustainability of the funds to run the organisation	Diversification of funding base is being pursued with indirect cost affordability assessed monthly
Dependency on limited funding sources impacts on delivery of the 2030 Strategy	Funder relations department resource increased to allow consideration of best approach to convert project ideas to funding proposals and increase opportunity for funder diversification

As well as the strategic risks noted in the table above, important financial risks are monitored and include the possible loss of bank deposits through fraud or theft, currency risk, liquidity risk and dependency on limited funding sources. The risk of loss of bank deposits is managed through the bank mandates in place and continued vigilance. Currency and liquidity risk are managed by following the Liquidity Management Policy. The 2030 Strategy and Funder Relations Strategy aims to address the limited funding sources issue.

### **GOING CONCERN**

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding of current programmes is assured: the VITAL Bridging grant will cover all organisational direct costs to September 2024 to enable the completion of VITAL by December 2024, with further funding from VITAL itself to cover organisational direct costs for the final three months of the programme. The VITAL Bridging grant will further ensure continuity of other project commitments and will allow the evolution of future project proposals.

We are currently in the process of developing our proposal for the next round of Gates Foundation funding, which is expected to commence in Q1 2025 at the latest and are in regular discussions with both our funders to ensure this programme is designed in line with their evolving strategies, as well as GALVmed priorities. We expect to submit our initial proposals to our funders (concept note) in Q2/Q3 2023 and a full funding proposal in Q1 2024.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2023**

An assessment of unrestricted funds has also been carried out. Designated funds are sufficient to cover any shortfall in indirect costs during the VITAL Bridging period if required, although it is anticipated this need will be small, if it is needed at all. General unrestricted reserves are also sufficient to maintain the minimum balance of £1.2m required within the reserves policy. There are therefore sufficient funds to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

**AUDITORS**

Henderson Loggie LLP, Chartered Accountants, were reappointed as auditors to the company at the Annual General Meeting in 2022, following a successful retender exercise. Their re-appointment was approved for an initial three-year term subject to annual consideration by both parties.


**STATEMENT OF DISCLOSURE OF INFORMATION TO AUDITORS**

To the knowledge and belief of each of the persons who is a Trustee at the time this report is approved:

- a) So far as the Trustee is aware, there is no relevant information of which the organisation's auditors are unaware; and
- b) He/or she has taken all steps that he/she ought to have taken as a Trustee to make himself/herself aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees have fulfilled their legal responsibilities with respect to the Trustees' Report, Strategic Report, and Financial Statements.

The Trustees' Report including the Strategic Report was approved by the Board of Trustees and signed on their behalf by:

  
Isabelle Dieuzy-Labayé - 2023-06-29, 07:42:30 UTC

Dr I Dieuzy-Labayé



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**RESPONSIBILITIES OF THE TRUSTEES  
For the year ended 31 March 2023**

The Trustees (who are also the Directors for the purposes of company law) are responsible for the preparation of the Trustees' Report, including the Strategic Report, and financial statements in accordance with applicable law and regulations.

Law applicable to incorporated charities in Scotland requires the Trustees to prepare an annual report and financial statements for each financial year in accordance with applicable law and regulations. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).

Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity at the end of the year and of its financial activities including its income and expenditure during the year then ended. In preparing those financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper and adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006, with the Charities and Trustee Investment (Scotland) Act 2005, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the maintenance and integrity of the charity.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
**For the year ended 31 March 2023**

**Opinion**

We have audited the financial statements of Global Alliance for Livestock Veterinary Medicines (the 'charitable company') for the year ended 31 March 2023 which comprise the Income and Expenditure Account and Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2023, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the auditor responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' (who are also the directors of the charitable company for the purpose of company law) use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2023

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report, included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor responsibilities for the audit of the financial statements**

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**Extent to which the audit was considered capable of detecting irregularities, including fraud**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below:

As part of our planning process:

- We enquired of management the systems and controls the charitable company has in place, the areas of the financial statements that are mostly susceptible to the risk of irregularities and fraud, and whether there was any known, suspected or alleged fraud. Management informed us that there were no instances of known, suspected or alleged fraud;

GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES  
For the year ended 31 March 2023

- We obtained an understanding of the legal and regulatory frameworks applicable to the charitable company. We determined that the following were most relevant: employment law in all relevant jurisdictions, GDPR, Health and Safety, and compliance with the UK Companies Act and charity legislation.
- We considered the incentives and opportunities that exist in the charitable company, including the extent of management bias, which present a potential for irregularities and fraud to be perpetrated, and tailored our risk assessment accordingly; and
- Using our knowledge of the charitable company, together with the discussions held with management at the planning stage, we formed a conclusion on the risk of misstatement due to irregularities including fraud and tailored our procedures according to this risk assessment.

The key procedures we undertook to detect irregularities including fraud during the course of the audit included:

- Inquiry of management about any known or suspected instances of non-compliance with laws and regulations and fraud;
- Reviewing of legal expenses and minutes of board and sub-committee meetings;
- Review of correspondence with regulators;
- Challenging assumptions and judgements made by management in their significant accounting estimates, in particular accruals; and
- Auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness.

Owing to the inherent limitations of an audit, there is unavoidable risk that some material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISAs (UK). For instance, the further removed non-compliance is from the events and transactions reflected in the financial statements, the less likely the auditor is to become aware of it or to recognise the non-compliance.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

#### Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, the charitable company's members as a body and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

  
Keith Macpherson - 2023-06-29, 16:20:49 UTC

#### Keith Macpherson (Senior Statutory Auditor)

For and on behalf of Henderson Loggie LLP

Chartered Accountants

Statutory Auditor

Henderson Loggie LLP is eligible to act as auditor in terms of section 1212 of the Companies Act 2006.

Ground Floor

11-15 Thistle Street

Edinburgh

EH2 1DF

...2023-06-26.. 2023

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INCOME AND EXPENDITURE ACCOUNT AND  
STATEMENT OF FINANCIAL ACTIVITIES**  
For the year ended 31 March 2023

	Notes	Unrestricted £	Restricted £	Total 2023 £	Total 2022 As restated £
<b>Income from:</b>					
Charitable Activities	2	956,083	10,811,600	11,767,683	13,357,284
Investments		62,539	300,053	362,592	5,638
Other: Gain on Foreign Exchange	6	159,446	798,631	958,077	718,009
<b>Total Income</b>		<u>1,178,068</u>	<u>11,910,284</u>	<u>13,088,352</u>	<u>14,080,931</u>
<b>Expenditure on:</b>					
Charitable Activities	3	818,153	10,277,324	11,095,477	11,551,355
<b>Total Expenditure</b>		<u>818,153</u>	<u>10,277,324</u>	<u>11,095,477</u>	<u>11,551,355</u>
<b>Net Income</b>	5	<u>359,915</u>	<u>1,632,960</u>	<u>1,992,875</u>	<u>2,529,576</u>
Net Movement in Funds		359,915	1,632,960	1,992,875	2,529,576
<b>Reconciliation of Funds</b>					
Total Funds Brought Forward at 1 April 2022	12	<u>2,939,004</u>	<u>13,592,221</u>	<u>16,531,225</u>	<u>14,001,649</u>
Total Funds Carried Forward at 31 March 2023	12	<u>3,298,919</u>	<u>15,225,181</u>	<u>18,524,100</u>	<u>16,531,225</u>

All the results of the company relate to continuing activities.

The company has no recognised gains or losses other than those set out above.


The notes on pages 19 to 31 form part of these financial statements

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**BALANCE SHEET**  
As at 31 March 2023

	Notes	2023		2022	
		£	£	£	£
<b>Fixed Assets</b>					
Tangible Assets	8		15,243		31,657
<b>Current Assets</b>					
Debtors	9	418,652		267,990	
Bank and Cash Balances	10	19,367,233		17,242,227	
		<u>19,785,885</u>		<u>17,510,217</u>	
<b>Liabilities:</b>					
Creditors: Amounts Falling Due Within One Year	11	(1,277,028)		(1,010,649)	
		<u></u>		<u></u>	
<b>Net Current Assets</b>			18,508,857		16,499,568
<b>Total Net Assets</b>			<u>18,524,100</u>		<u>16,531,225</u>
<b>Unrestricted Funds</b>					
General Reserve	12		1,753,614		1,617,810
Designated Funds	12		1,545,305		1,321,194
Total Unrestricted Funds			<u>3,298,919</u>		<u>2,939,004</u>
<b>Restricted Income Funds</b>	12		15,225,181		13,592,221
<b>Total Funds</b>			<u>18,524,100</u>		<u>16,531,225</u>

The financial statements were approved by the Trustees on 14th June 2023, and signed on their behalf by:

  
 Isabelle Dieuzy-Labaye - 2023-06-29, 07:42:30 UTC  
 Dr I Dieuzy-Labaye  
 Company No: 05393391

The notes on pages 19 to 31 form part of these financial statements

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**STATEMENT OF CASH FLOWS**  
For the year ended 31 March 2023

	Notes	2023 £	2022 £
<b>Cash Flows from Operating Activities:</b>			
<b>Net Cash Provided by Operating Activities</b>	<b>16</b>	1,000,506	2,379,256
<i>Cash Flows from Investing Activities:</i>			
Interest from Investments		175,506	2,628
Purchase of Property, Plant and Equipment		(10,151)	(9,620)
Proceeds on disposal of fixed assets		1,068	-
Net Cash Used in/(Received from) Investing Activities		166,423	(6,992)
<b>Change in Cash and Cash Equivalents in the Reporting Period</b>		1,166,929	2,372,264
Cash and Cash Equivalents at the Beginning of the Reporting Period		17,242,227	14,151,954
Change in Cash and Cash Equivalents due to Exchange Rate Movements		958,077	718,009
<b>Cash and Cash Equivalents at the End of the Reporting Period</b>		<u>19,367,233</u>	<u>17,242,227</u>
 <b>Analysis of Cash and Cash Equivalents</b>			
Bank and Cash Balances		<u>19,367,233</u>	<u>17,242,227</u>

The notes on pages 19 to 31 form part of these financial statements



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2023**

**1. Accounting Policies**

*Basis of Accounting*

GALVmed is a public benefit entity. The financial statements have therefore been prepared in accordance with the Companies Act 2006, applicable accounting standards, Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 as amended in 2010, and the Charities Act 2011. They have also been prepared under historical cost accounting rules. The financial statements are prepared in Sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

*Presentation of Financial Statements*

The trustees have reviewed the accounting for unrealised foreign exchange gains and losses and identified that in previous years this was presented after the net income/expenditure of the charitable company. In accordance with FRS 102, unrealised foreign exchange gains and losses should be presented as part of the reported net income and expenditure, and hence this has been corrected in the current year and the previous year restated accordingly. There was no impact on the net funds at either 1 April 2021 or 31 March 2022.

*Going Concern*

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding of current programmes is assured: the VITAL Bridging grant will cover all organisational direct costs to September 2024 to enable the completion of VITAL by December 2024, with further funding from VITAL itself to cover organisational direct costs for the final three months of the programme. The VITAL Bridging grant will further ensure continuity of other project commitments and will allow the evolution of future project proposals.

We are currently in the process of developing our proposal for the next round of Gates Foundation funding, which is expected to commence in Q1 2025 at the latest and are in regular discussions with both our funders to ensure this programme is designed in line with their evolving strategies, as well as GALVmed priorities. We expect to submit our initial proposals to our funders (concept note) in Q2/Q3 2023 and a full funding proposal in Q1 2024.

An assessment of unrestricted funds has also been carried out. Designated funds are sufficient to cover any shortfall in indirect costs during the VITAL Bridging period if required, although it is anticipated this need will be small, if it is needed at all. General unrestricted reserves are also sufficient to maintain the minimum balance of £1.2m required within the reserves policy. There are therefore sufficient funds to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

*Fund Accounting*

Funds received on which no restrictions are placed as to their use are accounted for as unrestricted funds. Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in note 12.

Funds received for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose, are accounted for as restricted funds.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS  
For the year to 31 March 2023**

**1. Accounting Policies (continued)**

*Income*

Funds received are recognised as income from charitable activities once there is entitlement, reasonable probability of receipt and the amount can be measured with sufficient reliability. Income is deferred where funder-imposed conditions that specify the performance conditions or time period in which the funds can be spent have not yet been met.

Investment income is recognised as earned.

*Value Added Tax (VAT)*

Expenditure is accounted for inclusive of VAT where appropriate as the company is not registered for VAT.

*Pension Scheme*

The company provides a defined contribution pension scheme for its staff and the pension charge in the Statement of Financial Activities (SOFA) represents the amounts payable by the company to the Company Personal Pension Scheme in respect of the year.

*Operating Leases*

Rentals payable under operating leases are charged to the SOFA on the straight-line basis over the lease term.

*Expenditure*

Expenditure is recognised on the accruals basis when a legal and/or constructive obligation exists. Expenditure through contractual agreements is recognised as goods and services are supplied. Grant payments are recognised as expenditure when payments are due in accordance with the terms of the contract.

Costs incurred by the company in the delivery of its activities and services are accounted for as charitable expenditure and categorised in the SOFA by the main activities of the company. Each category includes direct costs and support costs and, where support costs cannot be directly attributed to a category, they are apportioned on the basis of headcount.

Costs that, whilst necessary to deliver an activity do not themselves contribute directly to GALVmed's activity, are accounted for as support costs. Support costs include central office functions such as management, finance, information systems and administration activities.

*Foreign Currency*

Foreign currency transactions are recorded in Sterling at the previous month's month-end rate of exchange. Monetary assets and liabilities denominated in foreign currencies are translated into Sterling at the exchange rate at the balance sheet date.

All exchange differences are recognised through the SOFA.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2023**

**1. Accounting Policies (continued)**

*Tangible Fixed Assets*

Tangible fixed assets costing more than £1,000 are capitalised and stated at cost and depreciated over their useful economic lives as follows:

Office equipment	4 years
Computer equipment & software	3 years
Leasehold improvements	over the life of the lease

Assets are only depreciated when they are brought into use and depreciated up to, but not including, the month of disposal.

*Debtors and Prepayments*

Debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

*Cash at Bank and in Hand*

Cash at bank and in hand includes cash and short term highly liquid investments with a maturity of six months or less from the date of acquisition or opening of the deposit or similar account.

*Creditors*

Creditors are recognised where the company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party in the future and the amount due to settle obligations can be measured or estimated reliably. Creditors are recognised at their settlement amount.

*Critical Accounting Judgements and Estimation Uncertainty*

In preparing the financial statements, the Trustees are required to make judgements, estimates and assumptions, which may affect reported income, expenditure, assets, and liabilities. The estimates and associated assumptions are based on historical experience and other factors considered relevant. Actual results may differ from such estimates. Judgements made in preparing these financial statements comprise:

- The applicability of the estimated useful lives of fixed assets used to calculate the period over which depreciation is applied.
- The review of fixed assets for impairment or obsolescence.
- The assessment of leases to determine whether the risks and rewards of ownership remain with the lessor or are transferred to GALVmed.

*Financial Instruments*

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**2. Income from Charitable Activities**

	<b>UK Grant Funding £</b>	<b>Overseas Grant Funding £</b>	<b>2023 £</b>	<b>2022 £</b>
<b>Restricted income</b>				
AAT 3	(11,311)	741,641	730,330	1,757,429
VITAL Bridging	-	4,852,379	4,852,379	-
VITAL	956,057	2,366,591	3,322,648	6,593,980
AgResults Brucellosis	-	(18,356)	(18,356)	245,644
PREVENT	-	927,066	927,066	1,338,977
Bovine TB	-	(18,688)	(18,688)	872,846
AgResults FMD	-	346,470	346,470	307,367
MAHABA	-	736,041	736,041	1,012,314
Boehringer Ingelheim	-	-	-	(7,790)
TAHSSL	-	(66,290)	(66,290)	114,276
Health for Animals	-	-	-	2,264
<b>Total restricted income</b>	<b>944,746</b>	<b>9,866,854</b>	<b>10,811,600</b>	<b>12,237,307</b>
<b>Unrestricted income</b>	<b>108,394</b>	<b>847,689</b>	<b>956,083</b>	<b>1,119,977</b>
<b>Total income</b>	<b>1,053,140</b>	<b>10,714,543</b>	<b>11,767,683</b>	<b>13,357,284</b>

There is negative income in the AAT3, AgResults Brucellosis and Bovine TB programmes because of indirect core contributions towards unrestricted funds. There is negative income in the TAHSSL programme because of a refund of surplus funds at programme completion.

**3. Analysis of Expenditure**

	<b>Support £</b>	<b>Governance £</b>	<b>Staff £</b>	<b>Direct Cost £</b>	<b>Total 2023 £</b>	<b>Total 2022 £</b>
AAT 3	1,412	-	59,270	3,301,684	3,362,366	2,539,965
VITAL Bridging	140,380	-	519,635	253,381	913,396	-
VITAL	125,925	-	569,571	2,833,136	3,528,632	5,589,066
AgResults Brucellosis	1,385	-	-	121,037	122,422	103,467
PREVENT	-	-	-	928,342	928,342	1,201,776
Bovine TB	-	-	-	408,660	408,660	12,707
AgResults FMD	6,731	-	88,438	203,676	298,845	281,908
MAHABA	-	-	-	695,676	695,676	699,143
Boehringer Ingelheim	-	-	-	-	-	146,057
TAHSSL	192	-	8,598	7,920	16,710	95,654
Health for Animals	-	-	-	2,275	2,275	-
PLSHL 2	-	-	-	-	-	85,994
Unrestricted	65,733	130,536	450,826	171,058	818,153	795,618
<b>Total 2023</b>	<b>341,758</b>	<b>130,536</b>	<b>1,696,338</b>	<b>8,926,845</b>	<b>11,095,477</b>	<b>11,551,355</b>
<b>Total 2022</b>	<b>364,419</b>	<b>49,070</b>	<b>1,734,794</b>	<b>9,403,072</b>		<b>11,551,355</b>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**3. Analysis of Expenditure (continued)**

**Analysis of Support Costs**

	<b>Professional Fees</b>	<b>Office Costs</b>	<b>Information Technology</b>	<b>Audit Fees</b>	<b>Total 2023</b>	<b>Total 2022</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>
AAT 3	-	426	986	-	1,412	1,294
VITAL Bridging	27,646	79,188	31,866	1,680	140,380	-
VITAL	11,490	78,389	35,966	80	125,925	278,812
AgResults Brucellosis	-	193	1,192	-	1,385	1,582
AgResults FMD	-	293	6,438	-	6,731	5,057
Boehringer Ingelheim	-	-	-	-	-	79
TAHSSL	-	32	160	-	192	1,171
Unrestricted	9,540	25,925	16,921	13,347	65,733	76,424
<b>Total 2023</b>	<b>48,676</b>	<b>184,446</b>	<b>93,529</b>	<b>15,107</b>	<b>341,758</b>	<b>364,419</b>
<b>Total 2022</b>	<b>54,191</b>	<b>166,422</b>	<b>129,727</b>	<b>14,079</b>		<b>364,419</b>

**4. Staff Costs**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Total staff costs were as follows:		
Salaries	1,440,791	1,483,068
Social security costs	113,603	107,104
Pension contributions	98,452	99,920
Other employee benefits	43,492	44,702
	<b>1,696,338</b>	<b>1,734,794</b>

The average number of employees during the year was:

	<b>Number</b>	<b>Number</b>
Management	5	5
Project staff	11	13
Support staff	11	11
	<b>27</b>	<b>29</b>

During the year the company incurred expenses of £3,446 on behalf of, or reimbursed expenses to, 7 Trustees in connection with their governance responsibilities (2022: £1,514, 7 Trustees). 2 face-to-face meetings took place in 2022-23 with the lifting of all COVID-19 travel restrictions. No expenses were incurred for persons or entities connected with the Trustees (2022: £nil). No Trustees received remuneration in relation to consultancy services provided (2022: £nil).

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**4. Staff Costs (Continued)**

GALVmed provides to its UK-based staff a defined contribution pension scheme, the GALVmed Personal Pension Scheme, which is operated by Aviva, a life assurance company. Total employer contributions in the year were £58,189 (2022: £58,063). The total number of members in the scheme at 31 March 2023 was 15 (2022: 16).

To compensate for the fact that there is currently no pension scheme for international staff, an employer contribution of 6% of salary is paid to such staff on the understanding that this contribution should be paid into a pension scheme of their choice. Total such contributions in respect of the year were £40,263 (2022: £41,857).

The following number of employees received total employee salary and benefits (excluding employer pension) in excess of £60,000 in the period:

	2023	2022
£60,000 - £69,999	-	1
£70,000 - £79,999	1	3
£80,000 - £89,999	1	-
£90,000 - £99,999	1	1
£100,000 - £109,999	1	-
£150,000 - £159,999	-	1
£160,000 - £169,999	1	-

GALVmed considers the key management of the company to be the GALVmed Leadership Team (GLT), comprising the Chief Executive Officer, Executive Directors, and Senior Directors. The total cost of the employment of key management in the year was £537,515 (2022: £494,274), with a further £99,218 (2022: £86,891) paid to one consultant. Employer pension contributions for key management totalled £28,492 (2022: £26,196).

**5. Net Income**

	2023 £	2022 £
This is stated after charging:		
- Auditor's remuneration – audit fees	15,107	14,079
- Depreciation	25,398	39,935
- Loss on disposal of fixed assets	99	-
- Operating leases		
Land and buildings	123,688	115,701
Equipment	943	1,241

Auditors' remuneration includes £1,760 (2022: £1,384) for audit fees payable in India and £13,347 (2022: £12,695) for audit fees in the UK.

**6. Exchange Gains and Losses**

Unrealised gains and losses on foreign exchange relate to the revaluation of GALVmed's net current assets at 31 March 2023 and are included in other income (see note 12 for breakdown by programme). The gains of £958,077 (2022: £718,009) relate to advance funding in US Dollars and a weakening of Sterling against the US Dollar.

In addition, a realised loss of £13,005 (2022: £15,581 loss) is included in expenditure on charitable activities, which is a result of the difference between the currency rate invoiced and the currency rate paid to suppliers. GALVmed undertakes a variety of exchange mechanisms throughout the year to minimise realised exchange differences and help ensure there are adequate resources to deliver the programme outputs.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**7. Taxation**

The company has charitable status and is not liable for tax.

**8. Tangible Assets**

	<b>Leasehold improvements £</b>	<b>Office equipment £</b>	<b>Computer equipment £</b>	<b>Total £</b>
<b>Cost</b>				
At 1 April 2022	12,430	7,267	241,254	260,951
Additions	-	-	10,151	10,151
Disposals	-	-	(26,869)	(26,869)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2023	12,430	7,267	224,536	244,233
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
<b>Depreciation</b>				
At 1 April 2022	7,292	7,267	214,735	229,294
Charge for year	4,086	-	21,312	25,398
Eliminated on disposal	-	-	(25,702)	(25,702)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2023	11,378	7,267	210,345	228,990
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
<b>Net book value</b>				
At 31 March 2023	1,052	-	14,191	15,243
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
At 31 March 2022	5,138	-	26,519	31,657
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

**9. Debtors**

	<b>2023 £</b>	<b>2022 £</b>
Prepayments and accrued income	201,912	169,687
Other debtors	216,740	98,303
	<hr/>	<hr/>
	418,652	267,990
	<hr/> <hr/>	<hr/> <hr/>

Prepayments and accrued income include £94,841 (2022: £86,030) of accrued income in relation to the AgResults Foot and Mouth Disease (FMD) programme and other debtors include accrued investment income of £190,238 (2022: £3,152).

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**10. Bank and Cash Balances**

<b>2023</b>	<b>GBP</b>	<b>USD</b>	<b>Other</b>	<b>Total</b>
	<b>£</b>	<b>£</b>	<b>currencies</b>	<b>£</b>
			<b>£</b>	
Lloyds Bank	765,980	5,144,606	6,138	5,916,724
Bank of Scotland	503,696	6,498,255	-	7,001,951
NatWest	-	6,437,321	-	6,437,321
Standard Chartered	-	-	8,118	8,118
Cash	231	1,039	1,849	3,119
	<u>1,269,907</u>	<u>18,081,221</u>	<u>16,105</u>	<u>19,367,233</u>
<b>2022</b>	<b>GBP</b>	<b>USD</b>	<b>Other</b>	<b>Total</b>
	<b>£</b>	<b>£</b>	<b>currencies</b>	<b>£</b>
			<b>£</b>	
Lloyds Bank	1,603,617	4,101,315	5,970	5,710,902
Bank of Scotland	500,100	5,214,879	-	5,714,979
NatWest	-	5,805,740	-	5,805,740
Standard Chartered	-	-	5,755	5,755
Cash	252	3,129	1,470	4,851
	<u>2,103,969</u>	<u>15,125,063</u>	<u>13,195</u>	<u>17,242,227</u>

**11. Creditors: Amounts Falling Due Within One Year**

	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Accruals	741,962	624,236
Trade creditors	310,533	126,541
Deferred income	210,076	247,594
Other creditors	14,457	12,278
	<u>1,277,028</u>	<u>1,010,649</u>
Deferred income reconciliation:	<b>2023</b>	<b>2022</b>
	<b>£</b>	<b>£</b>
Balance brought forward	247,594	-
Amount released to the Statement of Financial Activities	(247,594)	-
Amount Deferred in the year	210,076	247,594
	<u>210,076</u>	<u>247,594</u>
Balance carried forward	<u>210,076</u>	<u>247,594</u>

The movement in accruals and trade creditors is because of large, contracted payments due to partners for the MAHABA and AAT 3 programmes.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**12. Funds Movement**

	31 March 2022	Income	Expenditure	Exchange gain/(loss)	Transfers	31 March 2023
	£	£	£	£	£	£
<b>2023</b>						
<b>Restricted funds:</b>						
AAT 3	6,319,826	824,660	(3,362,366)	414,262	-	4,196,382
VITAL Bridging	-	4,939,553	(913,396)	(753)	-	4,025,404
VITAL	3,826,130	3,405,174	(3,528,632)	169,992	-	3,872,664
AgResults Brucellosis	1,208,562	5,257	(122,422)	80,694	-	1,172,091
PREVENT	493,349	932,046	(928,342)	32,130	-	529,183
Bovine TB	863,071	(12,686)	(408,660)	60,257	-	501,982
AgResults FMD	347,707	346,486	(298,845)	20,120	-	415,468
MAHABA	339,336	737,453	(695,676)	17,135	-	398,248
Boehringer Ingelheim	111,614	-	-	2,145	-	113,759
TAHSSL	80,362	(66,290)	(16,710)	2,638	-	-
Health for Animals	2,264	-	(2,275)	11	-	-
<b>Total restricted funds</b>	<b>13,592,221</b>	<b>11,111,653</b>	<b>(10,277,324)</b>	<b>798,631</b>	<b>-</b>	<b>15,225,181</b>
<b>Unrestricted funds:</b>						
General reserve	1,617,810	1,018,622	(818,153)	159,446	(224,111)	1,753,614
Designated funds:						
Indirect future costs	1,321,194	-	-	-	224,111	1,545,305
<b>Total unrestricted funds</b>	<b>2,939,004</b>	<b>1,018,622</b>	<b>(818,153)</b>	<b>159,446</b>	<b>-</b>	<b>3,298,919</b>
<b>Total funds</b>	<b>16,531,225</b>	<b>12,130,275</b>	<b>(11,095,477)</b>	<b>958,077</b>	<b>-</b>	<b>18,524,100</b>
<b>2022</b>						
<b>Restricted funds:</b>						
AAT 3	6,870,447	1,759,640	(2,539,965)	229,704	-	6,319,826
VITAL	2,576,941	6,595,434	(5,589,066)	242,821	-	3,826,130
AgResults Brucellosis	1,015,272	246,251	(103,467)	50,506	-	1,208,562
PREVENT	416,252	1,338,986	(1,201,776)	(60,113)	-	493,349
Bovine TB	-	872,911	(12,707)	2,867	-	863,071
AgResults FMD	309,813	307,367	(281,908)	12,435	-	347,707
MAHABA	-	1,012,314	(699,143)	26,165	-	339,336
Boehringer Ingelheim	170,441	(7,784)	(146,057)	95,014	-	111,614
TAHSSL	64,103	114,276	(95,654)	(2,363)	-	80,362
Health for Animals	-	2,264	-	-	-	2,264
PLSHL 2	86,151	-	(85,994)	(157)	-	-
<b>Total restricted funds</b>	<b>11,509,420</b>	<b>12,241,659</b>	<b>(10,755,737)</b>	<b>596,879</b>	<b>-</b>	<b>13,592,221</b>
<b>Unrestricted funds:</b>						
General reserve	1,600,798	1,121,263	(795,618)	121,130	(429,763)	1,617,810
Designated funds:						
Indirect future costs	891,431	-	-	-	429,763	1,321,194
<b>Total unrestricted funds</b>	<b>2,492,229</b>	<b>1,121,263</b>	<b>(795,618)</b>	<b>121,130</b>	<b>-</b>	<b>2,939,004</b>
<b>Total funds</b>	<b>14,001,649</b>	<b>13,362,922</b>	<b>(11,551,355)</b>	<b>718,009</b>	<b>-</b>	<b>16,531,225</b>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2023**

**12. Funds Movement (continued)**

*Programme Objectives and Funding*

The purpose of the AAT 3 programme is to build upon the success of the work carried out under previous AAT programmes resulting in the improved tools for the control of Animal African Trypanosomiasis. The specific objective of AAT 3 is the commercial development of a registered therapeutic trypanocidal product, ready for sale through GALVmed's commercial partner in the AAT 3 programme, Boehringer Ingelheim. This programme is funded by both BMGF (\$19m) and FCDO (\$3.5m).

The VITAL Bridging programme aims to support the development and initiation of new programmes of work which will progress the next phase of work beyond VITAL and reflect the essence of the GALVmed 2030 strategy. This programme is funded by BMGF (\$7.7m).

The VITAL programme has two strands: product development and commercial development. The broad objectives are: 1) to develop six new high impact livestock vaccines ready for commercial production and suitable for widespread use by smallholders in Africa and South Asia; and 2) to partner the animal health industry to establish five large scale portfolio distribution networks in Africa and South Asia with each initiative being capable of generating positive cash flows by year 4 and achieving subsequent growth and expansion through these cash flows. The programme is jointly funded by BMGF (80%) and FCDO (20%). This programme was contracted to end on 30 September 2022 but has since been awarded a no-cost extension to March 2024 for FCDO and December 2024 for BMGF because of delays associated with COVID-19. This will allow the programme objectives to be fully achieved beyond the initial contractual end date.

The AgResults Brucellosis programme is a competition, managed by GALVmed, to develop and register a safe and efficacious vaccine against *Brucella melitensis*, the main cause of human infections with Brucella and a significant economic burden in developing countries. It is fully funded by the AgResults consortium.

The PREVENT (Promoting and Enabling Vaccination Efficiently, Now and Tomorrow) programme is fully funded by BMGF and is carried out in partnership with Ceva Santé Animale. The aim of this programme is to create an efficient sector of medium-sized African hatcheries applying hatchery vaccination and proactive marketing methods to initiate and increase vaccinated chick sales to poultry small scale producers.

The Bovine TB programme aims to enable and accelerate the development and implementation of rational evidence-based approaches to control TB, with a focus on India, and to provide a strong foundation for the development of control programmes in other developing countries. This project will establish and publish Target Product Profiles for novel tools to control TB and develop a roadmap for product development and commercialisation of novel diagnostic tests in India.

The AgResults Foot and Mouth programme is a competition, managed by GALVmed, to encourage the development and uptake of an improved vaccine tailored for the needs and requirements of East Africa. It is fully funded by the AgResults Consortium.

The MAHABA (Managing Animal Health and Acaricides for a Better Africa) programme is fully funded by BMGF and is carried out in partnership with Elanco Animal Health. The aim of the programme is to create effective tick control for SSPs, by building a clear understanding of acaricide usage, developing innovative methods to help educate on the effective use and by providing practical methods to counter resistance, avoid failures and allow sustainable tick control.

The Boehringer Ingelheim (BI) programme is fully funded by BMGF and is carried out in partnership with BI. Its objective is to deliver a viable business model for providing quality veterinary healthcare to smallholder farmers in Africa. The key activities for this programme are 1) a registration initiative of BI products in three key markets; and 2) a distribution and awareness initiative which accelerates the accessibility of a portfolio of products to areas which are normally very difficult to access through usual distribution networks.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**12. Funds Movement (continued)**

The TAHSSL (Transforming Animal-Health Solutions and Services for Low-Middle Income Countries) programme is a project to conduct research on animal-health product technologies to generate robust proof-of-concept results that are of high quality and to facilitate with the private sector product development, registration, and use. The focus is on developing veterinary medicines and diagnostic solutions to address animal health disease constraints in low-middle income countries and providing services to help fill the product development pipeline. TAHSSL is fully funded by the International Livestock Research Institute (ILRI). This programme ended during the year.

Other restricted funds represent income received from funders with a specific use of programme identified.

The general reserve represents the free funds of the charity. Designated funds comprise unrestricted funds that have been set aside by the Trustees for a particular purpose. Organisational (indirect) costs need to be covered by contributions from all programmes. Cumulative net indirect core cost contributions have been designated by the Board at 31 March 2023 to fund future indirect costs.

**13. Total Assets – Analysed Between Funds**

2023	Fixed assets £	Net current assets £	Total £
<b>Restricted funds</b>			
AAT 3	-	4,196,382	4,196,382
VITAL Bridging	624	4,024,780	4,025,404
VITAL	-	3,872,664	3,872,664
AgResults Brucellosis	-	1,172,091	1,172,091
PREVENT	-	529,183	529,183
Bovine TB	-	501,982	501,982
AgResults FMD	3,725	411,743	415,468
MAHABA	-	398,248	398,248
Boehringer Ingelheim	-	113,759	113,759
TAHSSL	-	-	-
Health for Animals	-	-	-
	4,349	15,220,832	15,225,181
<b>Unrestricted funds</b>			
General reserve	10,894	1,742,720	1,753,614
Designated funds	-	1,545,305	1,545,305
	15,243	18,508,857	18,524,100
<b>Total</b>	15,243	18,508,857	18,524,100

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**13. Total Assets – Analysed Between Funds continued**

2022	Fixed assets £	Net current assets £	Total £
<b>Restricted funds</b>			
AAT 3	294	6,319,532	6,319,826
VITAL	4,369	3,821,761	3,826,130
AgResults Brucellosis	294	1,208,268	1,208,562
PREVENT	-	493,349	493,349
Bovine TB	-	863,071	863,071
AgResults FMD	598	347,109	347,707
MAHABA	-	339,336	339,336
Boehringer Ingelheim	-	111,614	111,614
TAHSSL	1,009	79,353	80,362
Health for Animals	-	2,264	2,264
	6,564	13,585,657	13,592,221
<b>Unrestricted funds</b>			
General reserve	25,093	1,592,717	1,617,810
Designated funds	-	1,321,194	1,321,194
	31,657	16,499,568	16,531,225
<b>Total</b>	31,657	16,499,568	16,531,225

**14. Operating Lease Commitments**

At 31 March 2023 GALVmed was committed to a total of future minimum lease payments under non-cancellable operating leases for land, buildings, and equipment for each of the following periods:

	2023 £	2022 £
Not later than one year	86,188	100,726
Later than one year and not later than five years	30,166	58,775
	116,354	159,501
<b>Total</b>	116,354	159,501

**15. Share Capital**

The company is limited by guarantee and does not have share capital.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2023

**16. Reconciliation of Net Income to Net Cash Flow from Operating Activities**

	<b>2023</b>	<b>2022</b>
	£	£
		<b>As restated</b>
<b>Net income for the reporting period (as per the Statement of Financial Activities)</b>	1,992,875	2,529,576
<b>Adjustments for:</b>		
Gain on foreign exchange transactions	(958,077)	(718,009)
Depreciation charges	25,398	39,935
Loss on sale of assets	99	-
Interest from investments	(362,592)	(5,638)
Decrease in debtors	36,424	287,840
Increase in creditors	266,379	245,552
	<b>1,000,506</b>	<b>2,379,256</b>
	<b>1,000,506</b>	<b>2,379,256</b>

Debtors contains accrued investment income of £190,238 (2022: £3,152). The movement on accrued investment income is included in investments within the cash flow statement.

**17. Related Parties**

There were no related party transactions in this or the prior year, other than the expenses as disclosed in note 4 of these accounts. The Trustees consider all the transactions during the year to have been undertaken on an arm's length basis.

**18. Ultimate Controlling Party**

GALVmed is constituted under its Memorandum and Articles of Association and is managed by its appointed Board of Trustees.



# Henderson Loggie Secure Messaging

E-SIGNATURE CERTIFICATE

## Certificate Summary

ENVELOPE SUBJECT: Revised Galvmed financial statements for signing  
DOCUMENT: 2022-23 Trustees' Report Financial Statements - FINAL 260623.pdf  
DOCUMENT ORIGINATOR: Fiona Allison (fiona.allison@hlca.co.uk)

CERTIFICATE STATUS: **Completed**  
DELIVERED: Jun 26, 2023 3:17 PM UTC  
DOCUMENT PAGES: 32 CERTIFICATE PAGES: 1 TOTAL ENVELOPE PAGES: 33

ENVELOPE ID: 64117fd6-a7b6-420f-9226-98272b3a2230  
DOCUMENT ID: f3345001-b4b3-4d70-a81c-cad12af061dd  
ORIGINATOR IP ADDRESS: 209.93.133.131

COMPLETED SIGNATORIES: 2 / 2  
COMPLETED IN PLACE SIGNATURES: 3 / 3  
COMPLETED IN PLACE INITIALS: 0 / 0  
CARBON COPY RECIPIENTS: 0

## Signatures

## Timeline

E-SIGNED BY: Isabelle Dieuzy-Labaye (isabelle.dieuzy.labaye@gmail.com)  
SECURITY LEVEL: Secure Email (Authenticated)  
E-SIGNATURE ID: 9916ff42-de7a-4bdf-ba68-9cb829704237

SENT: Jun 26, 2023 3:17 PM UTC  
VIEWED: Jun 29, 2023 7:41 AM UTC  
SIGNED: Jun 29, 2023 7:42 AM UTC  
USING IP ADDRESS: 86.245.156.40

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: Isabelle Dieuzy-Labaye EMAIL: isabelle.dieuzy.labaye@gmail.com

E-SIGNED BY: Keith Macpherson (keith.macpherson@hlca.co.uk)  
SECURITY LEVEL: Secure Email (Authenticated)  
E-SIGNATURE ID: d31fb015-fb89-422c-b419-2c59c689f479

SENT: Jun 26, 2023 3:17 PM UTC  
VIEWED: Jun 29, 2023 12:50 PM UTC  
SIGNED: Jun 29, 2023 4:20 PM UTC  
USING IP ADDRESS: 87.246.91.14

I AGREE TO THE CONTENTS OF ALL PAGES ABOVE WITH AN ELECTRONIC SIGNATURE

PRINT NAME: Keith Macpherson EMAIL: keith.macpherson@hlca.co.uk

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**

England & Wales - Charity number 1115606

---

# Accounts

---

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

Registered in England No. 05393391  
England and Wales Charity No. 1115606  
Scottish Charity No. SC039197

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2022**



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
For the year ended 31 March 2022

**CONTENTS**

	<b><u>Page</u></b>
<b><u>REFERENCE AND ADMINISTRATIVE DETAILS</u></b>	2
<b><u>REPORT OF THE TRUSTEES</u></b>	
<b>INTRODUCTION</b>	3
<b>OBJECTS, OBJECTIVES AND ACTIVITIES</b>	3
Objects	3
Objectives & Activities	3
<b>STRUCTURE, GOVERNANCE AND MANAGEMENT</b>	3
Trustee Recruitment, Induction, Training and Evaluation	4
Trustees' and Members' Meetings and Business	4
Strategy and Decision Making	4
Key Management Remuneration	4
Diversity	5
Safeguarding	5
Partnerships and Related Parties	5
<b>STRATEGIC REPORT</b>	5
Performance and Achievements	5
- Key Performance Indicators	5
- Key Achievements	6
- Impact of Our Work	7
Financial Review	7
- Income	7
- Expenditure	7
- Unrealised Exchange Gains/Losses	8
- Balance Sheet	8
- Liquidity Management Policy	8
- CO <sub>2</sub> Emissions	8
- Reserves	8
- Unrestricted Reserves Policy	8
Future Plans	8
- Objectives	8
- Financial	9
Principal Risks and Uncertainties	9
- Risk Management	9
- COVID-19	10
<b>GOING CONCERN</b>	10
<b>AUDITORS</b>	11
<b><u>RESPONSIBILITIES OF THE TRUSTEES</u></b>	12
<b><u>INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES</u></b>	13
<b><u>INCOME AND EXPENDITURE ACCOUNT AND STATEMENT OF FINANCIAL ACTIVITIES</u></b>	16
<b><u>BALANCE SHEET</u></b>	17
<b><u>STATEMENT OF CASH FLOWS</u></b>	18
<b><u>NOTES TO THE FINANCIAL STATEMENTS</u></b>	19-30



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Trustees**

Prof P Wood	Chair Chair of Technical Scientific Advisory Committee
Dr W Amanfu	Vice-Chair Resigned 14 September 2021
Prof M Gill	Chair of Impact, Monitoring & Evaluation Advisory Committee
Dr I Dieuzy-Labayé	Chair of Commercial Development Advisory Committee
Dr J Maina	Chair of HR Committee Vice-Chair (from 14 September 2021)
Mr S Jha	
Mrs J Stevenson FCA	Chair of Finance & Risk Committee
Dr A Banga	
Dr F Kausche	
Dr H Wamwayi	Appointed 14 <sup>th</sup> September 2021
Prof K Pathak	Resigned 31 <sup>st</sup> March 2022

**Chief Executive Officer** Dr C Schumacher

**Company Secretary** Ms H Stevenson CA

**Independent Auditors**

Henderson Loggie LLP  
Chartered Accountants  
Ground Floor, 11-15 Thistle Street  
Edinburgh, EH2 1DF

**Legal Advisors**

Dentons LLP  
Quatermile One  
15 Lauriston Place  
Edinburgh, EH3 9EP

**Bankers**

Lloyds Bank plc  
City Office, PO Box 72  
Bailey Drive, Gillingham Business Park  
Kent, ME8 0LS

**Registered Office**

One Fleet Place  
London, EC4M 7WS

**Principal Office**

Doherty Building  
Pentlands Science Park  
Bush Loan, Edinburgh, EH26 0PZ

**Company No.** 05393391  
**England and Wales Charity No.** 1115606  
**Scotland Charity No.** SC039197



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2022

**INTRODUCTION**

The Trustees have pleasure in presenting their report for the year ended 31 March 2022. This report is prepared in accordance with the recommendations of *Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)* and in accordance with applicable law.

Global Alliance for Livestock Veterinary Medicines (the company) has complied with the duty in Section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

Global Alliance for Livestock Veterinary Medicines (GALVmed) is a company limited by guarantee and is registered as a charity with the Charity Commission and the Office of the Scottish Charity Regulator (OSCR). It is incorporated in the UK with its principal office in Edinburgh, UK. Other offices are maintained in New Delhi, India (South Asia office); and Nairobi, Kenya (Africa office). Other reference and administrative details are set out in the previous section.

**OBJECTS, OBJECTIVES AND ACTIVITIES**

**Objects**

Around 900 million poor people rely on livestock for their livelihoods. The company's objects, as set out in its Memorandum of Association, are for the benefit of the public:

- 1) to relieve financial hardship and promote good health (including improving food security) amongst small-holder livestock keepers (small-scale livestock producers) in developing countries through the promotion of affordable vaccines, pharmaceutical and diagnostic products and services aimed at improving the health of their livestock; and
- 2) to promote the effective use of resources to achieve the above charitable purposes through the identification, management, funding and co-ordination of: a) development of livestock vaccines, pharmaceuticals and diagnostics products and services; and b) delivery of these products and services at affordable prices, by working in partnership with others (whether charities, government; private bodies or institutions).

GALVmed's vision is the transformational improvement in the wellbeing and economic progression of small-scale livestock producers (SSPs). GALVmed's mission is to contribute to the transformation of small-scale livestock producers' lives by:

- understanding the constraints to animal health and how to overcome them;
- engaging the animal health industry; and
- ensuring awareness, availability, and adoption of effective animal health interventions.

**Objectives & Activities**

GALVmed achieves its charitable purpose by operating a series of Research and Development (R&D) and Commercialisation programmes, supported by enabling environment and monitoring and evaluation (M&E) activities, funded principally by the Bill and Melinda Gates Foundation (BMGF) and the UK Government through its Foreign, Commonwealth and Development Office (FCDO). These programmes are designed to identify products that SSPs can use to improve the health of their animals and to make such products more easily accessible. The two largest of these programmes are Veterinary Innovations Transforming Animal Health and Livelihoods (VITAL), with a budget of \$50m, and African Animal Trypanosomiasis (AAT) 3, with a budget of \$22.5m. 7 other programmes are also being operated, with values ranging from \$0.5m to \$5.0m (see note 12 for further programme information).

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

The Governance of the company is the responsibility of the Trustees and the company adopts the appropriate principles and recommended practices of the Charity Governance Code. The Members elect the Trustees in



accordance with the terms of the Memorandum and Articles of Association.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2022**

**Trustee Recruitment, Induction, Training and Evaluation**

The maximum number of Trustees permitted by the company's Articles is 10. Trustees are recruited for their individual skills and experience to fill current or impending vacancies, guided by a comprehensive skills and diversity matrix. Trustees serve a term of 3 years subject to a maximum of two consecutive terms and Board and AGM approval. Recruitment of Trustees is managed by a Trustee Selection Panel comprising 3 Trustees of which one is the HR Committee Chair. One Trustee retired in 2022 and was replaced at the AGM in September 2021 following an extensive recruitment process. Following the resignation of one other Trustee in March 2022, a further recruitment process is currently ongoing.

A formal Trustee induction process is in place to ensure clarity of the role of the Trustee and their responsibilities under company and charity legislation. Trustees, new and current, also receive training on their legal responsibilities annually prior to the AGM, although this did not take place in 2021 due to COVID-19. During the year trustees received training on financial compliance.

Trustee evaluation takes place annually and is based on self-assessment, peer-assessment and annual performance interviews with the Chair and Vice-Chair; the process includes procedures for identifying development requirements.

**Trustees' and Members' Meetings and Business**

Trustees meet formally four times a year, normally with two virtual and two physical meetings, the same time at which Members' meetings are physically held. Due to COVID-19 the majority of meetings were, successfully, held virtually. In March 2022, with the relaxation of some COVID restrictions, the Board met in Senegal face-to-face for the first time since September 2019, with some virtual attendees. The opportunity to hold a variety of other governance meetings was also taken. The business of all meetings is minuted.

On 31 March 2022 there were 15 Members and 9 Trustees. In addition, observers from 5 organisations, including BMGF and FCDO, the company's major funders, are invited to attend the Members' meetings, with the funders also invited to meet separately with the Board.

The Board is supported by the Finance & Risk and HR committees, to whom aspects of day-to-day accountability and governance are delegated. The HR Committee is also responsible for safeguarding. There are also three advisory committees - the Technical Scientific, Commercial Development (CD) and Impact, Monitoring and Evaluation committees. These committees provide guidance to the Board through the involvement of external experts.

**Strategy and Decision Making**

Development of the company's strategy for the achievement of its charitable objectives is overseen by the Board of Trustees and evolved by the Executive Directors. GALVmed's 2030 Strategy and the implementation plan was approved by the Board on 23 March 2021. In 2021-22, communication and funder relation strategies have been developed in collaboration with the Board, Members, funders and other key stakeholders.

In the year, the company commenced execution of the 2030 Strategy. The approach has been multi-faceted: extensive discussions with funders on project ideation; identification and formalisation of a strategy execution framework; and development of a partner strategic engagement process. The related corporate objectives and budget are set out in the Annual Plan. Progress in achieving these objectives is assessed by the Board through reports by the Chief Executive and the Executive Directors at Board meetings. Strategic and operational issues are brought to the Board for assessment and direction as required.

**Key Management Remuneration**

Key management includes the Chief Executive (CEO) and Executive Directors of the company who operate as the GALVmed Leadership Team (GLT).

The HR Committee has responsibility delegated to it for setting the framework for key management remuneration. The main responsibilities of the Committee in relation to key management remuneration are:



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2022

- to determine and agree with the Board the broad policy for key management’s remuneration.
- to approve the design, determine targets and approve payments of any performance related schemes; and
- to determine the total remuneration package of each member of the GLT.

The performance related pay scheme, which is based on departmental, and individual objectives developed from the corporate objectives, is applicable to all employees. This was implemented this year following its development in the prior year.

**Diversity**

The diversity of the Trustees, GLT and staff at 31 March 2022 is:

	Gender		Ethnicity		
	Male	Female	African	Asian	Caucasian
Trustees	5	4	3	1	5
GLT	3	3	2	-	4
Staff	9	14	9	3	11

**Safeguarding**

GALVmed is committed to addressing safeguarding throughout its work. It does so through a specific set of policies and procedures that include: Safeguarding Policy (which explicitly addresses prevention, reporting and response); Trustee and GLT training (on commencement and biennial thereafter); all-staff awareness; and contractual commitment to safeguarding by its partners and consultants. No safeguarding issues were reported in the year.

**Partnerships and Related Parties**

Partnerships with entities to whom research and development, commercialisation and other work can be subcontracted is a key part of the way the company operates and is instrumental in allowing it to pursue its charitable objectives. The company initiates, facilitates, brokers and contributes to such partnerships from two perspectives: 1) specific partnerships to deliver and support programme achievement and impact; and 2) higher level strategic partnerships to initiate and advance the livestock agenda. All such relationships are formalised through Memoranda of Understanding, Confidentiality Agreements and Contractual Agreements. All contractual arrangements and related party transactions (detailed in Note 17 to the Financial Statements) are conducted at arm’s length.

**STRATEGIC REPORT**

**Performance and Achievements**

*Key Performance Indicators*

The Trustees and GLT assess the financial and operational performance of each programme using the following key performance indicators (KPI):

- detailed milestones within specific activities as defined in the funder agreement for each programme;
- quarterly KPI dashboards, providing quantitative and qualitative measure of delivery across all functions;
- monthly and quarterly actual expenditure against Board approved budget and forecasts; and
- achievement of the annual corporate objectives.

The Advisory and Board Committees oversee the financial and operational performance of organisational and programme activities quarterly.

In addition, service level agreements have been established for all service-related functions, performance of which is assessed quarterly.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2022

*Key Achievements*

The company has made good progress during the year in achieving its charitable purpose. Its corporate objectives for the year to 31 March 2022 together with key achievements are:

<b>Objective</b>	<b>Achievements</b>
<b>Strategic</b>	
Execute the GALVmed 2030 Strategy including the completion of the Strategy Execution Handbook and partner engagement process development. Conduct the BMGF VITAL mid-term evaluation, including consideration of a no-cost extension and a new funding mechanism.	
	Execution of the 2030 Strategy was initiated with key priorities identified and actively managed through weekly meetings. The exercise culminated in: 1) development of a partner engagement process and related tools; 2) the drafting of a Strategy Execution Handbook (a framework to guide, operationalise and standardise the successful execution of the Strategy); 3) Successful completion of the BMGF VITAL mid-term review which provided a solid foundation for engagement with GALVmed's funders on future funding opportunities resulting in submission, and progression of a funding proposal to BMGF for a 2-year bridging grant, incorporating a no-cost extension for the VITAL programme. Approval is expected by June 2022.
<b>Tactical</b>	
Deliver VITAL, AgResults, AAT 3, BI Last Mile, TAHSSL, PREVENT and other programme outputs on plan and budget.	
	All programmes are progressing well, despite some delays (mainly COVID-19 related), to the satisfaction of partners and funders. The company successfully secured funding for two new programmes of \$6.3m, TB Control Tools and MAHABA, which were effectively resourced and integrated into GALVmed's operations. BI Last Mile was completed on target in the year.
<b>Process</b>	
Ensure strategy and project delivery is underpinned by appropriate human resourcing and efficient processes – including: implementing new organisational structure, including a replacement R&D Director; improving staff development processes, including training and coaching; and reviewing data management and storage processes and integrated project management systems.	
	A key element of the Strategy Implementation Plan was the review and restructure of GALVmed to maximise on skills and expertise utilisation. This was successfully undertaken and effective from October 2021 including the appointment of a new R&D Director. The approach to staff development was improved with a training catalogue and coaching opportunities to be rolled out in 2022-23. A successful data management project was carried out, where all data was migrated to SharePoint, and data management procedures were enhanced.
<b>Outreach</b>	
Expand GALVmed's engagement with external stakeholders including; communication approach reviewed and optimised; strategy communication plan defined; partner engagement goals defined; and Board actively supported to identify new Members and Trustees.	
	The communication approach was reviewed for reach and impact and included the completion of internal and external stakeholder surveys and the roll out of communication plans. The Stakeholder Management and Partner Engagement process was also developed with strategy socialisation to be launched in 2022-23. Stakeholder mapping and engagement planning is ongoing and is complemented by enhanced CEO engagement with partners. One new trustee has been recruited to the Board, and one new member, Hester Biosciences Limited, has joined.
<b>Development</b>	
Broaden GALVmed's funding base and secure fresh funding in line with GALVmed 2030 Strategy.	
	Five concept notes (an outline proposal for a project) have been developed and submitted, four subsequent funding proposals were submitted, with two approved during the year. In addition, a funding proposal for a two-year bridging grant was submitted. This will allow for the continuity of VITAL project delivery and development of R&D and CD strategic project proposals, the latter of which BMGF and the animal health industry are engaged in reviewing and refining, prior to submission for funding in 2022-23. Securing funding from current funders has been prioritised but a Board working group on African Funders Diversification was established resulting in screening of the African funding environment with 11 diversification topics identified for further analysis and vetting with potential funders in 2022-23.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2022

*The Impact of our Work*

GALVmed's mission is to contribute to the transformation of smallholder farmers' lives by ensuring awareness, availability and adoption of effective animal health interventions which have a beneficial impact on livelihoods.

In 2019 research was commissioned by GALVmed on one specific area of our work. It showed the increased uptake in vaccines to counter Newcastle Disease in poultry had the effect of increasing flock size thereby improving the income of the poultry keepers and the amount of protein consumption and increasing the amount which was spent on household education. We have a wide range of animal health products and developing products and markets are steps on GALVmed's pathway to generating impact, the key indicator of success. The complexity of GALVmed's environment necessitated the launch of a substantial review of impact in two phases, the first of which, through a series of internal workshops, considered the determinants of GALVmed's impact, the impact pathway, modelling, framework and frame of reference. The second phase in 2022-23 will focus on and frame, GALVmed's theory of change, indicators of impact, impact measurement (in conjunction with modelling) and ultimately to link impact to organisational performance.

During 2021-22 a broad portfolio of animal health products has been sold through multiple initiatives across various geographies, including VITAL, BI Last Mile and PREVENT. Collectively an estimated 685 million doses of vaccines and therapeutics have been sold to SSP customers across 13 countries (India, Nepal, Kenya, Tanzania, Senegal, Ghana, Cameroon, Mali, Nigeria, Burkina Faso, Ethiopia, Chad and Ivory Coast).

It is recognised that early insight regarding the generation of SSP impact through these initiatives is key, and it is also recognised that a primary objective of the Commercial Development initiatives is financial viability, therefore both components are actively monitored and reported on. To this end, GALVmed employs a strategic decision-making tool the "Impact Framework", which comprises of three components:

1. SSP Customer Number Model
2. Product Portfolio / Customer Profile Matrix
3. Impact Model

The outputs of the Impact Framework allows GALVmed to estimate the number of SSP customers who have been served with animal health products, and to estimate the economic benefit per SSP customer. The approximate estimates of impact generated and understanding of the factors which facilitate delivery of impact inform strategic decisions on where to target resources.

**Financial Review**

Income in the year was £13.4m (2021: £16.9m) and total resources expended were £11.6m (2021: £11.2m).

*Income*

Restricted income of £12.2m (2021: £15.8m) includes £1.8m in respect of AAT 3 and £6.6m in respect of VITAL; funding for other programmes totalled £3.9m. Unrestricted income of £1.1m was received (2021: £1.1m) from contributions from programmes to overheads, and from interest.

*Expenditure*

Expenditure remained broadly consistent at £11.6m (2021: £11.2m). VITAL costs of £5.6m continue to make up the largest proportion of expenditure, 48% (2021: 50%). Expenditure on AAT 3 has decreased to £2.5m, 22% (2021: £3.1m, 28%). Unrestricted spend has remained broadly consistent at £0.8m (2021: £0.7m).



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2022

*Unrealised Exchange Gains/Losses*

An unrealised exchange gain of £0.7m has arisen (2020-21: loss of £1.6m) on the conversion of foreign currency balances at year end exchange rates. The gain is a result of the weakening of Sterling against the US Dollar (in which most of the company's funding is received) from 1.38 to 1.32 in the year. The company minimises the effects of currency fluctuations by taking a number of steps, including contracting in the funded currency where possible and optimising the timing of foreign currency conversions.

*Balance Sheet*

The level of cash held has increased from £14.2m to £17.2m in the year as a result of advanced AAT 3 funding.

*Liquidity Management Policy*

The company's liquidity management and investment objectives, responsibilities, risk, and strategy are clearly set out in a Liquidity Management Policy which is subject to review annually. The related liquidity and investment activity is reviewed quarterly by the Finance & Risk Committee.

*Climate Change*

The Board is committed to reducing the company's greenhouse gas emissions, particularly those resulting from air travel. The Company generated and offset 68 tonnes of emissions in the year (2019-20 (pre-COVID): 250 tonnes), following the lifting of COVID-19 travel restrictions from February 2022. Carbon offset is through investment in like-purposed initiatives. In future, given the successful adaption by GALVmed to travel restrictions during COVID-19, alternatives to air travel will be a pre-requisite consideration before travel is undertaken.

*Reserves*

Reserves at 31 March 2022 total £16.5m (2021: £14.0m), of which available funds not tied up in fixed assets amount to £16.5m (2021: £13.9m). Reserves related to restricted funds of £13.6m (2021: £11.5m) mainly relate to advance funding for AAT 3.

*Unrestricted Reserves Policy*

Unrestricted reserves at 31 March 2022 amount to £2.9m (2021: £2.5m). From this amount, the Trustees have established a designated fund of £1.3m (2021: £0.9m) which comprises unrestricted reserves that have been set aside for a particular purpose, in this case for any future shortfall in the recovery of overhead costs from programmes.

The objective of the company's unrestricted reserves strategy is to build sufficient funds to protect the company from any adverse changes in its financial circumstances and to pursue operational opportunities that, in the initial phase, are not funded by 3<sup>rd</sup> parties. By considering a variety of risks, the Trustees have concluded that £1.1m of unrestricted reserves should be ring-fenced to cover possible adverse events or circumstances. Additional unrestricted reserves are currently held to ensure financial sustainability in the event that VITAL Bridging funding is not received and to allow for the future investment in the 2030 Strategy. The unrestricted reserves policy is reviewed every 6 months to ensure that it reflects current circumstances.

**Future Plans**

*Objectives*

GALVmed is operating in accordance with the vision of the 2030 Strategy. This builds upon the evolution of the company since inception as a product development partnership working on a strong portfolio of new products, technologies and processes while continuing to facilitate scale-orientated commercial development initiatives.

GALVmed has identified the following key objectives for 2022-23:



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2022

<b>Objective</b>	
<b>Strategic</b>	Execute GALVmed 2030 Strategy including: developing R&D project pipelines and analysing the strategic themes; evolving the CD SEAMLiSS platform and business case; developing downstream last-mile bridging strategies; and developing the proposal for R&D and CD project portfolios in South Asia.
<b>Tactical</b>	Deliver VITAL R&D, AgResults Brucella & FMD, Tryps, ASF, Bovine TB, TAHSSL, VITAL CD, PREVENT, MAHABA on plan and on budget.
<b>Process</b>	Ensure strategy and project delivery is underpinned by appropriate human resourcing and efficient processes through: 1) implementing a new staff learning & development programme; 2) evolving the M&E methodology to evaluate & reflect GALVmed's output, outcomes and impact generation; 3) identifying key principles of knowledge management processes; 4) rolling out and embedding the Strategy Execution Handbook; 5) embedding 6-4 Project Management principles into all new projects; 6) assessing key systems including project risk management; and 7) ensuring that GALVmed is staffed appropriately with succession plans in place.
<b>Outreach</b>	Expand GALVmed's engagement with external stakeholders by: finalising and launching the GALVmed 2030 Strategy communication plan and tools; updating the corporate communication deck; cultivating active partner engagement; and supporting new Members and Trustees identification and induction.
<b>Development</b>	Broaden GALVmed's funding base and secure fresh funding in line with GALVmed 2030 Strategy, including: securing funding for TAHSSL and VITAL bridging; ensuring future sustainability of core costs; engaging with new funders including the exploration of the African funding environment; and consideration of the long-term sustainability of GALVmed.

*Financial*

The 2022-23 expenditure budget is £14.6m, a 27% increase on 2021-22 actual expenditure. This increase is mainly because of the increased AAT 3 sub-award activity as the programme progresses through the developmental stage.

**Principal Risks and Uncertainties**

*Risk Management*

The company's governance structure includes risk management. During the year significant work was undertaken to strengthen risk management. Risk appetite statements were identified for each risk category and incorporated into the Risk Management Policy, the structure and content of which was amended to strengthen risk identification and management. The structure of the Corporate Risk Register was amended to focus on net risk post mitigation instead of gross risk. The approach to project risk management is being overhauled to increase synergy with corporate risk management and ultimately ensure greater visibility, aggregation, and escalation of project risks.

The Risk Management Policy details the company's risk management objectives, processes, reporting and responsibilities. The Risk Register highlights the major risks to which the company is exposed and for each risk the score, lead risk owner, mitigations and actions stated. It is maintained to support strategic, financial, and operational planning and therefore to assist in achieving the company's objectives and targets. The key risks, that GALVmed faces at the time of this report, and key mitigations, are:



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
For the year ended 31 March 2022

<b>Risk</b>	<b>Key Mitigations</b>
Failure to design and implement projects which achieve economic impact for small-scale livestock producers	Pursue the routes to SSP markets before product development is completed
Geo-political instability impacts on GALVmed's beneficiaries, operations, and resources	Be vigilant of the multi-faceted impact through a separate risk register (includes: cost of SSPs inputs & supply chain)
Loss of highly experienced key staff impacts on project delivery, reputation & staff morale	Succession planning and managing staff expectations on career progression perspective
Barriers to product registration reduces product availability	Support harmonisation of product registration in Africa and engage with international organisations
Failure to deliver by partners affects the outcomes and impact	Stringent identification, contracting and management of partners through policy and procedures adoption
Data security breach results in loss of, or corrupted, data	Multi-pronged systems, software, support and user awareness approaches to ensure robust mechanisms and ever cautious

Important financial risks are the possible loss of bank deposits through fraud or theft, currency risk, liquidity risk and dependency on limited funding sources. The risk of loss of bank deposits is managed through the bank mandates in place and continued vigilance. Currency and liquidity risk are managed by following the Liquidity Management Policy. The 2030 Strategy and Funder Relations Strategy aims to address the limited funding sources issue.

*COVID-19*

The risks surrounding COVID-19 were identified at the start of the pandemic in a separate Risk Register. It considers risk across 3 categories (people, projects and finance) and notes for each risk the mitigation, actions, lead risk owner and target date for mitigation. The COVID-19 Risk Register, amongst other related matters were considered fortnightly by the COVID Crisis Management team.

The impact of COVID-19 on the company over the past year and on an ongoing basis has been considered. With the easing of restrictions in 2021-22 and a successful vaccination programme in the UK, Kenya and India all offices were successfully reopened in February 2022. Travel restrictions were also lifted in February 2022, with the first face-to-face Board meeting since 2019 held in Senegal in March 2022. Programme funding has not been impacted by COVID-19. To date, the majority of programmes have continued to deliver, but with COVID-19 related challenges experienced by most. It is expected that all programmes will continue to be delivered in full with project extensions expected across the VITAL, TAHSSL and Brucellosis programmes to accommodate COVID-19 delays.

**GOING CONCERN**

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding for the VITAL programme ends in September 2022. Prior to this all direct (project support) costs are funded through VITAL with sufficient contribution from this and all other current programmes to fully cover indirect (organisational) costs. Other programmes are fully funded.

There is currently no confirmed funding for direct costs beyond October 2022. We are in the final stages of applying for funding from the Bill & Melinda Gates Foundation for a two-year bridging period to September 2024 to enable completion of the VITAL programme, continuity of other project commitments and to evolve future project proposals. While formal confirmation of funding is not expected until July 2022, based on discussions with our funders we are confident that funding will be approved prior to October 2022.

In the event that VITAL bridging funding is not received, or confirmation is delayed, there are sufficient designated reserves to cover direct costs and the shortfall in indirect costs to May 2023. The remaining shortfall (to cover the period of 12 months from signing the financial statements) can comfortably be funded from general unrestricted



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2022**

reserves, while maintaining the balance of this reserve at £1.5m. There is therefore sufficient reserves to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

**AUDITORS**

Henderson Loggie LLP, Chartered Accountants, were reappointed as auditors to the company at the Annual General Meeting in 2017. Their re-appointment was approved up to a maximum 10 years from the date of their first appointment in 2011 subject to annual consideration by both parties. A further one-year extension in respect of the 2021-22 financial year was approved at the AGM in September 2021.

The Trustees' Report including the Strategic Report was approved by the Board of Trustees and signed on their behalf by:

*Paul Wood*  
Paul Wood - 2022-06-21, 11:22:16 UTC

Prof P Wood



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**RESPONSIBILITIES OF THE TRUSTEES**  
For the year ended 31 March 2022

The Trustees (who are also the Directors for the purposes of company law) are responsible for the preparation of the Trustees' Report, including the Strategic Report, and financial statements in accordance with applicable law and regulations.

Law applicable to incorporated charities in Scotland requires the Trustees to prepare an annual report and financial statements for each financial year in accordance with applicable law and regulations. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).

Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity at the end of the year and of its financial activities including its income and expenditure during the year then ended. In preparing those financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper and adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006, with the Charities and Trustee Investment (Scotland) Act 2005, the Charities Act 2011 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the maintenance and integrity of the charity.

The Trustees have fulfilled their legal responsibilities with respect to the Trustees' Report, Strategic Report, and Financial Statements.

**Statement of Disclosure of Information to Auditors**

To the knowledge and belief of each of the persons who is a Trustee at the time this report is approved:

- a) So far as the Trustee is aware, there is no relevant information of which the organisation's auditors are unaware; and
- b) He/or she has taken all steps that he/she ought to have taken as a Trustee to make himself/herself aware of any relevant audit information and to establish that the auditors are aware of that information.

*Paul Wood*  
Paul Wood - 2022-06-21, 11:22:16 UTC

Prof P Wood



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2022

**Opinion**

We have audited the financial statements of Global Alliance for Livestock Veterinary Medicines (the 'charitable company') for the year ended 31 March 2022 which comprise the Income and Expenditure Account and Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flow and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2022 and of its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities Act 2011, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

**Basis of opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (FRC) Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the Trustees' report, other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2022

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Strategic Report and the Trustees' Report for the financial period for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Trustees' Report have been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Trustees' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Act 2011, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of Trustees**

As explained more fully in the Trustees' Responsibilities Statement, the Trustees (who are also the Directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

We have been appointed as auditor under sections 144 of the Charities Act 2011 and 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud, is detailed below:

- Enquiring with management about any known or suspected instances of non-compliance with laws and regulations, including GDPR and employment law, and fraud;
- Review of correspondence with regulators including OSCR, the Charities Commission for England and Wales and the Health & Safety Executive;
- Review of legal fee expenditure and board minutes;
- Challenging assumptions and judgements made by management in their significant accounting estimates; and



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES**  
For the year ended 31 March 2022

- Auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness

Because of the field in which the client operates, we identified the following areas as those most likely to have a material impact on the financial statements: Health and Safety; employment law (including the Working Time Directive); GDPR; and compliance with the UK Companies Act and the Charities legislation.

Owing to the inherent limitations of an audit, there is an unavoidable risk that some material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISAs (UK). For instance, the further removed non-compliance is from the events and transactions reflected in the financial statements, the less likely the auditor is to become aware of it or to recognise the non-compliance. A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

This report is made solely to the Members of Global Alliance for Livestock Veterinary Medicines, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's Trustees, as a body, in accordance with Section 154 of the Charities Act 2011, Section 44 (1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the Members and the charitable company's Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, its Members as a body and its Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

*James Davidson*  
James Davidson - 2022-06-21, 12:04:11 UTC

**James Davidson (Senior Statutory Auditor)**  
**For and on behalf of Henderson Loggie LLP**  
**Chartered Accountants**  
**Statutory Auditor**  
**Eligible to act as an auditor in terms of section 1212 of the Companies Act 2006**

Ground Floor, 11-15 Thistle Street  
Edinburgh  
EH2 1DF

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INCOME AND EXPENDITURE ACCOUNT AND  
STATEMENT OF FINANCIAL ACTIVITIES**  
For the year ended 31 March 2022

	Notes	Unrestricted £	Restricted £	Total 2022 £	Total 2021 £
<b>Income from:</b>					
Charitable Activities	2	1,119,977	12,237,307	13,357,284	16,913,549
Investments		1,286	4,352	5,638	13,778
<b>Total Income</b>		<u>1,121,263</u>	<u>12,241,659</u>	<u>13,362,922</u>	<u>16,927,327</u>
<b>Expenditure on:</b>					
Charitable Activities	3	795,618	10,755,737	11,551,355	11,191,562
<b>Total Expenditure</b>		<u>795,618</u>	<u>10,755,737</u>	<u>11,551,355</u>	<u>11,191,562</u>
<b>Net Income</b>	5	325,645	1,485,922	1,811,567	5,735,765
<b>Other Recognised Gains/(Losses):</b>					
Unrealised Gain/(Loss) on Foreign Exchange	6	121,130	596,879	718,009	(1,629,707)
Net Movement in Funds		446,775	2,082,801	2,529,576	4,106,058
<b>Reconciliation of Funds</b>					
Total Funds Brought Forward at 1 April 2021	12	2,492,229	11,509,420	14,001,649	9,895,591
Total Funds Carried Forward at 31 March 2022	12	<u>2,939,004</u>	<u>13,592,221</u>	<u>16,531,225</u>	<u>14,001,649</u>

All the results of the company relate to continuing activities.

The company has no recognised gains or losses other than those set out above.

The notes on pages 19 to 30 form part of these financial statements



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**BALANCE SHEET**  
As at 31 March 2022

	Notes	2022		2021	
		£	£	£	£
<b>Fixed Assets</b>					
Tangible Assets	8		31,657		61,972
<b>Current Assets</b>					
Debtors	9	267,990		552,820	
Bank and Cash Balances	10	17,242,227		14,151,954	
		<u>17,510,217</u>		<u>14,704,774</u>	
<b>Liabilities:</b>					
Creditors: Amounts Falling Due Within One Year	11	(1,010,649)		(765,097)	
<b>Net Current Assets</b>			<u>16,499,568</u>		<u>13,939,677</u>
<b>Total Net Assets</b>			<u><u>16,531,225</u></u>		<u><u>14,001,649</u></u>
<b>Unrestricted Funds</b>					
General Reserve	12		1,617,810		1,600,798
Designated Funds	12		1,321,194		891,431
			<u>2,939,004</u>		<u>2,492,229</u>
<b>Total Unrestricted Funds</b>			2,939,004		2,492,229
<b>Restricted Income Funds</b>	12		13,592,221		11,509,420
			<u>16,531,225</u>		<u>14,001,649</u>
<b>Total Funds</b>			<u><u>16,531,225</u></u>		<u><u>14,001,649</u></u>

The financial statements were authorised for issue and approved by the Trustees.

*Paul Wood*  
Paul Wood - 2022-06-21, 11:22:16 UTC

Prof. P Wood  
Company No: 05393391

The notes on pages 19 to 30 form part of these financial statements



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**STATEMENT OF CASH FLOWS**  
For the year ended 31 March 2022

	<b>Notes</b>	<b>2022</b>	<b>2021</b>
		£	£
<b>Cash Flows from Operating Activities:</b>			
<b>Net Cash Provided by Operating Activities</b>	<b>16</b>	2,379,256	5,477,874
<i>Cash Flows from Investing Activities:</i>			
Interest from Investments		2,628	18,611
Purchase of Property, Plant and Equipment		(9,620)	(13,787)
<b>Net Cash Used in/(Received from) Investing Activities</b>		<u>(6,992)</u>	<u>4,824</u>
<b>Change in Cash and Cash Equivalents in the Reporting Period</b>		2,372,264	5,482,698
Cash and Cash Equivalents at the Beginning of the Reporting Period		14,151,954	10,298,963
Change in Cash and Cash Equivalents due to Exchange Rate Movements		718,009	(1,629,707)
<b>Cash and Cash Equivalents at the End of the Reporting Period</b>		<u><u>17,242,227</u></u>	<u><u>14,151,954</u></u>
 <b>Analysis of Cash and Cash Equivalents</b>			
 Bank and Cash Balances		 <u><u>17,242,227</u></u>	 <u><u>14,151,954</u></u>

The notes on pages 19 to 30 form part of these financial statements



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**1. Accounting Policies**

*Basis of Accounting*

GALVmed is a public benefit entity. The financial statements have therefore been prepared in accordance with the Companies Act 2006, applicable accounting standards, Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 as amended in 2010, and the Charities Act 2011. They have also been prepared under historical cost accounting rules. The financial statements are prepared in Sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

*Going Concern*

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding for the VITAL programme ends in September 2022. Prior to this all direct (project support) costs are funded through VITAL with sufficient contribution from this and all other current programmes to fully cover indirect (organisational) costs. Other programmes are fully funded.

There is currently no confirmed funding for direct costs beyond October 2022. We are in the final stages of applying for funding from the Bill & Melinda Gates Foundation for a two-year bridging period to September 2024 to enable completion of the VITAL programme, continuity of other project commitments and to evolve future project proposals. While formal confirmation of funding is not expected until July 2022, based on discussions with our funders we are confident that funding will be approved prior to October 2022.

In the event that VITAL bridging funding is not received, or confirmation is delayed, there are sufficient designated reserves to cover direct costs and the shortfall in indirect costs to May 2023. The remaining shortfall (to cover the period of 12 months from signing the financial statements) can comfortably be funded from general unrestricted reserves, while maintaining the balance of this reserve at £1.5m. There is therefore sufficient reserves to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

*Fund Accounting*

Funds received on which no restrictions are placed as to their use are accounted for as unrestricted funds. Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in note 12.

Funds received for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose, are accounted for as restricted funds.

*Income*

Funds received are recognised as income from charitable activities once there is entitlement, reasonable probability of receipt and the amount can be measured with sufficient reliability. Income is deferred where funder-imposed conditions that specify the time period in which the funds can be spent have not yet been met.

Investment income is recognised as earned.

*Value Added Tax (VAT)*

Expenditure is accounted for inclusive of VAT where appropriate as the company is not registered for VAT.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**1. Accounting Policies (continued)**

*Pension Scheme*

The company provides a defined contribution pension scheme for its staff and the pension charge in the Statement of Financial Activities (SOFA) represents the amounts payable by the company to the Company Personal Pension Scheme in respect of the year.

*Operating Leases*

Rentals payable under operating leases are charged to the SOFA on the straight-line basis over the lease term.

*Expenditure*

Expenditure is recognised on the accruals basis when a legal and constructive obligation exists. Expenditure through contractual agreements is recognised as goods and services are supplied. Grant payments are recognised as expenditure when payments are due in accordance with the terms of the contract.

Costs incurred by the company in the delivery of its activities and services are accounted for as charitable expenditure and categorised in the SOFA by the main activities of the company. Each category includes direct costs and support costs and, where support costs cannot be directly attributed to a category, they are apportioned on the basis of headcount.

Costs that, whilst necessary to deliver an activity do not themselves contribute directly to GALVmed's activity, are accounted for as support costs. Support costs include central office functions such as management, finance, information systems and administration activities.

*Foreign Currency*

Foreign currency transactions are recorded in Sterling at the previous month's month-end rate of exchange. Monetary assets and liabilities denominated in foreign currencies are translated into Sterling at the exchange rate at the balance sheet date.

All exchange differences are recognised through the SOFA.

*Tangible Fixed Assets*

Tangible fixed assets costing more than £1,000 are capitalised and stated at cost and depreciated over their useful economic lives as follows:

Office equipment	4 years
Computer equipment & software	3 years
Leasehold improvements	over the life of the lease

Assets are only depreciated when they are brought into use and depreciated up to, but not including, the month of disposal.

*Debtors and Prepayments*

Debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

*Cash at Bank and in Hand*

Cash at bank and in hand includes cash and short term highly liquid investments with a maturity of six months or less from the date of acquisition or opening of the deposit or similar account.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**1. Accounting Policies (continued)**

*Creditors*

Creditors are recognised where the company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party in the future and the amount due to settle obligations can be measured or estimated reliably. Creditors are recognised at their settlement amount.

*Critical Accounting Judgements and Estimation Uncertainty*

In preparing the financial statements, the Trustees are required to make judgements, estimates and assumptions, which may affect reported income, expenditure, assets and liabilities. The estimates and associated assumptions are based on historical experience and other factors considered relevant. Actual results may differ from such estimates. Judgements made in preparing these financial statements comprise:

- The applicability of the estimated useful lives of fixed assets used to calculate the period over which depreciation is applied.
- The review of fixed assets for impairment or obsolescence.
- The assessment of leases to determine whether the risks and rewards of ownership remain with the lessor or are transferred to GALVmed

*Financial Instruments*

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

**2. Incoming Resources from Charitable Activities**

	UK Grant Funding £	Overseas Grant Funding £	2022 £	2021 £
<b>Restricted income</b>				
AAT 3	(8,545)	1,765,974	1,757,429	9,127,520
VITAL	1,246,710	5,347,270	6,593,980	4,367,236
AgResults Brucellosis	-	245,644	245,644	286,944
Bovine TB	-	872,846	872,846	-
PREVENT	-	1,338,977	1,338,977	1,058,127
AgResults FMD	-	307,367	307,367	419,452
MAHABA	-	1,012,314	1,012,314	-
Boehringer Ingelheim	-	(7,790)	(7,790)	507,012
TAHSSL	-	114,276	114,276	92,088
Health for Animals	-	2,264	2,264	-
Royal Veterinary College	-	-	-	5,317
AAT Ethiopia	-	-	-	(40,000)
<b>Total restricted income</b>	<b>1,238,165</b>	<b>10,999,142</b>	<b>12,237,307</b>	<b>15,823,696</b>
<b>Unrestricted income</b>	<b>171,341</b>	<b>948,636</b>	<b>1,119,977</b>	<b>1,089,853</b>
<b>Total income</b>	<b>1,409,506</b>	<b>11,947,778</b>	<b>13,357,284</b>	<b>16,913,549</b>

There is negative income in the AAT3 and Boehringer Ingelheim programmes because of indirect core contributions towards unrestricted funds.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**3. Analysis of Expenditure**

	Support £	Governance £	Staff £	Direct Costs £	Total 2022 £	Total 2021 £
AAT 3	1,294	-	70,878	2,467,793	2,539,965	3,116,397
VITAL	278,812	-	1,010,898	4,299,356	5,589,066	5,589,788
AgResults Brucellosis	1,582	-	1,674	100,211	103,467	94,042
Bovine TB	-	-	-	12,707	12,707	-
PREVENT	-	-	-	1,201,776	1,201,776	641,875
AgResults FMD	5,057	-	79,661	197,190	281,908	328,327
MAHABA	-	-	-	699,143	699,143	-
Boehringer Ingelheim	79	-	-	145,978	146,057	433,928
TAHSSL	1,171	-	86,536	7,947	95,654	110,600
PLSHL 2	-	-	-	85,994	85,994	183,356
Royal Veterinary College	-	-	-	-	-	5,317
Unrestricted	76,424	49,070	485,147	184,977	795,618	687,932
<b>Total 2022</b>	<b>364,419</b>	<b>49,070</b>	<b>1,734,794</b>	<b>9,403,072</b>	<b>11,551,355</b>	<b>11,191,562</b>
<b>Total 2021</b>	<b>328,541</b>	<b>(20,321)</b>	<b>1,712,318</b>	<b>9,171,024</b>	<b>11,191,562</b>	

Negative governance costs in 2020-21 were incurred because of refunds received for the March 2020 Board meeting, which was cancelled because of COVID-19.

**Analysis of Support Costs**

	Professional Fees £	Office Costs £	Information Technology £	Audit Fees £	Total 2022 £	Total 2021 £
AAT 3	-	-	1,294	-	1,294	1,591
VITAL	44,737	137,457	95,234	1,384	278,812	249,506
AgResults Brucellosis	-	221	1,361	-	1,582	1,556
AgResults FMD	-	285	4,772	-	5,057	7,979
Boehringer Ingelheim	-	79	-	-	79	-
TAHSSL	-	234	937	-	1,171	943
Unrestricted	9,454	28,146	26,129	12,695	76,424	66,966
<b>Total 2022</b>	<b>54,191</b>	<b>166,422</b>	<b>129,727</b>	<b>14,079</b>	<b>364,419</b>	<b>328,541</b>
<b>Total 2021</b>	<b>50,850</b>	<b>166,137</b>	<b>97,612</b>	<b>13,942</b>	<b>328,541</b>	

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**4. Staff Costs**

	<b>2022</b>	<b>2021</b>
	£	£
Total staff costs were as follows:		
Salaries	1,483,068	1,458,427
Social security costs	107,104	110,322
Pension contributions	99,920	98,066
Other employee benefits	44,702	45,503
	<u>1,734,794</u>	<u>1,712,318</u>

The average number of employees during the year was:

	<b>Number</b>	<b>Number</b>
Management	5	5
Project staff	13	13
Support staff	11	11
	<u>29</u>	<u>29</u>

During the year the company incurred expenses of £1,514 on behalf of, or reimbursed expenses to, 7 Trustees in connection with their governance responsibilities (2021: £240, 4 Trustees). One face-to-face meeting took place in 2021-22. All Board meetings in 2020-21 were held virtually due to COVID-19. No expenses were incurred for persons or entities connected with the Trustees (2021: £nil). No Trustees received remuneration in relation to consultancy services provided (2021: One Trustee, £73).

GALVmed provides to its UK-based staff a defined contribution pension scheme, the GALVmed Personal Pension Scheme, which is operated by Aviva, a life assurance company. Total employer contributions in the year were £58,063 (2021: £60,205). The total number of members in the scheme at 31 March 2022 was 16 (2021: 19).

To compensate for the fact that there is currently no pension scheme for international staff, an employer contribution of 6% of salary is paid to such staff on the understanding that this contribution should be paid into a pension scheme of their choice. Total such contributions in respect of the year were £41,857 (2021: £38,051).

The following number of employees received total employee salary and benefits (excluding employer pension) in excess of £60,000 in the period:

	<b>2022</b>	<b>2021</b>
£60,000 - £69,999	1	-
£70,000 - £79,999	3	2
£90,000 - £99,999	1	1
£100,000 - £109,999	-	1
£150,000 - £159,999	1	1
	<u>1</u>	<u>1</u>

GALVmed considers the key management of the company to be the GALVmed Leadership Team (GLT), comprising the Chief Executive Officer, Executive Directors and Senior Directors. The total cost of the employment of key management in the year was £494,274 (2021: £540,377), with a further £86,891 (2021: £89,584) paid to one consultant. The reduction within key management costs is because of delays associated with recruitment of the replacement R&D Executive Director. The position was filled in October 2021. Employer pension contributions for key management totalled £26,196 (2021: £30,573).

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**5. Net Incoming Resources**

	2022	2021 £
This is stated after charging:		
- Auditor's remuneration – audit fees	14,079	13,942
- Depreciation	39,935	36,266
- Loss on disposal of fixed assets	-	2,325
- Operating leases		
Land and buildings	115,701	118,702
Equipment	1,241	1,701

Auditors' remuneration includes £1,384 (2021: £1,852) for audit fees payable in India and £12,695 (2021: £12,090) for audit fees in the UK.

**6. Unrealised Exchange Gains and Losses**

Unrealised gains and losses on foreign exchange relate to the revaluation of GALVmed's net current assets at 31 March 2022 (see note 12 for unrealised exchange gains/losses by programme). The gains predominantly relate to advance funding in US Dollars and a weakening of Sterling against the US Dollar.

In addition, a realised loss of £15,581 (2021: £5,312 gain) is included in the expended charitable resources, which is a result of the difference between the currency rate invoiced and the currency rate paid to suppliers. GALVmed undertakes a variety of exchange mechanisms throughout the year to minimise realised exchange differences and help ensure there are adequate resources to deliver the programme outputs.

**7. Taxation**

The company has charitable status and is not liable for tax.

**8. Tangible Assets**

	Leasehold improvements £	Office equipment £	Computer equipment £	Total £
<b>Cost</b>				
At 1 April 2021	12,430	7,267	270,505	290,202
Additions	-	-	9,620	9,620
Disposals	-	-	(38,871)	(38,871)
At 31 March 2022	<u>12,430</u>	<u>7,267</u>	<u>241,254</u>	<u>260,951</u>
<b>Depreciation</b>				
At 1 April 2021	3,207	7,267	217,756	228,230
Charge for year	4,085	-	35,850	39,935
Eliminated on disposal	-	-	(38,871)	(38,871)
At 31 March 2022	<u>7,292</u>	<u>7,267</u>	<u>214,735</u>	<u>229,294</u>
<b>Net book value</b>				
At 31 March 2022	<u>5,138</u>	<u>-</u>	<u>26,519</u>	<u>31,657</u>
At 31 March 2021	<u>9,223</u>	<u>-</u>	<u>52,749</u>	<u>61,972</u>



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**9. Debtors**

	2022 £	2021 £
Prepayments and accrued income	169,687	527,890
Other debtors	98,303	24,930
	<u>267,990</u>	<u>552,820</u>

Prepayments and accrued income include £86,030 (2021: £90,460) of accrued income in relation to the AgResults Foot and Mouth Disease (FMD) programme; £nil (2021: £70,003) in relation to the AgResults Brucellosis programme; £nil in relation to the VITAL programme (2021: £293,491); and other debtors include accrued investment income of £3,152 (2021: £142).

**10. Bank and Cash Balances**

2022	GBP £	USD £	Other currencies £	Total £
Lloyds Bank	1,603,617	4,101,315	5,970	5,710,902
Bank of Scotland	500,100	5,214,879	-	5,714,979
NatWest	-	5,805,740	-	5,805,740
Standard Chartered	-	-	5,755	5,755
Cash	252	3,129	1,470	4,851
	<u>2,103,969</u>	<u>15,125,063</u>	<u>13,195</u>	<u>17,242,227</u>
2021	GBP £	USD £	Other currencies £	Total £
Lloyds Bank	668,030	3,695,610	5,118	4,368,758
Bank of Scotland	1,000,000	3,773,708	-	4,773,708
NatWest	-	4,989,922	-	4,989,922
Standard Chartered	-	-	14,341	14,341
Cash	234	3,281	1,710	5,225
	<u>1,668,264</u>	<u>12,462,521</u>	<u>21,169</u>	<u>14,151,954</u>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**11. Creditors: Amounts Falling Due Within One Year**

	2022 £	2021 £
Accruals	624,236	153,433
Deferred income	247,594	-
Trade creditors	126,541	610,286
Other creditors	12,278	1,378
	<u>1,010,649</u>	<u>765,097</u>

Creditors includes £247,594 of deferred income in relation to the VITAL programme. The movement in accruals and trade creditors is because of large, contracted payments due to partners for the AAT 3 programme.

**12. Funds Movement**

2022	31 March 2021 £	Incoming resources £	Resources expended £	Exchange gain/(loss) £	Transfers £	31 March 2022 £
<b>Restricted funds:</b>						
AAT 3	6,870,447	1,759,640	(2,539,965)	229,704	-	6,319,826
VITAL	2,576,941	6,595,434	(5,589,066)	242,821	-	3,826,130
AgResults Brucellosis	1,015,272	246,251	(103,467)	50,506	-	1,208,562
Bovine TB	-	872,911	(12,707)	2,867	-	863,071
PREVENT	416,252	1,338,986	(1,201,776)	(60,113)	-	493,349
AgResults FMD	309,813	307,367	(281,908)	12,435	-	347,707
MAHABA	-	1,012,314	(699,143)	26,165	-	339,336
Boehringer Ingelheim	170,441	(7,784)	(146,057)	95,014	-	111,614
TAHSSL	64,103	114,276	(95,654)	(2,363)	-	80,362
Health for Animals	-	2,264	-	-	-	2,264
PLSHL 2	86,151	-	(85,994)	(157)	-	-
<b>Total restricted funds</b>	<u>11,509,420</u>	<u>12,241,659</u>	<u>(10,755,737)</u>	<u>596,879</u>	<u>-</u>	<u>13,592,221</u>
<b>Unrestricted funds:</b>						
General reserve	1,600,798	1,121,263	(795,618)	121,130	(429,763)	1,617,810
Designated funds:						
Indirect future costs	891,431	-	-	-	429,763	1,321,194
<b>Total unrestricted funds</b>	<u>2,492,229</u>	<u>1,121,263</u>	<u>(795,618)</u>	<u>121,130</u>	<u>-</u>	<u>2,939,004</u>
<b>Total funds</b>	<u>14,001,649</u>	<u>13,362,922</u>	<u>(11,551,355)</u>	<u>718,009</u>	<u>-</u>	<u>16,531,225</u>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**12. Funds Movement (continued)**

	31 March 2020	Incoming resources	Resources expended	Exchange gain/(loss)	Transfers	31 March 2021
	£	£	£	£	£	£
<b>2021</b>						
<b>Restricted funds:</b>						
AAT 3	1,340,656	9,130,126	(3,116,397)	(483,938)	-	6,870,447
VITAL	4,443,169	4,374,654	(5,589,788)	(651,094)	-	2,576,941
AgResults Brucellosis	922,252	287,861	(94,042)	(100,799)	-	1,015,272
PREVENT	-	1,058,127	(641,875)	-	-	416,252
AgResults FMD	249,450	419,452	(328,327)	(30,762)	-	309,813
Boehringer Ingelheim	221,795	507,716	(433,928)	(125,142)	-	170,441
TAHSSL	82,615	92,088	(110,600)	-	-	64,103
PLSHL 2	293,106	342	(183,356)	(23,941)	-	86,151
Royal Veterinary College	-	5,317	(5,317)	-	-	-
AAT – Ethiopia	40,052	(40,052)	-	-	-	-
<b>Total restricted funds</b>	<b>7,593,095</b>	<b>15,835,631</b>	<b>(10,503,630)</b>	<b>(1,415,676)</b>	<b>-</b>	<b>11,509,420</b>
<b>Unrestricted funds:</b>						
General reserve	1,851,227	1,091,696	(687,932)	(214,031)	(440,162)	1,600,798
Designated funds:						
Indirect future costs	451,269	-	-	-	440,162	891,431
<b>Total unrestricted funds</b>	<b>2,302,496</b>	<b>1,091,696</b>	<b>(687,932)</b>	<b>(214,031)</b>	<b>-</b>	<b>2,492,229</b>
<b>Total funds</b>	<b>9,895,591</b>	<b>16,927,327</b>	<b>(11,191,562)</b>	<b>(1,629,707)</b>	<b>-</b>	<b>14,001,649</b>

*Programme Objectives and Funding*

The purpose of the AAT 3 programme is to build upon the success of the work carried out under previous AAT programmes resulting in the improved tools for the control of Animal African Trypanosomiasis. The specific objective of AAT 3 is the commercial development of a registered therapeutic trypanocidal product, ready for sale through GALVmed's commercial partner in the AAT 3 programme, Boehringer Ingelheim. This programme is funded by both BMGF (\$19m) and FCDO (\$3.5m).

The VITAL programme has two strands: product development and commercial development. The broad objectives are: 1) to develop six new high impact livestock vaccines ready for commercial production and suitable for widespread use by smallholders in Africa and South Asia; and 2) to partner the animal health industry to establish five large scale portfolio distribution networks in Africa and South Asia with each initiative being capable of generating positive cash flows by year 4 and achieving subsequent growth and expansion through these cash flows. The programme is jointly funded by BMGF (80%) and FCDO (20%). This programme is contracted to end on 30 September 2022. Delays associated with COVID-19 have led to on-going discussions with our funders regarding a no-cost extension to allow the programme objectives to be fully achieved beyond this contractual end date.

The AgResults Brucellosis programme is a competition, managed by GALVmed, to develop and register a safe and efficacious vaccine against *Brucella melitensis*, the main cause of human infections with Brucella and a significant economic burden in developing countries. It is fully funded by the AgResults consortium.

The Bovine TB programme aims to enable and accelerate the development and implementation of rational evidence-based approaches to control TB, with a focus on India, and to provide a strong foundation for the development of control programmes in other developing countries. This project will establish and publish Target Product Profiles for novel tools to control TB and develop a roadmap for product development and commercialisation of novel diagnostic tests in India.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**12. Funds Movement (continued)**

The PREVENT (PRomoting and Enabling Vaccination Efficiently, Now and Tomorrow) programme is fully funded by BMGF and is carried out in partnership with Ceva Santé Animale. The aim of this programme is to create an efficient sector of medium-sized African hatcheries applying hatchery vaccination and proactive marketing methods to initiate and increase vaccinated chick sales to poultry small scale producers.

The AgResults Foot and Mouth programme is a competition, managed by GALVmed, to encourage the development and uptake of an improved vaccine tailored for the needs and requirements of East Africa. It is fully funded by the AgResults Consortium.

The MAHABA (Managing Animal Health and Acaricides for a Better Africa) programme is fully funded by BMGF and is carried out in partnership with Elanco Animal Health. The aim of the programme is to create effective tick control for small-scale livestock producers, by building a clear understanding of acaricide usage, developing innovative methods to help educate on the effective use and by providing practical methods to counter resistance, avoid failures and allow sustainable tick control.

The Boehringer Ingelheim (BI) programme is fully funded by BMGF and is carried out in partnership with BI. Its objective is to deliver a viable business model for providing quality veterinary healthcare to smallholder farmers in Africa. The key activities for this programme are 1) a registration initiative of BI products in three key markets; and 2) a distribution and awareness initiative which accelerates the accessibility of a portfolio of products to areas which are normally very difficult to access through usual distribution networks.

The TAHSSL (Transforming Animal-Health Solutions and Services for Low-Middle Income Countries) programme is a project to conduct research on animal-health product technologies to generate robust proof-of-concept results that are of high quality and to facilitate with the private sector product development, registration and use. The focus is on developing veterinary medicines and diagnostic solutions to address animal health disease constraints in low-middle income countries and providing services to help fill the product development pipeline. TAHSSL is fully funded by the International Livestock Research Institute (ILRI).

The purpose of the PLSHL 2 programme was to build on the work carried out under PLSHL 1, but with more focus given to increasing market development and access initiatives to benefit a greater number of poor livestock keepers. The programme was jointly funded by BMGF (80%) and FCDO (20%) and was completed on 31 March 2018. Expenditure during the year relates to the delivery of additional project work to utilise surplus funds at the request of BMGF. Funds at 31 March 2022 are now fully disbursed.

Other restricted funds represent income received from funders with a specific use of programme identified.

The general reserve represents the free funds of the charity. Designated funds comprise unrestricted funds that have been set aside by the Trustees for a particular purpose. Organisational (indirect) costs need to be covered by contributions from all programmes. Cumulative net indirect core cost contributions have been designated by the Board at 31 March 2022 to fund future indirect costs.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**13. Total Assets – Analysed Between Funds**

2022	Fixed assets £	Net current assets £	Total £
<b>Restricted funds</b>			
AAT 3	294	6,319,532	6,319,826
VITAL	4,369	3,821,761	3,826,130
AgResults Brucellosis	294	1,208,268	1,208,562
Bovine TB	-	863,071	863,071
PREVENT	-	493,349	493,349
AgResults FMD	598	347,109	347,707
MAHABA	-	339,336	339,336
Boehringer Ingelheim	-	111,614	111,614
TAHSSL	1,009	79,353	80,362
Health for Animals	-	2,264	2,264
	<u>6,564</u>	<u>13,585,657</u>	<u>13,592,221</u>
<b>Unrestricted funds</b>			
General reserve	25,093	1,592,717	1,617,810
Designated funds	-	1,321,194	1,321,194
	<u>31,657</u>	<u>16,499,568</u>	<u>16,531,225</u>
<b>Total</b>	<u><u>31,657</u></u>	<u><u>16,499,568</u></u>	<u><u>16,531,225</u></u>

2021	Fixed assets £	Net current assets £	Total £
<b>Restricted funds</b>			
AAT 3	733	6,869,714	6,870,447
VITAL	8,117	2,568,824	2,576,941
AgResults Brucellosis	733	1,014,539	1,015,272
PREVENT	-	416,252	416,252
AgResults FMD	2,264	307,549	309,813
Boehringer Ingelheim	-	170,441	170,441
TAHSSL	1,847	62,256	64,103
PLSHL 2	-	86,151	86,151
	<u>13,694</u>	<u>11,495,726</u>	<u>11,509,420</u>
<b>Unrestricted funds</b>			
General reserve	48,278	1,552,520	1,600,798
Designated funds	-	891,431	891,431
	<u>61,972</u>	<u>13,939,677</u>	<u>14,001,649</u>
<b>Total</b>	<u><u>61,972</u></u>	<u><u>13,939,677</u></u>	<u><u>14,001,649</u></u>

**14. Operating Lease Commitments**

At 31 March 2022 GALVmed was committed to a total of future minimum lease payments under non-cancellable operating leases for land, buildings and equipment for each of the following periods:

	2022 £	2021 £
Not later than one year	100,726	116,539
Later than one year and not later than five years	58,775	156,978



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2022

**15. Share Capital**

The company is limited by guarantee and does not have share capital.

**16. Reconciliation of Net Income to Net Cash Flow from Operating Activities**

	2022 £	2021 £
<b>Net income for the reporting period (as per the Statement of Financial Activities)</b>	1,811,567	5,735,765
<b>Adjustments for:</b>		
Depreciation charges	39,935	36,266
Loss on sale of assets	-	2,325
Interest from investments	(5,638)	(13,778)
Decrease/(increase) in debtors	287,840	(115,110)
Increase/(decrease) in creditors	245,552	(167,594)
<b>Net cash provided by operating activities</b>	<u>2,379,256</u>	<u>5,477,874</u>

Debtors contains accrued investment income of £3,152 (2021: £142). The movement on accrued investment income is included in investments within the cash flow statement.

**17. Related Parties**

There were no related party transactions in the year (2021: £73 remuneration for consultancy services 1 Trustee), other than the expenses as disclosed in note 4 of these accounts. The Trustees consider all the transactions during the year to have been undertaken on an arm's length basis

**18. Ultimate Controlling Party**

GALVmed is constituted under its Memorandum and Articles of Association and is managed by its appointed Board of Trustees.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**

England & Wales - Charity number 1115606

---

# Accounts

---

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

Registered in England No. 05393391  
England and Wales Charity No. 1115606  
Scottish Charity No. SC039197

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 MARCH 2021**



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**For the year ended 31 March 2021**

**CONTENTS**

	<u>Page</u>
<b><u>REFERENCE AND ADMINISTRATIVE DETAILS</u></b>	<b>2</b>
<b><u>REPORT OF THE TRUSTEES</u></b>	
<b>INTRODUCTION</b>	<b>3</b>
<b>OBJECTS, OBJECTIVES AND ACTIVITIES</b>	<b>3</b>
Objects	3
Objectives & Activities	3
<b>STRUCTURE, GOVERNANCE AND MANAGEMENT</b>	<b>3</b>
Trustee Recruitment, Induction, Training and Evaluation	4
Trustees' and Members' Meetings and Business	4
Strategy and Decision Making	4
Key Management Remuneration	4
Diversity	5
Safeguarding	5
Partnerships and Related Parties	5
<b>STRATEGIC REPORT</b>	<b>5</b>
Performance and Achievements	5
- Key Performance Indicators	5
- Key Achievements	6
- Impact of Our Work	6
Financial Review	7
- Income	7
- Expenditure	7
- Unrealised Exchange Gains/Losses	7
- Balance Sheet	7
- Liquidity Management Policy	7
- CO <sub>2</sub> Emissions	7
- Reserves	8
- Unrestricted Reserves Policy	8
Future Plans	8
- Objectives	8
- Financial	8
Principal Risks and Uncertainties	9
- Risk Management	9
- COVID-19	9
<b>GOING CONCERN</b>	<b>9</b>
<b>AUDITORS</b>	<b>10</b>
<b><u>RESPONSIBILITIES OF THE TRUSTEES</u></b>	<b>11</b>
<b><u>INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES</u></b>	<b>12</b>
<b><u>INCOME AND EXPENDITURE ACCOUNT AND STATEMENT OF FINANCIAL ACTIVITIES</u></b>	<b>15</b>
<b><u>BALANCE SHEET</u></b>	<b>16</b>
<b><u>STATEMENT OF CASH FLOWS</u></b>	<b>17</b>
<b><u>NOTES TO THE FINANCIAL STATEMENTS</u></b>	<b>18-29</b>



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Trustees**

Prof P Wood	Chair Chair of Technical Scientific Advisory Committee
Dr W Amanfu	Vice-Chair
Prof M Gill	Chair of Impact, Monitoring & Evaluation Advisory Committee
Prof K Pathak	-
Dr I Dieuzy-Labayé	Chair of Commercial Development Advisory Committee
Dr J Maina	Chair of HR Committee
Mr S Jha	-
Mrs J Stevenson FCA	Appointed 15 September 2020 Chair of Finance & Risk Committee
Dr A Banga	Appointed 15 September 2020
Dr F Kausche	Appointed 15 September 2020
Prof M Rweyemamu	Resigned 15 September 2020
Mr M J Ince FCA MBA	Resigned 15 September 2020

**Chief Executive Officer** Dr C Schumacher

**Company Secretary** Ms H Stevenson CA

**Independent Auditors**

MHA Henderson Loggie  
Chartered Accountants  
Ground Floor, 11-15 Thistle Street  
Edinburgh, EH2 1DF

**Legal Advisors**

Dentons LLP  
Quartermile One  
15 Lauriston Place  
Edinburgh, EH3 9EP

**Bankers**

Lloyds Bank plc  
City Office, PO Box 72  
Bailey Drive, Gillingham Business Park  
Kent, ME8 0LS

**Registered Office**

One Fleet Place  
London, EC4M 7WS

**Principal Office**

Doherty Building  
Pentlands Science Park  
Bush Loan, Edinburgh, EH26 0PZ

**Company No.** 05393391

**England and Wales Charity No.** 1115606

**Scotland Charity No.** SC039197



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**TRUSTEES' REPORT  
For the year ended 31 March 2021**

**INTRODUCTION**

The Trustees have pleasure in presenting their report for the year ended 31 March 2021. This report is prepared in accordance with the recommendations of *Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)* and in accordance with applicable law.

Global Alliance for Livestock Veterinary Medicines (the company) has complied with the duty in Section 4 of the Charities Act 2011 to have due regard to public benefit guidance published by the Charity Commission.

Global Alliance for Livestock Veterinary Medicines (GALVmed) is a company limited by guarantee and is registered as a charity with the Charity Commission and the Office of the Scottish Charity Regulator (OSCR). It is incorporated in the UK with its principal office in Edinburgh, UK. Other offices are maintained in New Delhi, India (South Asia office); and Nairobi, Kenya (Africa office). Other reference and administrative details are set out in the previous section.

**OBJECTS, OBJECTIVES AND ACTIVITIES**

**Objects**

Around 900 million poor people rely on livestock for their livelihoods. The company's objects, as set out in its Memorandum of Association, are for the benefit of the public:

- 1) to relieve financial hardship and promote good health (including improving food security) amongst small-holder livestock keepers in developing countries through the promotion of affordable vaccines, pharmaceutical and diagnostic products and services aimed at improving the health of their livestock; and
- 2) to promote the effective use of resources to achieve the above charitable purposes through the identification, management, funding and co-ordination of: a) development of livestock vaccines, pharmaceuticals and diagnostics products and services; and b) delivery of these products and services at affordable prices, by working in partnership with others (whether charities, government; private bodies or institutions).

GALVmed's vision is the transformational improvement in the wellbeing and economic progression of small-scale livestock producers. Our mission is to contribute to the transformation of small-scale livestock producers' lives by:

- understanding the constraints to animal health and how to overcome them;
- engaging the animal health industry; and
- ensuring awareness, availability and adoption of effective animal health interventions.

**Objectives & Activities**

GALVmed achieves its charitable purpose by operating a series of Research and Development and Commercialisation programmes, supported by enabling environment and monitoring and evaluation activities, funded principally by the Bill and Melinda Gates Foundation (BMGF) and the UK Government through its Foreign, Commonwealth and Development Office (FCDO). These programmes are designed to identify products that smallholder livestock farmers can use to improve the health of their animals and to make such products more easily accessible to those farmers. The two largest of these programmes are Veterinary Innovations Transforming Animal Health and Livelihoods (VITAL), with a budget of \$50m, and African Animal Trypanosomiasis (AAT) 3, with a budget of \$22.5m. 5 other programmes are also being operated, with values ranging from \$0.5m to \$4.9m (see note 12 for further programme information).

**STRUCTURE, GOVERNANCE AND MANAGEMENT**

The Governance of the company is the responsibility of the Trustees and the company adopts the appropriate principles and recommended practices of the Charity Governance Code. The Members elect the Trustees in accordance with the terms of the Memorandum and Articles of Association.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**TRUSTEES' REPORT  
For the year ended 31 March 2021**

There has been a period of consolidation of the governance of the company following extensive strengthening of the governance framework and procedures in 2019-20.

**Trustee Recruitment, Induction, Training and Evaluation**

The maximum number of Trustees permitted by the company's Articles is 10. Trustees are recruited for their individual skills and experience to fill current or impending vacancies. Trustees serve a term of 3 years subject to a maximum of two consecutive terms and Board and AGM approval. Recruitment of Trustees is managed by a Trustee Selection Panel comprising 3 Trustees of which one is the HR Committee Chair. One Trustee retires in 2021. The replacement appointment is subject to AGM approval in September 2021.

The Trustee induction process has been strengthened and formalised to ensure clarity of the role of the Trustee and their responsibilities under company and charity legislation. Trustees, new and current, also receive training on their legal responsibilities annually prior to the AGM, although this did not take place in 2020 due to COVID-19.

Trustee evaluation takes place annually and is based on self-assessment, peer-assessment and annual performance interviews with the Chair and Vice-Chair; the process includes procedures for dealing with poor performance.

**Trustees' and Members' Meetings and Business**

Trustees meet formally four times a year, normally with two virtual and two physical meetings, the same time at which Members' meetings are physically held. Due to COVID-19 all meetings in the year were, successfully, held virtually. The business of all meetings is minuted.

On 31 March 2021 there were 14 Members and 10 Trustees. In addition, observers from 5 organisations, including BMGF and FCDO, the company's major funders, are invited to attend the Members' meetings, with the funders also invited to meet separately with the Board.

The Board is supported by the Finance & Risk and HR committees, to whom aspects of day to day accountability and governance are delegated. The HR Committee is also responsible for safeguarding. There are also three advisory committees - the Technical Scientific, Commercial Development; and Impact, Monitoring and Evaluation committees. These committees provide guidance to the Board through the involvement of external experts.

**Strategy and Decision Making**

Development of the company's strategy for the achievement of its charitable objectives is overseen by the Board of Trustees and evolved by the Executive Directors. Extensive work on GALVmed's 2030 Strategy and the implementation plan took place during the year and concluded with Board approval on 23 March 2021. Throughout the process there was invaluable collaboration with the Board, Members, funders and other key stakeholders. Communication, funding and execution of the Strategy will be the key focus of 2021-22.

In the year the company continued to implement its 2015-2021 Strategy and the corporate objectives set out in the related Business Plan. Progress in achieving these objectives is assessed by the Board through reports by the Chief Executive and the Executive Directors at Board meetings. Strategic and operational issues are brought to the Board for assessment and direction as required.

**Key Management Remuneration**

Key management includes the Chief Executive (CEO) and Executive Directors of the company who operate as the GALVmed Leadership Team (GLT).

The HR Committee has responsibility delegated to it for setting the framework for key management remuneration. The main responsibilities of the Committee in relation to key management remuneration are:

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**TRUSTEES' REPORT  
For the year ended 31 March 2021**

- to determine and agree with the Board the broad policy for key management's remuneration;
- to approve the design, determine targets and approve payments of any performance related schemes; and
- to determine the total remuneration package of each member of the GLT.

The performance related pay scheme, which is based on departmental, and individual objectives developed from the corporate objectives, is applicable to all employees and has been redesigned in the year. Job evaluation and salary benchmarking exercises have also been completed this year.

**Diversity**

The diversity of the Trustees, GLT and staff at 31 March 2021 is:

	Gender		Ethnicity		
	Male	Female	African	Asian	Caucasian
Trustees	6	4	3	2	5
GLT	3	3	1	-	5
Staff	10	15	9	3	13

**Safeguarding**

GALVmed is committed to addressing safeguarding throughout its work. It does so through a specific set of policies and procedures that include: Safeguarding Policy (which explicitly addresses prevention, reporting and response); Trustee and GLT training; all-staff awareness; and contractual commitment to safeguarding by its partners and consultants. All Trustees, GLT and staff were trained, and no safeguarding issues were reported in the year.

**Partnerships and Related Parties**

Partnerships with entities to whom research and development, commercialisation and other work can be subcontracted is a key part of the way the company operates and is instrumental in allowing it to pursue its charitable objectives. The company initiates, facilitates, brokers and contributes to such partnerships from two perspectives: 1) specific partnerships to deliver and support programme achievement and impact; and 2) higher level strategic partnerships to initiate and advance the livestock agenda. All such relationships are formalised through Memoranda of Understanding, Confidentiality Agreements and Contractual Agreements. All contractual arrangements and related party transactions (detailed in Note 17 to the Financial Statements) are conducted at arm's length.

**STRATEGIC REPORT**

**Performance and Achievements**

*Key Performance Indicators*

The Trustees and GLT assess the financial and operational performance of each programme using the following key performance indicators (KPI):

- detailed milestones within specific activities as defined in the funder agreement for each programme;
- quarterly KPI dashboards, providing quantitative and qualitative measure of delivery across all functions;
- monthly and quarterly actual expenditure against Board approved budget and forecasts; and
- achievement of the annual corporate objectives.

The Advisory and Board Committees oversee the financial and operational performance of organisational and programme activities quarterly.

In addition, service level agreements have been established for all service-related functions, performance of which is assessed quarterly.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2021**

*Key Achievements*

The company has made good progress during the year in achieving its charitable purpose. Its corporate objectives for the year to 31 March 2021 together with key achievements are:

<b>Objective</b>	<b>Achievements</b>
<b>Strategic</b>	
Finalise GALVmed 2030 organisational strategy and budget; and prepare and present VITAL mid-term review.	
	The GALVmed 2030 Strategy was expanded in close collaboration with funders, the Board, Members and partners. This was endorsed by the Board in September 2020, evolved and approved by the Board in March 2021. The VITAL mid-year review was expanded to include the entire portfolio of GALVmed's ongoing programmes and was delayed until after the approval of the Strategy. The exercise was formally started in January 2021 and is expected to be concluded in June 2021.
<b>Tactical</b>	
Deliver VITAL, AgResults, AAT 3, BI-Last-Mile, OSEA and M&E project outputs on plan and budget. Develop a Strategy Implementation Plan.	
	All programmes are progressing well, despite some COVID-19 related delays, to the satisfaction of partners and funders. The company successfully secured funding for one new programme and effectively resourced and integrated it into GALVmed's operations. A Performance Dashboard and new Project Management Framework was rolled out and applied to enhance delivery. The Strategy Implementation Plan was approved by the Board in March 2021.
<b>Process</b>	
Match GALVmed's future strategic ambitions with a comprehensive resource plan and organisational review and enhance Member recruitment process and GALVmed membership.	
	A New Performance Management system has been developed and rolled out. , A new organisational blueprint supporting delivery of GALVmed's 2030 Strategy has been designed and will be rolled out in June 2021. A succession plan for senior leaders has been evolved and junior management strengthened. A Member recruitment approach has been devised, with one new Member recruited in the year and the ongoing approach developed.
<b>Outreach</b>	
Strengthen animal health industry & project partner engagement to foster collaboration, delivery & impact, and develop new partner engagement processes.	
	Multiple industry partner consultations were conducted in support of the definition of GALVmed's 2030 strategic priorities, with unanimous partner approval of the Strategy. The partner selection and engagement process for R&D and Commercial Development was developed in the context of the GALVmed strategic exercise. An industry value chain approach was adopted to identify barriers to animal health investment and facilitate partnerships, with one new programme funded in the year in direct collaboration with a partner.
<b>Development</b>	
Develop new concept note process & portfolio and build a comprehensive forward looking Funder Relations Strategy.	
	This year two concept notes (an outline proposal for a project) have been developed and submitted, and one funding proposal submitted and approved. There are a further three concepts currently in development, and project descriptions developed for all priority projects, supporting delivery of GALVmed's 2030 Strategy. A Funder Relations strategy was developed and endorsed by the Board in March 2021, following a broad cross-functional approach. In addition a South Asia Strategy and an M&E Strategy were developed and approved.

*The Impact of our Work*

GALVmed's two principal activities, product development and commercialisation, are undertaken with the express purpose of providing small-scale livestock producers with improved animal health products and services. These new products and services enable improved livestock health and productivity, and this results in improved livelihoods for these



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**TRUSTEES' REPORT**  
**For the year ended 31 March 2021**

farmers. The nature and timeframe of the resultant impact varies significantly from project to project, but typical project metrics will include:

- *Adoption Rates*: the proportion of small-scale producer households which are using/purchasing a new product or service;
- *Livestock Productivity Measures*: e.g. flock and herd size, litres of milk sold per day, chickens sold/consumed per month etc;
- *Economic Benefit*: the net economic benefit for the small-scale livestock producer households arising from the livestock productivity improvement;
- *Gender Effects*: the change in household dynamics with focus on women's participation in livestock management activities and investment decisions; and
- *Wider Livelihood Issues*: e.g. household nutrition, education, standard of housing etc.

GALVmed's Monitoring and Evaluation work, which assesses the resultant impact, is undertaken with a range of collaborating partners and in close conjunction with the funders of the projects.

### **Financial Review**

Income in the year was £16.9m (2020: £12.4m) and total resources expended were £11.2m (2020: £11.4m).

#### *Income*

Restricted income of £15.8m (2020: £11.1m) includes £9.1m in respect of AAT 3 and £4.4m in respect of VITAL; funding for other programmes totalled £2.3m. Unrestricted income of £1.1m (2020: £1.3m) was received in 2020-21 from contributions from programmes to overheads, and from interest.

#### *Expenditure*

Expenditure remained broadly consistent at £11.2m (2020: £11.4m). VITAL costs of £5.6m continue to make up the largest proportion of expenditure (50%, 2020: 61%). Expenditure on AAT 3 has increased to £3.1m, 28% (2020: £1.6m, 14%). Unrestricted spend has remained broadly consistent at £0.7m (2020: £0.9m)

#### *Unrealised Exchange Gains/Losses*

An unrealised exchange loss of £1.6m has arisen in 2020-21 (2019-20: gain of £0.3m) on the conversion of foreign currency balances at year end exchange rates; the loss is a result of the strengthening of Sterling against the US Dollar, from 1.24 to 1.38 in the year, in which most of the company's funding is received. The company minimises the effects of currency fluctuations by taking a number of steps, including contracting in the funded currency where possible and optimising the timing of foreign currency conversions.

#### *Balance Sheet*

The level of cash held has increased from £10.3m to £14.2m in the year as a result of advanced AAT 3 funding.

#### *Liquidity Management Policy*

The company's liquidity management and investment objectives, responsibilities, risk, and strategy are clearly set out in a Liquidity Management Policy which is subject to review annually. The related liquidity and investment activity is reviewed quarterly by the Finance & Risk Committee.

#### *CO<sub>2</sub> Emissions*

The Board is committed to reducing the company's CO<sub>2</sub> emissions, particularly those resulting from air travel. The Company generated and offset only 3 tonnes of CO<sub>2</sub> emissions in the year (2019-20: 250 tonnes), a significant reduction due to COVID-19 related travel restrictions.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**TRUSTEES' REPORT  
For the year ended 31 March 2021**

*Reserves*

Reserves at 31 March 2021 total £14.0m (2020: £9.9m), of which available funds not tied up in fixed assets amount to £13.9m (2020: £9.8m). Reserves related to restricted funds of £11.5m (2020: £7.6m) mainly relate to advance funding for AAT 3. Unrestricted reserves are £2.5m (2020: £2.3m) as noted below.

*Unrestricted Reserves Policy*

Unrestricted reserves at 31 March 2021 amount to £2.5m (2020: £2.3m). From this amount, the Trustees have established a designated fund of £0.9m which comprises unrestricted reserves that have been set aside for a particular purpose, in this case for any future shortfall in the recovery of overhead costs from programmes.

The objective of the company's unrestricted reserves strategy is to build sufficient funds to protect the company from any adverse changes in its financial circumstances and to pursue operational opportunities that, in the initial phase, are not funded by 3<sup>rd</sup> parties. By considering a variety of risks, the Trustees have concluded that £1.1m of unrestricted reserves should be ring-fenced to cover possible adverse events or circumstances. Additional unrestricted reserves are currently held to ensure financial sustainability and to allow for the future investment in the 2030 Strategy. The unrestricted reserves policy is reviewed every 6 months to ensure that it reflects current circumstances

**Future Plans**

*Objectives*

GALVmed is currently operating in accordance with the vision of the 2015-21 Strategy and Business Plan, with the execution of the 2030 Strategy due to start in 2021-22. This builds upon the evolution of the company since inception as a product development partnership working on a strong portfolio of new products, technologies and processes while continuing to facilitate scale-orientated commercial development initiatives.

GALVmed has identified the following key objectives for 2021-22:

<b>Objective</b>	
<b>Strategic</b>	Execute GALVmed 2030 Strategy including the completion of the Strategy Execution Process Handbook and partner engagement process development. Conduct the BMGF VITAL mid-term evaluation, including consideration of a no-cost extension and a new funding mechanism.
<b>Tactical</b>	Deliver VITAL, AgResults, AAT 3, BI, TAHSSL, PREVENT and other programme outputs on plan and budget.
<b>Process</b>	Ensure strategy and project delivery is underpinned by appropriate human resourcing and efficient processes – including: implementing new organisational structure, including a replacement R&D Director; improving staff development processes, including training and coaching; and reviewing data management and storage processes and integrated project management systems.
<b>Outreach</b>	Expand GALVmed's engagement with external stakeholders including; communication approach reviewed and optimised; strategy communication plan defined; partner engagement goals defined; and Board actively supported to identify new Members and Trustees.
<b>Development</b>	Broaden GALVmed's funding base and secure fresh funding in line with GALVmed 2030 Strategy.

*Financial*

The 2021-22 expenditure budget is £17.3m, a 54% increase on 2020-21 actual expenditure. This increase is mainly because of the increased VITAL sub-award activity as the programme end, scheduled for September 2022, approaches.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**TRUSTEES' REPORT  
For the year ended 31 March 2021**

**Principal Risks and Uncertainties**

*Risk Management*

The company's governance structure includes a Risk Management Strategy and a Risk Register and is designed to identify and ensure the proper management of risks inherent in conducting its activity.

The Risk Management Strategy details the company's risk management objectives, processes, reporting and responsibilities. The Risk Register highlights the major risks to which the company is exposed and for each risk the mitigation, actions, lead risk owner and target date for mitigation is identified. It is maintained to support strategic, financial and operational planning and therefore to assist in achieving the company's objectives and targets. In 2020-21 risk (strategic and appetite) were key components of the development of GALVmed's 2030 Strategy and related strategy implementation plan. In addition, an internal Project Management Framework was devised and rolled out for adoption of which project risk is a key component. Given these and other related factors a comprehensive review of risk management will be undertaken in 2021-22.

The 6 highest key risks that GALVmed believes it faces are: failure to design and implement projects which achieve economic impact for small-scale livestock producers; a major public health crisis impacting on staff and partner health and productivity (currently COVID-19); failure to deliver by partners affecting the outcomes & impact, especially of Commercial Development projects; dependency on limited funding sources; barriers to product registration; and future funding being adversely impacted by failure to deliver on commitments or to align with funders' strategies.

Important financial risks are the possible loss of bank deposits through fraud or theft, currency risk, liquidity risk and dependency on limited funding sources. The risk of loss of bank deposits is managed through the bank mandates in place and continued vigilance. Currency and liquidity risk are managed by following the Liquidity Management Policy. The 2030 Strategy and Funder Relations Strategy aims to address the limited funding sources issue.

*COVID-19*

The risks surrounding COVID-19 have been identified in a separate Risk Register. It considers risk across 3 categories (people, projects and finance) and notes for each risk the mitigation, actions, lead risk owner and target date for mitigation.

The impact of COVID-19 on the company over the past year and on an ongoing basis has been considered. All offices have been, and continue to remain closed during the pandemic, with staff successfully working from home during this time. Programme funding has not been impacted by COVID-19. To date, the majority of programmes have continued to deliver, despite COVID-19, and it is expected that all programmes will continue to be delivered in full, potentially with programme end extensions. We will continue to monitor the impact on our work, particularly across Africa and India where case numbers continue to rise.

**GOING CONCERN**

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding of current programmes is assured: as a result of funding proposals submitted to BMGF and FCDO in 2017, BMGF has awarded \$40m and FCDO \$10m for the 5 years to September 2022 for VITAL. This programme covers all direct operating costs, with sufficient contribution from this and all other current programmes to fully cover indirect costs.

The UK Government recently announced a temporary reduction in Official Development Assistance from a target of 0.7% to 0.5% GNI. As a result, the company was advised in April 2021 of a 17% (£410k) reduction in FCDO funding for 2021-22. The company do not believe it will have a significant impact on its operations nor delivery but is in discussions with both FCDO and BMGF to take all necessary steps to ensure so. The financial sustainability beyond the end of VITAL is being considered and discussed with our funders. The target in 2021-22 is to secure additional funding of \$9m. Other programmes are fully funded.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**TRUSTEES' REPORT**  
**For the year ended 31 March 2021**

The impact of the COVID-19 pandemic on programme delivery has been considered where it is expected that all programmes will continue to be delivered in full.

An assessment of unrestricted funds has also been carried out. If necessary, these funds would be sufficient to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

**AUDITORS**

MHA Henderson Loggie, Chartered Accountants, were reappointed as auditors to the company at the Annual General Meeting in 2017. Their re-appointment was approved up to a maximum 10 years from the date of their first appointment in 2011 in respect of the 2011-12 financial year, subject to annual consideration by both parties.

The Trustees' Report including the Strategic Report was approved by the Board of Trustees and signed on their behalf by:

---

Prof P Wood  
15 June 2021

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**RESPONSIBILITIES OF THE TRUSTEES**  
**For the year ended 31 March 2021**

The Trustees (who are also the Directors for the purposes of company law) are responsible for the preparation of the Trustees' Report, including the Strategic Report, and financial statements in accordance with applicable law and regulations.

Law applicable to incorporated charities in Scotland requires the Trustees to prepare an annual report and financial statements for each financial year in accordance with applicable law and regulations. Under that law the Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law).

Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity at the end of the year and of its financial activities including its income and expenditure during the year then ended. In preparing those financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping proper and adequate accounting records which disclose with reasonable accuracy at any time the financial position of the charity and which enable them to ensure that the financial statements comply with the Companies Act 2006, with the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are also responsible for the maintenance and integrity of the charity.

The Trustees have fulfilled their legal responsibilities with respect to the Trustees' Report, Strategic Report, and Financial Statements.

**Statement of Disclosure of Information to Auditors**

To the knowledge and belief of each of the persons who is a Trustee at the time this report is approved:

- a) So far as the Trustee is aware, there is no relevant information of which the organisation's auditors are unaware; and
- b) He/or she has taken all steps that he/she ought to have taken as a Trustee to make himself/herself aware of any relevant audit information and to establish that the auditors are aware of that information.



---

Prof P Wood  
15 June 2021



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES  
For the year ended 31 March 2021**

**Opinion**

We have audited the financial statements of Global Alliance for Livestock Veterinary Medicines (the 'charitable company') for the year ended 31 March 2021 which comprise the Income and Expenditure Account and Statement of Financial Activities, the Balance Sheet, the Statement of Cash Flow and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 March 2021 and of its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and Regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

**Basis of opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the Financial Reporting Council's (FRC) Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the Trustees' report, other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES  
For the year ended 31 March 2021**

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of our audit:

- the information given in the Strategic Report and the Trustees' Report for the financial period for which the financial statements are prepared is consistent with the financial statements; and
- the Strategic Report and the Trustees' Report have been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report and the Trustees' Report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities and Trustees Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of Trustees**

As explained more fully in the Trustees' Responsibilities Statement, the Trustees (who are also the Directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud, is detailed below:

- Enquiring with management about any known or suspected instances of non-compliance with laws and regulations, including GDPR and employment law, and fraud;
- Review of correspondence with regulators including OSCR, the Charities Commission for England and Wales and the Health & Safety Executive;
- Review of legal fee expenditure and board minutes;
- Challenging assumptions and judgements made by management in their significant accounting estimates; and



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES  
(a company limited by guarantee)**

**INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS AND TRUSTEES  
For the year ended 31 March 2021**

- Auditing the risk of management override of controls, including through testing journal entries and other adjustments for appropriateness

Because of the field in which the client operates, we identified the following areas as those most likely to have a material impact on the financial statements: Health and Safety; employment law (including the Working Time Directive); GDPR; and compliance with the UK Companies Act and the Charities legislation

Owing to the inherent limitations of an audit, there is an unavoidable risk that some material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with the ISAs (UK). For instance, the further removed non-compliance is from the events and transactions reflected in the financial statements, the less likely the auditor is to become aware of it or to recognise the non-compliance. A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

This report is made solely to the Members of Global Alliance for Livestock Veterinary Medicines, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006, and to the charitable company's Trustees, as a body, in accordance with Section 44 (1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and regulation 10 of the Charities Accounts (Scotland) Regulations 2006 (as amended). Our audit work has been undertaken so that we might state to the Members and the charitable company's Trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company, its Members as a body and its Trustees as a body, for our audit work, for this report, or for the opinions we have formed.

MHA Henderson Loggie

**James Davidson (Senior Statutory Auditor)  
For and on behalf of MHA Henderson Loggie  
Chartered Accountants  
Statutory Auditor  
Eligible to act as an auditor in terms of section 1212 of the Companies Act 2006**

Ground Floor, 11-15 Thistle Street  
Edinburgh  
EH2 1DF

16 June 2021

MHA Henderson Loggie is a trading name of Henderson Loggie LLP

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**INCOME AND EXPENDITURE ACCOUNT AND  
STATEMENT OF FINANCIAL ACTIVITIES**  
For the year ended 31 March 2021

	Notes	Unrestricted	Restricted	Total 2021	Total 2020
		£	£	£	£
<b>Income from:</b>					
Charitable Activities	2	1,089,853	15,823,696	16,913,549	12,162,310
Investments		1,843	11,935	13,778	199,842
<b>Total Income</b>		<u>1,091,696</u>	<u>15,835,631</u>	<u>16,927,327</u>	<u>12,362,152</u>
<b>Expenditure on:</b>					
Charitable Activities	3	687,932	10,503,630	11,191,562	11,420,959
<b>Total Expenditure</b>		<u>687,932</u>	<u>10,503,630</u>	<u>11,191,562</u>	<u>11,420,959</u>
<b>Net Income</b>	5	403,764	5,332,001	5,735,765	941,193
<b>Other Recognised (Loss)/Gains:</b>					
Unrealised (Loss)/Gain on Foreign Exchange	6	(214,031)	(1,415,676)	(1,629,707)	260,902
Net Movement in Funds		189,733	3,916,325	4,106,058	1,202,095
<b>Reconciliation of Funds</b>					
Total Funds Brought Forward at 1 April 2020	12	2,302,496	7,593,095	9,895,591	8,693,496
Total Funds Carried Forward at 31 March 2021	12	<u>2,492,229</u>	<u>11,509,420</u>	<u>14,001,649</u>	<u>9,895,591</u>

All the results of the company relate to continuing activities.

The company has no recognised gains or losses other than those set out above.

The notes on pages 18 to 29 form part of these financial statements

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**BALANCE SHEET**  
As at 31 March 2021

	Notes	2021		2020	
		£	£	£	£
<b>Fixed Assets</b>					
Tangible Assets	8		61,972		86,776
<b>Current Assets</b>					
Debtors	9	552,820		442,543	
Bank and Cash Balances	10	14,151,954		10,298,963	
		<u>14,704,774</u>		<u>10,741,506</u>	
<b>Liabilities:</b>					
Creditors: Amounts Falling Due Within One Year	11	(765,097)		(932,691)	
		<u></u>		<u></u>	
<b>Net Current Assets</b>			13,939,677		9,808,815
<b>Total Net Assets</b>			<u>14,001,649</u>		<u>9,895,591</u>
<b>Unrestricted Funds</b>					
General Reserve	12		1,600,798		1,851,227
Designated Funds	12		891,431		451,269
			<u>2,492,229</u>		<u>2,302,496</u>
Total Unrestricted Funds			2,492,229		2,302,496
<b>Restricted Income Funds</b>	12		11,509,420		7,593,095
<b>Total Funds</b>			<u>14,001,649</u>		<u>9,895,591</u>

The financial statements were authorised for issue and approved by the Trustees on 15 June 2021.




---

Prof. P Wood  
Company No: 05393391

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**STATEMENT OF CASH FLOWS**  
For the year ended 31 March 2021

	Notes	2021 £	2020 £
<b>Cash Flows from Operating Activities:</b>			
<b>Net Cash Provided By Operating Activities</b>	<b>16</b>	5,477,874	277,933
<i>Cash Flows from Investing Activities:</i>			
Interest from Investments		18,611	208,976
Purchase of Property, Plant and Equipment		(13,787)	(54,992)
Net Cash Received from Investing Activities		<u>4,824</u>	<u>153,984</u>
<b>Change in Cash and Cash Equivalents in the Reporting Period</b>		5,482,698	431,917
Cash and Cash Equivalents at the Beginning of the Reporting Period		10,298,963	9,606,144
Change in Cash and Cash Equivalents due to Exchange Rate Movements		<u>(1,629,707)</u>	<u>260,902</u>
<b>Cash and Cash Equivalents at the End of the Reporting Period</b>		<u><u>14,151,954</u></u>	<u><u>10,298,963</u></u>
 <b>Analysis of Cash and Cash Equivalents</b>			
Bank and Cash Balances		<u><u>14,151,954</u></u>	<u><u>10,298,963</u></u>

The notes on pages 18 to 29 form part of these financial statements



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2021**

**1. Accounting Policies**

*Basis of Accounting*

GALVmed is a public benefit entity. The financial statements have therefore been prepared in accordance with the Companies Act 2006, applicable accounting standards, Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 as amended in 2010, and the Charities Act 2011. They have also been prepared under historical cost accounting rules. The financial statements are prepared in Sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

*Going Concern*

The Board of Trustees has considered the financial position of GALVmed for the next twelve months and concluded that the use of the going concern basis of accounting is appropriate. Funding of current programmes is assured: as a result of funding proposals submitted to BMGF and FCDO in 2017, BMGF has awarded \$40m and FCDO \$10m for the 5 years to September 2022 for VITAL. This programme covers all direct operating costs, with sufficient contribution from this and all other current programmes to fully cover indirect costs. Other programmes are fully funded. The impact of the COVID-19 pandemic on programme delivery has been considered where it is expected that all programmes will continue to be delivered in full.

An assessment of unrestricted funds has also been carried out. If necessary, these funds would be sufficient to maintain GALVmed as a going concern for at least twelve months from the date of signing the financial statements.

*Fund Accounting*

Funds received on which no restrictions are placed as to their use are accounted for as unrestricted funds. Designated funds comprise unrestricted funds that have been set aside by the Trustees for particular purposes. The aim and use of each designated fund is set out in note 12.

Funds received for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose, are accounted for as restricted funds.

*Income*

Funds received are recognised as income from charitable activities once there is entitlement, reasonable probability of receipt and the amount can be measured with sufficient reliability. Income is deferred where funder-imposed conditions that specify the time period in which the funds can be spent have not yet been met.

Investment income is recognised as earned.

*Value Added Tax (VAT)*

Expenditure is accounted for inclusive of VAT where appropriate as the company is not registered for VAT.

*Pension Scheme*

The company provides a defined contribution pension scheme for its staff and the pension charge in the Statement of Financial Activities (SOFA) represents the amounts payable by the company to the Company Personal Pension Scheme in respect of the year.

*Operating Leases*

Rentals payable under operating leases are charged to the SOFA on the straight-line basis over the lease term.



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2021**

**1. Accounting Policies (continued)**

*Expenditure*

Expenditure is recognised on the accruals basis when a legal and constructive obligation exists. Expenditure through contractual agreements is recognised as goods and services are supplied. Grant payments are recognised as expenditure when payments are due in accordance with the terms of the contract.

Costs incurred by the company in the delivery of its activities and services are accounted for as charitable expenditure and categorised in the SOFA by the main activities of the company. Each category includes direct costs and support costs and, where support costs cannot be directly attributed to a category, they are apportioned on the basis of headcount.

Costs that, whilst necessary to deliver an activity do not themselves contribute directly to GALVmed's activity, are accounted for as support costs. Support costs include central office functions such as management, finance, information systems and administration activities.

Redundancy costs are charged in the year in which the commitment has been made to the employee.

*Foreign Currency*

Foreign currency transactions are recorded in Sterling at the previous month's month-end rate of exchange. Monetary assets and liabilities denominated in foreign currencies are translated into Sterling at the exchange rate at the balance sheet date.

All exchange differences are recognised through the SOFA.

*Tangible Fixed Assets*

Tangible fixed assets costing more than £1,000 are capitalised and stated at cost and depreciated over their useful economic lives as follows:

Office equipment	4 years
Computer equipment & software	3 years
Leasehold improvements	over the life of the lease

Assets are only depreciated when they are brought into use and depreciated up to, but not including, the month of disposal.

*Debtors and Prepayments*

Debtors are recognised at the settlement amount due. Prepayments are valued at the amount prepaid.

*Cash at Bank and in Hand*

Cash at bank and in hand includes cash and short term highly liquid investments with a maturity of six months or less from the date of acquisition or opening of the deposit or similar account.

*Creditors*

Creditors are recognised where the company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party in the future and the amount due to settle obligations can be measured or estimated reliably. Creditors are recognised at their settlement amount.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**1. Accounting Policies (continued)**

*Critical Accounting Judgements and Estimation Uncertainty*

In preparing the financial statements, the Trustees are required to make judgements, estimates and assumptions, which may affect reported income, expenditure, assets and liabilities. The estimates and associated assumptions are based on historical experience and other factors considered relevant. Actual results may differ from such estimates. Judgements made in preparing these financial statements comprise:

- The applicability of the estimated useful lives of fixed assets used to calculate the period over which depreciation is applied.
- The review of fixed assets for impairment or obsolescence.
- The assessment of leases to determine whether the risks and rewards of ownership remain with the lessor or are transferred to GALVmed

*Financial Instruments*

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

**2. Incoming Resources from Charitable Activities**

	<b>UK Grant Funding</b>	<b>Overseas Grant Funding</b>	<b>2021</b>	<b>2020</b>
	£	£	£	£
<b>Restricted income</b>				
AAT 3	983,826	8,143,694	9,127,520	1,083,263
VITAL	1,312,423	3,054,813	4,367,236	7,944,332
AgResults Brucellosis	-	286,944	286,944	308,650
PREVENT	-	1,058,127	1,058,127	-
AgResults FMD	-	419,452	419,452	525,219
Boehringer Ingelheim	-	507,012	507,012	678,392
TAHSSL	-	92,088	92,088	106,412
AAT Ethiopia	(40,000)	-	(40,000)	-
Royal Veterinary College	5,317	-	5,317	6,982
AAT 2	-	-	-	254,966
Project Mesha	-	-	-	9,106
Other	-	-	-	1,000
<b>Total restricted income</b>	<b>2,261,566</b>	<b>13,562,130</b>	<b>15,823,696</b>	<b>10,918,322</b>
<b>Unrestricted income</b>	<b>176,602</b>	<b>913,251</b>	<b>1,089,853</b>	<b>1,243,988</b>
<b>Total income</b>	<b>2,438,168</b>	<b>14,475,381</b>	<b>16,913,549</b>	<b>12,162,310</b>

There is negative income in the AAT Ethiopia fund because income was returned to the Universities of Edinburgh and Glasgow in the year because it was not required.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**3. Analysis of Expenditure**

	<b>Support</b>	<b>Governance</b>	<b>Staff</b>	<b>Direct</b>	<b>Total 2021</b>	<b>Total 2020</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>Costs £</b>	<b>£</b>	<b>£</b>
AAT 3	1,591	-	18,147	3,096,659	3,116,397	1,572,660
VITAL	249,506	-	994,018	4,346,264	5,589,788	6,953,545
AgResults Brucellosis	1,556	-	6,173	86,313	94,042	81,356
PREVENT	-	-	-	641,875	641,875	-
AgResults FMD	7,979	-	79,809	240,539	328,327	278,176
Boehringer Ingelheim	-	-	-	433,928	433,928	653,336
PLSHL 2	-	-	-	183,356	183,356	237,132
TAHSSL	943	-	83,830	25,827	110,600	23,798
Royal Veterinary College	-	-	499	4,818	5,317	6,982
AAT 2	-	-	-	-	-	730,698
Project Mesha	-	-	-	-	-	8,928
Other	-	-	-	-	-	1,000
Unrestricted	66,966	(20,321)	529,842	111,445	687,932	873,348
<b>Total 2021</b>	<b>328,541</b>	<b>(20,321)</b>	<b>1,712,318</b>	<b>9,171,024</b>	<b>11,191,562</b>	<b>11,420,959</b>
<b>Total 2020</b>	<b>388,828</b>	<b>86,284</b>	<b>1,802,757</b>	<b>9,143,090</b>	<b>11,420,959</b>	

Negative Governance costs of £20,321 have been incurred because of refunds received for the March 2020 Board meeting, which was cancelled because of COVID-19. Governance costs, excluding these refunds of £24,082, are £3,761.

**Analysis of Support Costs**

	<b>Professional</b>	<b>Office</b>	<b>Information</b>	<b>Audit</b>	<b>Total 2021</b>	<b>Total 2020</b>
	<b>Fees</b>	<b>Costs</b>	<b>Technology</b>	<b>Fees</b>	<b>£</b>	<b>£</b>
	<b>£</b>	<b>£</b>	<b>£</b>	<b>£</b>		
AAT 3	-	343	1,248	-	1,591	1,220
VITAL	49,351	133,884	64,489	1,782	249,506	290,784
AgResults Brucellosis	-	-	1,556	-	1,556	1,464
AgResults FMD	-	27	7,952	-	7,979	2,374
PLSHL 2	-	-	-	-	-	494
TAHSSL	-	57	886	-	943	212
AAT 2	-	-	-	-	-	348
Other	-	-	-	-	-	1,000
Unrestricted	1,499	31,826	21,481	12,160	66,966	90,932
<b>Total 2021</b>	<b>50,850</b>	<b>166,137</b>	<b>97,612</b>	<b>13,942</b>	<b>328,541</b>	<b>388,828</b>
<b>Total 2020</b>	<b>80,821</b>	<b>174,374</b>	<b>119,970</b>	<b>13,663</b>	<b>388,828</b>	

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**4. Staff Costs**

	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
Total staff costs were as follows:		
Salaries	1,458,427	1,540,724
Social security costs	110,322	126,618
Pension contributions	98,066	103,877
Other employee benefits	45,503	31,538
	<u>1,712,318</u>	<u>1,802,757</u>

The average number of employees during the year was:

	<b>Number</b>	<b>Number</b>
Management	5	6
Project staff	13	13
Support staff	11	12
	<u>29</u>	<u>31</u>

During the year the company incurred expenses of £240 on behalf of, or reimbursed expenses to, 4 Trustees in connection with their governance responsibilities (2020: £43,547, 11 Trustees). All Board meetings in 2020-21 were held virtually due to COVID-19. No expenses were incurred for persons or entities connected with the Trustees (2020: £nil). One Trustee received remuneration of £73 in relation to consultancy services provided (2020: no remuneration).

GALVmed provides to its UK-based staff a defined contribution pension scheme, the GALVmed Personal Pension Scheme, which is operated by Aviva, a life assurance company. Total employer contributions in the year were £60,205 (2020: £70,492). The total number of members in the scheme at 31 March 2021 was 19 (2020: 20). To compensate for the fact that there is currently no pension scheme for international staff, an employer contribution of 6% of salary is paid to such staff on the understanding that this contribution should be paid into a pension scheme of their choice. Total such contributions in respect of the year were £38,051 (2020: £33,385).

The following number of employees received total employee salary and benefits (excluding employer pension) in excess of £60,000 in the period:

	<b>2021</b>	<b>2020</b>
£60,000 - £69,999	-	2
£70,000 - £79,999	2	1
£80,000 - £89,999	-	1
£90,000 - £99,999	1	1
£100,000 - £109,999	1	1
£110,000 - £119,999	-	-
£130,000 - £139,999	-	-
£140,000 - £149,999	-	1
£150,000 - £159,999	1	-
	<u>1</u>	<u>-</u>



**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**4. Staff Costs (continued)**

GALVmed considers the key management of the company to be the GALVmed Leadership Team (GLT), comprising the Chief Executive Officer, Senior Executive Directors and Executive Directors. The total cost of the employment of key management in the year was £540,377 (2020: £634,943), with a further £89,584 (2020: £nil) paid to one consultant. Employer pension contributions for key management totalled £30,573 (2020: £34,940).

Redundancy costs of £nil were incurred during the year (2020: £10,703).

**5. Net Incoming Resources**

	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
This is stated after charging:		
- Auditor's remuneration – audit fees	13,942	13,663
- Depreciation	36,266	30,207
- Loss on Disposal of Fixed Assets	2,325	-
- Operating leases		
Land and buildings	118,702	109,049
Equipment	1,701	1,353

Auditors remuneration includes £1,852 (2020: £1,927) for audit fees payable in India and £12,090 (2020: £11,736) for audit fees in the UK.

**6. Unrealised Exchange Gains and Losses**

Unrealised losses on foreign exchange relate to the revaluation of GALVmed's net current assets at 31 March 2021 (see note 12 for unrealised exchange gains/losses by programme). The losses predominantly relate to advance funding in US Dollars from BMGF and a strengthening of Sterling against the US Dollar.

In addition, a realised gain of £5,312 (2020: £11,621 gain) is included in the expended charitable resources, which is a result of the difference between the currency rate invoiced and the currency rate paid to suppliers. GALVmed undertakes a variety of exchange mechanisms throughout the year to minimise realised exchange differences and help ensure there are adequate resources to deliver the programme outputs.

**7. Taxation**

The company has charitable status and is not liable for tax.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**8. Tangible Assets**

	Leasehold improvements £	Office equipment £	Computer equipment & software £	Total £
<b>Cost</b>				
At 1 April 2020	45,019	7,267	267,475	319,761
Additions	1,191	-	12,596	13,787
Disposals	(33,780)	-	(9,566)	(43,346)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2021	12,430	7,267	270,505	290,202
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
<b>Depreciation</b>				
At 1 April 2020	30,496	7,267	195,222	232,985
Charge for year	4,166	-	32,100	36,266
Eliminated on disposal	(31,455)	-	(9,566)	(41,021)
	<hr/>	<hr/>	<hr/>	<hr/>
At 31 March 2021	3,207	7,267	217,756	228,230
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
<b>Net book value</b>				
At 31 March 2021	9,223	-	52,749	61,972
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>
At 31 March 2020	14,523	-	72,253	86,776
	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>	<hr/> <hr/>

**9. Debtors**

	2021 £	2020 £
Prepayments and accrued income	527,890	402,530
Other debtors	24,930	40,013
	<hr/>	<hr/>
	552,820	442,543
	<hr/> <hr/>	<hr/> <hr/>

Prepayments and accrued income includes £90,460 (2020: £140,380) of accrued income in relation to the AgResults FMD Disease programme; £70,003 (2020: £84,961) in relation to the AgResults Brucellosis programme; £293,491 in relation to the VITAL programme (2020: £nil); £nil (2020: £109,982) in relation to the TAHSSL programme; £nil (2020: £766) in relation to the Project Mesha Programme; £nil (2020: £734) in relation to the Royal Veterinary College programme; and other debtors include accrued investment income of £142 (2020: £4,975).

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**10. Bank and Cash Balances**

<b>2021</b>	<b>GBP £</b>	<b>USD £</b>	<b>Other currencies £</b>	<b>Total £</b>
Lloyds Bank	668,030	3,695,610	5,118	4,368,758
Bank of Scotland	1,000,000	3,773,708	-	4,773,708
NatWest	-	4,989,922	-	4,989,922
Standard Chartered	-	-	14,341	14,341
Cash	234	3,281	1,710	5,225
	<u>1,668,264</u>	<u>12,462,521</u>	<u>21,169</u>	<u>14,151,954</u>
<b>2020</b>	<b>GBP £</b>	<b>USD £</b>	<b>Other currencies £</b>	<b>Total £</b>
Lloyds Bank	696,352	2,415,660	54,457	3,166,469
Bank of Scotland	-	3,779,841	-	3,779,841
NatWest	-	3,335,174	-	3,335,174
Standard Chartered	-	-	11,768	11,768
Cash	239	3,854	1,618	5,711
	<u>696,591</u>	<u>9,534,529</u>	<u>67,843</u>	<u>10,298,963</u>

**11. Creditors: Amounts Falling Due Within One Year**

	<b>2021 £</b>	<b>2020 £</b>
Trade creditors	610,286	143,031
Accruals	153,433	747,035
Other creditors	1,378	4,441
Deferred income	-	38,184
	<u>765,097</u>	<u>932,691</u>

Creditors includes £nil (2020: £38,184) of deferred income in relation to the VITAL programme. The movement in accruals and trade creditors is because of large, contracted payments due to partners for the VITAL programme.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**12. Funds Movement**

<b>2021</b>	<b>31 March 2020</b>	<b>Incoming resources</b>	<b>Resources expended</b>	<b>Exchange (losses)</b>	<b>Transfers</b>	<b>31 March 2021</b>
	£	£	£	£	£	£
<b>Restricted funds:</b>						
AAT 3	1,340,656	9,130,126	(3,116,397)	(483,938)	-	6,870,447
VITAL	4,443,169	4,374,654	(5,589,788)	(651,094)	-	2,576,941
AgResults Brucellosis	922,252	287,861	(94,042)	(100,799)	-	1,015,272
PREVENT	-	1,058,127	(641,875)	-	-	416,252
AgResults FMD	249,450	419,452	(328,327)	(30,762)	-	309,813
Boehringer Ingelheim	221,795	507,716	(433,928)	(125,142)	-	170,441
PLSHL 2	293,106	342	(183,356)	(23,941)	-	86,151
TAHSSL	82,615	92,088	(110,600)	-	-	64,103
AAT – Ethiopia	40,052	(40,052)	-	-	-	-
Royal Veterinary College	-	5,317	(5,317)	-	-	-
<b>Total restricted funds</b>	<b>7,593,095</b>	<b>15,835,631</b>	<b>(10,503,630)</b>	<b>(1,415,676)</b>	<b>-</b>	<b>11,509,420</b>
<b>Unrestricted funds:</b>						
General reserve	1,851,227	1,091,696	(687,932)	(214,031)	(440,162)	1,600,798
Designated funds:						
Indirect future costs	451,269	-	-	-	440,162	891,431
<b>Total unrestricted funds</b>	<b>2,302,496</b>	<b>1,091,696</b>	<b>(687,932)</b>	<b>(214,031)</b>	<b>-</b>	<b>2,492,229</b>
<b>Total funds</b>	<b>9,895,591</b>	<b>16,927,327</b>	<b>(11,191,562)</b>	<b>(1,629,707)</b>	<b>-</b>	<b>14,001,649</b>
<b>2020</b>	<b>31 March 2019</b>	<b>Incoming resources</b>	<b>Resources expended</b>	<b>Exchange gains/ (losses)</b>	<b>Transfers</b>	<b>31 March 2020</b>
	£	£	£	£	£	£
<b>Restricted funds:</b>						
AAT 3	1,705,614	1,119,039	(1,572,659)	88,662	-	1,340,656
VITAL	3,283,176	8,068,548	(6,953,545)	44,990	-	4,443,169
AgResults Brucellosis	650,465	316,067	(81,356)	37,076	-	922,252
AgResults FMD	-	525,219	(278,176)	2,407	-	249,450
Boehringer Ingelheim	180,309	683,908	(653,336)	10,914	-	221,795
PLSHL 2	505,0042	7,997	(237,133)	17,200	-	293,106
TAHSSL	-	106,413	(23,798)	-	-	82,615
AAT – Ethiopia	40,000	52	-	-	-	40,052
Royal Veterinary College	-	6,982	(6,982)	-	-	-
AAT 2	469,024	256,156	(730,698)	5,518	-	-
Project Mesha	-	9,106	(8,928)	(178)	-	-
Other	-	1,000	(1,000)	-	-	-
<b>Total restricted funds</b>	<b>6,833,630</b>	<b>11,100,487</b>	<b>(10,547,611)</b>	<b>206,589</b>	<b>-</b>	<b>7,593,095</b>
<b>Unrestricted funds:</b>						
General reserve	1,859,866	1,261,665	(873,348)	54,313	(451,269)	1,851,227
Designated funds:						
Indirect future costs	-	-	-	-	451,269	451,269
<b>Total unrestricted funds</b>	<b>1,859,866</b>	<b>1,261,665</b>	<b>(873,348)</b>	<b>54,313</b>	<b>-</b>	<b>2,302,496</b>
<b>Total funds</b>	<b>8,693,496</b>	<b>12,362,152</b>	<b>(11,420,959)</b>	<b>260,902</b>	<b>-</b>	<b>9,895,591</b>

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
**(a company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**For the year to 31 March 2021**

**12. Funds Movement (continued)**

*Programme Objectives and Funding*

The purpose of the AAT 3 programme is to build upon the success of the work carried out under previous AAT programmes resulting in the improved tools for the control of Animal African Trypanosomiasis. The specific objective of AAT 3 is the commercial development of a registered therapeutic trypanocidal product, ready for sale through GALVmed's commercial partner in the AAT 3 programme, Boehringer Ingelheim. This programme is funded by both BMGF (\$19m) and FCDO (\$3.5m)

The VITAL programme has two strands: product development and commercial development. The broad objectives are: 1) to develop six new high impact livestock vaccines ready for commercial production and suitable for widespread use by smallholders in Africa and South Asia; and 2) to partner the animal health industry to establish five large scale portfolio distribution networks in Africa and South Asia with each initiative being capable of generating positive cash flows by year 4 and achieving subsequent growth and expansion through these cash flows. The programme is jointly funded by BMGF (80%) and FCDO (20%). This programme ends on 30 September 2022.

The AgResults Brucellosis programme is a competition, managed by GALVmed, to develop and register a safe and efficacious vaccine against *Brucella melitensis*, the main cause of human infections with Brucella and a significant economic burden in developing countries. It is fully funded by the AgResults consortium.

The PREVENT programme is fully funded by BMGF, with a sub-award to Ceva Santé Animale through GALVmed, whose aim is to create an efficient sector of medium-sized African hatcheries applying hatchery vaccination and proactive marketing methods to initiate and increase vaccinated chick sales to poultry small scale producers.

The AgResults Foot and Mouth programme is a competition, managed by GALVmed, to encourage the development and uptake of an improved vaccine tailored for the needs and requirements of East Africa. It is fully funded by the AgResults Consortium.

The Boehringer Ingelheim (BI) programme is fully funded by BMGF with a sub-award to BI through GALVmed. Its objective is to deliver a viable business model for providing quality veterinary healthcare to smallholder farmers in Africa. The key activities for this programme are 1) a registration initiative of BI products in three key markets; and 2) a distribution and awareness initiative which accelerates the accessibility of a portfolio of products to areas which are normally very difficult to access through usual distribution networks.

The purpose of the PLSHL 2 programme was to build on the work carried out under PLSHL 1, but with more focus given to increasing market development and access initiatives to benefit a greater number of poor livestock keepers. Work was also extended into the following diseases: PPR, CBPP and CCP, which were previously feasibility studies under PLSHL 1. The programme was jointly funded by BMGF (80%) and FCDO (20%). This programme was completed on 31 March 2018. Expenditure during the year relates to the delivery of additional project work to utilise surplus funds at the request of BMGF. Funds at 31 March 2021 are fully committed.

The TAHSSL programme is a project to conduct research on animal-health product technologies to generate robust proof-of-concept results that are of high quality and to facilitate with the private sector product development, registration and use. The focus is on developing veterinary medicines and diagnostic solutions to address animal health disease constraints in low-middle income countries and providing services to help fill the product development pipeline. TAHSSL is fully funded by the International Livestock Research Institute (ILRI).

Other restricted funds represent income received from funders with a specific use of programme identified. There is negative income in the AAT Ethiopia fund because income was returned to the Universities of Edinburgh and Glasgow in the year because it was not required.

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**12. Funds Movement (continued)**

The general reserve represents the free funds of the charity. Designated funds comprise unrestricted funds that have been set aside by the Trustees for a particular purpose. Organisational (indirect) costs need to be covered by contributions from all programmes. Cumulative net indirect core cost contributions have been designated by the Board at 31 March 2021 to fund future indirect costs to September 2022.

**13. Total Assets – Analysed Between Funds**

<b>2021</b>	<b>Fixed assets £</b>	<b>Net current assets £</b>	<b>Total £</b>
<b>Restricted funds</b>			
AAT 3	733	6,869,714	6,870,447
VITAL	8,117	2,568,824	2,576,941
AgResults Brucellosis	733	1,014,539	1,015,272
PREVENT	-	416,252	416,252
AgResults FMD	2,264	307,549	309,813
Boehringer Ingelheim	-	170,441	170,441
PLSHL 2	-	86,151	86,151
TAHSSL	1,847	62,256	64,103
	13,694	11,495,726	11,509,420
<b>Unrestricted funds</b>			
General reserve	48,278	1,552,520	1,600,798
Designated funds	-	891,431	891,431
	61,972	13,939,677	14,001,649
	61,972	13,939,677	14,001,649
<b>2020</b>	<b>Fixed assets £</b>	<b>Net current assets £</b>	<b>Total £</b>
<b>Restricted funds</b>			
AAT 3	1,173	1,339,483	1,340,656
VITAL	11,238	4,431,931	4,443,169
AgResults Brucellosis	1,173	921,079	922,252
AgResults FMD	3,930	245,520	249,450
Boehringer Ingelheim	-	221,795	221,795
PLSHL 2	32,864	260,242	293,106
TAHSSL	962	81,653	82,615
AAT – Ethiopia	-	40,052	40,052
	51,340	7,541,755	7,593,095
<b>Unrestricted funds</b>			
General reserve	35,436	1,815,791	1,851,227
Designated funds	-	451,269	451,269
	86,776	9,808,815	9,895,591
	86,776	9,808,815	9,895,591

**GLOBAL ALLIANCE FOR LIVESTOCK VETERINARY MEDICINES**  
(a company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
For the year to 31 March 2021

**14. Operating Lease Commitments**

At 31 March 2021 GALVmed was committed to a total of future minimum lease payments under non-cancellable operating leases for land, buildings and equipment for each of the following periods:

	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
Not later than one year	116,539	95,604
Later than one year and not later than five years	156,978	70,200

**15. Share Capital**

The company is limited by guarantee and does not have share capital.

**16. Reconciliation of Net Income to Net Cash Flow from Operating Activities**

	<b>2021</b>	<b>2020</b>
	<b>£</b>	<b>£</b>
<b>Net income for the reporting period (as per the Statement of Financial Activities)</b>	5,735,765	941,193
<b>Adjustments for:</b>		
Depreciation charges	36,266	30,207
Loss on sale of assets	2,325	-
Interest from investments	(13,778)	(199,842)
(Increase) in debtors	(115,110)	(200,357)
(Decrease) in creditors	(167,594)	(293,268)
<b>Net cash provided by operating activities</b>	<u>5,477,874</u>	<u>277,933</u>

Debtors contains accrued investment income of £142 (2020: £4,975). The movement on accrued investment income is included in investments within the cash flow statement.

**17. Related Parties**

One Trustee received remuneration of £73 in relation to consultancy services provided (2020: no remuneration).

**18. Ultimate Controlling Party**

GALVmed is constituted under its Memorandum and Articles of Association and is managed by its appointed Board of Trustees.